Purification platform for obtaining pharmaceutical compositions with reduced rates of hydrolytic enzyme activity

JP2023548826A5Pending Publication Date: 2024-11-06GENENTECH INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2023526026
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2020-10-30
Filing Date
2021-10-28
Publication Date
2024-11-06

AI Technical Summary

Technical Problem

Current purification methods for biotherapeutic products, such as antibodies produced from host cell cultures, fail to effectively remove host cell proteins and impurities, including hydrolases, which can degrade the purification targets and additives, affecting product quality and therapeutic efficacy.

Method used

A purification platform incorporating a capture step, ion exchange chromatography, depth filtration, and optional hydrophobic interaction chromatography steps to reduce hydrolase activity, utilizing specific chromatography media like Capto™ Adhere and Capto™ MMC, and depth filters like X0SP and EMPHAZE™, to enhance purification efficiency.

Benefits of technology

The method significantly reduces hydrolase activity by at least 20%, improving the stability and shelf life of pharmaceutical compositions, particularly those containing antibodies, by minimizing degradation of additives like polysorbate.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The present disclosure provides purification platforms that include a depth filter step and / or a hydrophobic interaction chromatography (HIC) step and / or a MM-HIC / IEX chromatography step, and is useful for providing methods for reducing the rate of hydrolytic enzyme activity in compositions obtained from said purification platforms. Also disclosed herein are methods of using the purification platforms described herein and compositions, e.g., pharmaceutical compositions, obtained therefrom.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] Cross-reference of related applications This application claims priority to U.S. Provisional Application No. 63 / 108,194, filed on 30 October 2020, the contents of which are incorporated herein by reference in their entirety.

[0002] Technical field This disclosure relates to a purification platform for obtaining compositions such as pharmaceutical compositions in which the hydrolytic enzyme activity rate has been reduced. Methods using the purification platform described herein and the compositions obtained therefrom are also disclosed herein. [Background technology]

[0003] background Biotherapeutic products, such as antibodies, produced from host cell cultures require purification to remove host cell proteins and other impurities that may affect product quality and therapeutic efficacy. Current purification methods do not remove all host cell proteins and impurities, including host cell hydrolases. Therefore, impurities remaining with host cell proteins and the purified target may affect the purified target itself as well as other additives, such as surfactants and other components added for formulation purposes. Thus, improved methods are needed for purifying biotherapeutic products produced from host cell cultures for pharmaceutical use.

[0004] All references cited herein, including patent applications and publications, are incorporated herein by reference in their entirety. [Overview of the project]

[0005] Brief Overview In some embodiments, a method is provided for reducing the hydrolytic enzyme activity rate of a composition obtained from a purification platform, comprising subjecting a sample to a purification platform comprising a capture step; one or more ion exchange (IEX) chromatography steps; and a deep filtration step, thereby reducing the hydrolytic enzyme activity rate of the composition compared to the purification of a sample without the deep filtration step.

[0006] In some embodiments, each of the one or more IEX chromatography steps is selected from the group consisting of anion exchange (AEX) chromatography steps, cation exchange (CEX) chromatography steps, and multimodal ion exchange (MMIEX) chromatography steps. In some embodiments, the MMIEX chromatography step includes a multimodal cation exchange / anion exchange (MM-AEX / CEX) chromatography step.

[0007] In some embodiments, the method further includes a virus filtration step.

[0008] In some embodiments, the method further includes an ultrafiltration / diafiltration (UF / DF) step.

[0009] In some embodiments, the purification platform includes, in order, a capture step; a CEX chromatography step; an AEX chromatography step; a deep filtration step; a viral filtration step; and a UF / DF step.

[0010] In some embodiments, the deep filtration process includes processing through a depth filter, which is an X0SP depth filter, a C0SP depth filter, a D0SP depth filter, or an EMPHAZE® depth filter.

[0011] In some embodiments, the method further includes a HIC step involving treatment via Sartobind® phenyl.

[0012] In another embodiment, a method is provided for reducing the hydrolytic enzyme activity rate of a composition obtained from a purification platform, comprising subjecting a sample to a purification platform comprising a capture step; a multimodal hydrophobic interaction / ion exchange (MM-HIC / IEX) chromatography step; and a hydrophobic interaction chromatography (HIC) step, thereby reducing the hydrolytic enzyme activity rate of the composition compared to the purification of a sample without the HIC step and / or the MM-HIC / IEX chromatography step.

[0013] In some embodiments, the MM-HIC / IEX chromatography process involves processing via MM-HIC / IEX chromatography medium and is carried out at a pH of about 5.5 to about 8. In some embodiments, the MM-HIC / IEX chromatography process is a multimodal hydrophobic interaction / anion exchange (MM-HIC / AEX) chromatography process. In some embodiments, the MM-HIC / AEX chromatography process involves processing via Capto® Adhere or Capto® Adhere ImpRes. In some embodiments, the MM-HIC / IEX chromatography process is a multimodal hydrophobic interaction / cation exchange (MM-HIC / CEX) chromatography process. In some embodiments, the MM-HIC / CEX chromatography process includes Capto® MMC or Capto® MMC ImpRes.

[0014] In some embodiments, the purification platform includes, in order, a capture step; an MM-HIC / IEX chromatography step; and an HIC step.

[0015] In some embodiments, the method further includes a virus filtration step.

[0016] In some embodiments, the method further includes an ultrafiltration / diafiltration (UF / DF) step.

[0017] In some embodiments, the purification platform includes, in order, a capture step; an MM-HIC / AEX chromatography step; a HIC step; a virus filtration step; and a UF / DF step.

[0018] In some embodiments, the method further includes a depth filtration step.

[0019] In some embodiments, the purification platform includes, in order, a capture step; a depth filtration step; an MM-HIC / AEX chromatography step; and a HIC step. In some embodiments, the depth filtration step includes treatment through a depth filter, and the depth filter is an X0SP depth filter. In some embodiments, the depth filtration step includes treatment through a depth filter, and the depth filter is an EMPHAZE™ depth filter.

[0020] In some embodiments, the depth filter is used as a load filter together with the MM-HIC / AEX chromatography step.

[0021] In some embodiments, the MM-HIC / AEX chromatography step includes treatment through Capto™ Adhere or Capto™ Adhere ImpRes.

[0022] In some embodiments, the purification platform includes, in order, a capture step; an MM-HIC / AEX chromatography step; a depth filtration step; and a HIC step. In some embodiments, the depth filtration step includes treatment through a depth filter, and the depth filter is an X0SP depth filter, a C0SP depth filter, or a D0SP depth filter. In some embodiments, the depth filtration step includes treatment through a depth filter, and the depth filter is an EMPHAZE™ depth filter. In some embodiments, the MM-HIC / AEX chromatography step includes treatment through Capto™ Adhere or Capto™ Adhere ImpRes.

[0023] In another embodiment, a method is provided for reducing the hydrolytic enzyme activity rate of a composition obtained from a purification platform, comprising subjecting a sample to a purification platform comprising a capture step; one or more ion exchange (IEX) chromatography steps; and a hydrophobic interaction chromatography (HIC) step, thereby reducing the hydrolytic enzyme activity rate of the composition compared to the purification of a sample without the HIC step.

[0024] In some embodiments, one or more IEX chromatography steps are cation exchange (CEX) chromatography steps.

[0025] In some embodiments, the method further includes a virus filtration step.

[0026] In some embodiments, the method further includes an ultrafiltration / diafiltration (UF / DF) step.

[0027] In some embodiments, the method further includes a deep filtration step performed at any stage prior to the UF / DF step.

[0028] In some embodiments, the purification platform includes, in order, a capture step; a CEX chromatography step; a HIC step; a virus filtration step; and a UF / DF step.

[0029] In another embodiment, a method is provided for reducing the hydrolytic enzyme activity rate of a composition obtained from a purification platform, comprising subjecting a sample to a purification platform comprising one or more ion exchange (IEX) chromatography steps; hydrophobic interaction chromatography (HIC) steps; and deep filtration steps, thereby reducing the hydrolytic enzyme activity rate of the composition compared to the purification of the sample without the HIC or deep filtration steps. In some embodiments, the reduction is compared to the purification of the sample without the HIC and deep filtration steps.

[0030] In some embodiments, each of the one or more IEX chromatography steps is selected from the group consisting of anion exchange (AEX) chromatography steps, cation exchange (CEX) chromatography steps, and multimodal ion exchange (MMIEX) chromatography steps. In some embodiments, the MMIEX chromatography step includes a multimodal cation exchange / anion exchange (MM-AEX / CEX) chromatography step.

[0031] In some embodiments, the method further includes an ultrafiltration / diafiltration (UF / DF) step.

[0032] In some embodiments, the purification platform includes, in order: a CEX chromatography step; a HIC step; an MMIEX chromatography step; an AEX chromatography step; a deep filtration step; and a UF / DF step.

[0033] In another embodiment, a method is provided for reducing the hydrolytic enzyme activity rate of a composition obtained from a purification platform, comprising subjecting a sample to a purification platform comprising a capture step; one or more ion exchange (IEX) chromatography steps; a multimodal hydrophobic interaction / ion exchange (MM-HIC / IEX) chromatography step; and one or both of a hydrophobic interaction chromatography (HIC) step and a deep filtration step, thereby reducing the hydrolytic enzyme activity rate of the composition compared to the purification of a sample without the HIC step or deep filtration step.

[0034] In some embodiments, the reduction is compared to the purification of the sample without HIC and deep filtration steps.

[0035] In some embodiments, the method further includes a virus filtration step.

[0036] In some embodiments, the method further includes an ultrafiltration / diafiltration (UF / DF) step.

[0037] In some embodiments, the deep filtration step is performed as a load filter for the MM-HIC / IEX chromatography step, as a load filter for the HIC step, or following the HIC step.

[0038] In some embodiments, each of the one or more IEX chromatography steps is selected from the group consisting of cation exchange (CEX) chromatography steps, anion exchange (AEX) chromatography steps, and multimodal ion exchange (MMIEX) chromatography steps.

[0039] In some embodiments, the MM-HIC / IEX chromatography step is a multimodal hydrophobic interaction / anion exchange (MM-HIC / AEX) chromatography step. In some embodiments, the MM-HIC / AEX chromatography step includes processing via Capto® Adhere or Capto® Adhere ImpRes.

[0040] In some embodiments, the capture step includes processing via affinity chromatography. In some embodiments, it is carried out in capture-bound elution mode. In some embodiments, the affinity chromatography is selected from the group consisting of protein A chromatography, protein G chromatography, protein A / G chromatography, FcXL chromatography, protein XL chromatography, kappa chromatography, and kappa XL chromatography.

[0041] In some embodiments, the deep filtration process includes processing through a depth filter. In some embodiments, the depth filter is used as a load filter. In some embodiments, the depth filter includes a substrate comprising one or more of the following: a diatomaceous earth composition, a silica composition, cellulose fibers, polymer fibers, a cohesive resin, and an ash composition. In some embodiments, at least a portion of the substrate of the depth filter includes a surface modification. In some embodiments, the surface modification is one or more of the following: a quaternary amine surface modification (quaternary ammonium, Q-functional, etc.), a guanidinium surface modification, a cationic surface modification, and an anionic surface modification. In some embodiments, the depth filter is selected from the group consisting of X0SP depth filters, D0SP depth filters, C0SP depth filters, EMPHAZE® depth filters, PDD1 depth filters, PDE1 depth filters, PDH5 depth filters, ZETA PLUS® 120ZA depth filters, ZETA PLUS® 120ZB depth filters, ZETA PLUS® DELI depth filters, ZETA PLUS® DELP depth filters, and Polisher ST (salt-resistant) depth filters. In some embodiments, the depth filter is an X0SP depth filter, a D0SP depth filter, or a C0SP depth filter, and the treatment through the depth filter is carried out at a pH of about 4.5 to about 8. In some embodiments, the depth filter is an EMPHAZE® depth filter, and the treatment through the depth filter is carried out at a pH of about 7 to about 9.5. In some embodiments, the depth filter is a Polisher ST depth filter, and processing through the depth filter is carried out at a pH of approximately 5 to approximately 9.

[0042] In some embodiments, the HIC process includes processing via an HIC membrane or HIC column. In some embodiments, the processing via the HIC membrane or HIC column is carried out using a low salt concentration. In some embodiments, the processing via the HIC membrane or HIC column is carried out in flow-through mode. In some embodiments, the HIC membrane or HIC column contains a substrate comprising one or more ether groups, ethyl groups, propyl groups, isopropyl groups, butyl groups, hexyl groups, octyl groups, and phenyl groups. In some embodiments, the HIC membrane or HIC column is selected from the group consisting of Bakerbond WP HI-Propyl®, Phenyl Sepharose® Fast Flow (phenyl-SFF), Phenyl Sepharose® Fast Flow Hi-sub (phenyl-SFF HS), Toyopearl® Hexyl-650C, Toyopearl® Hexyl-650M, Toyopearl® Hexyl-650S, Poros® Benzyl Ultra, and Sartobind® Phenyl. In some embodiments, the processing via the HIC membrane or HIC column is carried out at a pH of about 4.5 to about 7.

[0043] In some embodiments, each of the one or more IEX chromatography steps includes processing via an IEX chromatography membrane or IEX chromatography column. In some embodiments, the IEX chromatography or IEX chromatography column is selected from the group consisting of SPSFF, QSFF, SPXL, Streamline® SPXL, ABx®, Poros® XS, Poros® 50HS, DEAE, DMAE, TMAE, QAE, and MEP-Hypercel®.

[0044] In some embodiments, the purification platform is for purifying the target from the sample, the sample containing the target and one or more host cell impurities. In some embodiments, the target contains a polypeptide. In some embodiments, the target is an antibody moiety. In some embodiments, the antibody moiety is a monoclonal antibody. In some embodiments, the antibody is a human antibody, a humanized antibody, or a chimeric antibody. In some embodiments, the antibody moiety is selected from the group consisting of anti-TAU antibody, anti-TGFβ3 antibody, anti-VEGF-A antibody, anti-CD20 antibody, anti-CD40 antibody, anti-HER2 antibody, anti-IL6 antibody, anti-IgE antibody, anti-IL13 antibody, anti-TIGIT antibody, anti-PD-L1 antibody, anti-VEGF-A / ANG2 antibody, anti-CD79b antibody, anti-ST2 antibody, anti-factor D antibody, anti-factor IX antibody, anti-factor X antibody, anti-abeta antibody, anti-CEA antibody, anti-CEA / CD3 antibody, anti-CD20 / CD3 antibody, anti-FcRH5 / CD3 antibody, anti-Her2 / CD3 antibody, anti-FGFR1 / KLB antibody, FAP-4-1BBL fusion protein, FAP-IL2v fusion protein, and TYRP1 TCB antibody. In some embodiments, the antibody moiety is selected from the group consisting of ocrelizumab, pertuzumab, ranibizumab, trastuzumab, tocilizumab, falisimab, polatuzumab, gantenerumab, sibisatamab, crenezumab, mosnetuzumab, tilagolmab, bevacizumab, rituximab, atezolizumab, obinutuzumab, lamparizumab, omalizumab, ranibizumab, emicizumab, sericrelumab, pracinezumab, RO6874281, and RO7122290.

[0045] In some embodiments, one or more host cell impurities include host cell proteins. In some embodiments, the host cell proteins are hydrolases. In some embodiments, the hydrolases are lipases, esterases, thioesterases, phospholipases, carboxylesterases, hydrolases, cutinases, or ceramidases.

[0046] In some embodiments, the sample comprises host cells or components derived therefrom. In some embodiments, the sample is a cell culture sample or derived from a cell culture sample. In some embodiments, the cell culture sample comprises host cells, which are Chinese hamster ovary (CHO) cells or E. coli cells.

[0047] In some embodiments, the method further includes a sample processing step.

[0048] In some embodiments, the reduction in hydrolase activity rate is at least about 20%.

[0049] In some embodiments, the method further includes determining the hydrolytic enzyme activity rate of the composition.

[0050] In some embodiments, the method further includes determining the level of one or more hydrolytic enzymes in the composition.

[0051] In some embodiments, the composition includes a polysorbate. In some embodiments, the polysorbate is selected from the group consisting of polysorbate 20, polysorbate 40, polysorbate 60, and polysorbate 80.

[0052] In another embodiment, pharmaceutical compositions obtained from the method described herein are provided.

[0053] In another embodiment, a formulated antibody partial composition comprising an antibody moiety and a polysorbate is provided, wherein the rate of polysorbate hydrolysis is reduced and the composition has a shelf life of more than 12 months.

[0054] In another embodiment, a formulated antibody partial composition is provided, comprising an antibody moiety and a polysorbate, wherein the rate of polysorbate hydrolysis activity is reduced, and the shelf life of the composition is extended compared to the shelf life indicated in a document submitted to the health authorities relating to the formulated antibody partial composition, the shelf life being extended by at least three months compared to the shelf life indicated in the document.

[0055] In some embodiments, the rate of polysorbate hydrolysis is reduced by at least about 20%.

[0056] In another embodiment, a formulated antibody partial composition is provided, comprising an antibody moiety, wherein the degradation of the polysorbate is reduced, such degradation being at least about 20% less than the degradation described in the documentation submitted to the health authorities relating to the formulated antibody partial composition.

[0057] In another embodiment, a formulated antibody partial composition is provided, comprising an antibody portion and a polysorbate, wherein the polysorbate is degraded by 50% or less per year during storage of the liquid composition.

[0058] In some embodiments, the antibody portion is a monoclonal antibody. In some embodiments, the antibody is a human antibody, a humanized antibody, or a chimeric antibody. In some embodiments, the antibody portion is selected from the group consisting of anti-TAU antibody, anti-TGFβ3 antibody, anti-VEGF-A antibody, anti-CD20 antibody, anti-CD40 antibody, anti-HER2 antibody, anti-IL6 antibody, anti-IgE antibody, anti-IL13 antibody, anti-TIGIT antibody, anti-PD-L1 antibody, anti-VEGF-A / ANG2 antibody, anti-CD79b antibody, anti-ST2 antibody, anti-factor D antibody, anti-factor IX antibody, anti-factor X antibody, anti-abeta antibody, anti-CEA antibody, anti-CEA / CD3 antibody, anti-CD20 / CD3 antibody, anti-FcRH5 / CD3 antibody, anti-Her2 / CD3 antibody, anti-FGFR1 / KLB antibody, FAP-4-1BBL fusion protein, FAP-IL2v fusion protein, and TYRP1 TCB antibody. In some embodiments, the antibody portion is selected from the group consisting of ocrelizumab, pertuzumab, ranibizumab, trastuzumab, tocilizumab, falisimab, polatuzumab, gantenerumab, cibisatamab, crenezumab, mosnetuzumab, tilagolmab, bevacizumab, rituximab, atezolizumab, obinutuzumab, lamparizumab, omalizumab, ranibizumab, emicizumab, sericrelumab, pracinezumab, RO6874281, and RO7122290.

[0059] In some embodiments, the polysorbate is selected from the group consisting of polysorbate 20, polysorbate 40, polysorbate 60, and polysorbate 80.

[0060] Those skilled in the art will recognize that several embodiments are possible within the scope and spirit of the present invention. The present disclosure is further illustrated by the following embodiments, but these embodiments should not be construed as limiting the scope or spirit of the present disclosure to the specific procedures described therein. [Brief explanation of the drawing]

[0061] [Figure 1A-1E] Figures 1A–1E show schematic diagrams of exemplary purification platforms described herein.

[0062] [Figure 2] Figure 2 shows bar graphs of the hydrolytic activity (normalized to control) of compositions obtained from an exemplary purification platform. The hydrolytic activity rate was measured using a FAMS assay.

[0063] [Figure 3] Figure 3 shows a bar graph of the hydrolytic activity (normalized to control) of compositions obtained from an exemplary purification platform. The hydrolytic activity rate was measured using a FAMS assay.

[0064] [Figure 4] Figure 4 shows a bar graph of the hydrolytic activity (normalized to control) of compositions obtained from an exemplary purification platform. The hydrolytic activity rate was measured using a FAMS assay.

[0065] [Figure 5] Figure 5 shows a bar graph of the hydrolytic activity (normalized to control) of compositions obtained from an exemplary purification platform. The hydrolytic activity rate was measured using a FAMS assay.

[0066] [Figure 6] Figure 6 shows a bar graph of the hydrolytic activity (normalized to control) of compositions obtained from an exemplary purification platform. The hydrolytic activity rate was measured using a FAMS assay.

[0067] [Figure 7] Figure 7 shows a bar graph of the hydrolytic activity (normalized to control) of compositions obtained from an exemplary purification platform. The hydrolytic activity rate was measured using a FAMS assay. [Modes for carrying out the invention]

[0068] Detailed explanation In some embodiments, this application provides a method for purifying a target from a sample containing the target, comprising subjecting the sample to a purification platform disclosed herein, which includes one or more deep filtration steps and / or one or more hydrophobic interaction chromatography (HIC) steps and / or one or more multimodal hydrophobic interaction / ion exchange (MM-HIC / IEX) chromatography steps. In some embodiments, the purified target is for use in a pharmaceutical composition. In some embodiments, the target is a polypeptide, such as a recombinant polypeptide, e.g., an antibody moiety.

[0069] This disclosure is based, at least in part, on an unexpected finding that a purification platform comprising one or more deep filtration steps and / or one or more HIC steps and / or one or more MM-HIC / IEX chromatography steps reduces the hydrolytic enzyme activity rate of compositions obtained therefrom compared to compositions obtained from a purification platform that does not comprise one or more deep filtration steps and / or one or more HIC steps and / or MM-HIC / IEX chromatography steps. The unexpected finding demonstrates that the purification platform described herein is particularly useful for purifying targets produced by host cells. As discussed herein, certain host cell proteins and impurities, including host cell hydrolases, may tend to co-purify with targets. Such host cell hydrolases may degrade targets and / or additives added to targets that are useful for preparing and formulating their compositions. The demonstrated reduction in hydrolytic enzyme activity rate in compositions obtained from the purification platform described herein ensures that additives in the target composition, such as surfactants, such as polysorbates, are not degraded by host cell impurities, thereby improving the stability of the target and the shelf life of the composition.

[0070] Accordingly, in some embodiments, a method is provided for reducing the hydrolytic enzyme activity rate of a composition obtained from a purification platform, comprising supplying a sample to a purification platform comprising a capture step; one or more ion exchange (IEX) chromatography steps; and a deep filtration step, thereby reducing the hydrolytic enzyme activity rate of the composition compared to the purification of a sample without the deep filtration step.

[0071] In another embodiment, a method is provided for reducing the hydrolytic enzyme activity rate of a composition obtained from a purification platform, comprising subjecting a sample to a purification platform comprising a capture step; a multimodal hydrophobic interaction / ion exchange (MM-HIC / IEX) chromatography step; and a hydrophobic interaction chromatography (HIC) step, thereby reducing the hydrolytic enzyme activity rate of the composition compared to the purification of a sample without the HIC step and / or the MM-HIC / IEX chromatography step.

[0072] In another embodiment, a method is provided for reducing the hydrolytic enzyme activity rate of a composition obtained from a purification platform, comprising subjecting a sample to a purification platform comprising a capture step; one or more ion exchange (IEX) chromatography steps; and a hydrophobic interaction chromatography (HIC) step, thereby reducing the hydrolytic enzyme activity rate of the composition compared to the purification of a sample without the HIC step.

[0073] In another embodiment, a method is provided for reducing the hydrolytic enzyme activity rate of a composition obtained from a purification platform, comprising subjecting a sample to a purification platform comprising one or more ion exchange (IEX) chromatography steps; hydrophobic interaction chromatography (HIC) steps; and deep filtration steps, thereby reducing the hydrolytic enzyme activity rate of the composition compared to the purification of a sample without the HIC step or deep filtration step.

[0074] In another embodiment, a method is provided for reducing the hydrolytic enzyme activity rate of a composition obtained from a purification platform, comprising subjecting a sample to a purification platform comprising a capture step; one or more ion exchange (IEX) chromatography steps; a multimodal hydrophobic interaction / ion exchange (MM-HIC / IEX) chromatography step; and one or both of a hydrophobic interaction chromatography (HIC) step and a deep filtration step, thereby reducing the hydrolytic enzyme activity rate of the composition compared to the purification of a sample without the HIC step or the deep filtration step and / or the MM-HIC / IEX chromatography step.

[0075] In other embodiments, pharmaceutical compositions obtained from the methods described herein are provided herein.

[0076] In another embodiment, a formulated antibody moiety composition comprising an antibody moiety and a polysorbate is provided herein, wherein the rate of polysorbate hydrolysis is reduced and the composition has a shelf life of more than 12 months.

[0077] In another embodiment, a formulated antibody partial composition comprising an antibody portion and a polysorbate is provided, wherein the rate of polysorbate hydrolysis is reduced, and the shelf life of the composition is extended compared to the shelf life indicated in a document submitted to a health authority relating to the formulated antibody partial composition, the shelf life being extended by at least three months compared to the shelf life indicated in the document.

[0078] In another embodiment, a formulated antibody partial composition is provided, comprising an antibody moiety, wherein the formulated antibody partial composition exhibits reduced polysorbate degradation, the degradation being reduced by at least about 50% compared to the degradation described in the documentation submitted to the health authorities relating to the formulated antibody partial composition.

[0079] In another embodiment, a formulated antibody partial composition is provided, comprising an antibody portion and a polysorbate, wherein the polysorbate is degraded by 50% or less per year during storage of the liquid composition.

[0080] Those skilled in the art will understand that modifications to the forms and details of the embodiments described herein can be made without departing from the scope of this disclosure. Furthermore, although various advantages, aspects, and objectives have been described with reference to various embodiments, the scope of this disclosure should not be limited by reference to such advantages, aspects, and objectives.

[0081] I. Definition For the purposes of interpreting this Spec., the following definitions shall apply, and wherever appropriate, a term used in the singular form shall also include the plural form, and conversely, a term used in the plural form shall also include the singular form. In the event of any conflict between any of the following definitions and any document incorporated herein by reference, the following definition shall prevail.

[0082] The term “antibody portion” includes the full-length antibody and its antigen-binding fragment. In some embodiments, the full-length antibody comprises two heavy chains and two light chains. The variable regions of the light and heavy chains are responsible for antigen binding. The variable regions of both chains generally contain three highly variable loops called complementarity-determining regions (CDRs) (light chain (LC)CDRs including LC-CDR1, LC-CDR2, and LC-CDR3; heavy chain (HC)CDRs including HC-CDR1, HC-CDR2, and HC-CDR3). The CDR boundaries of the antibodies and antigen-binding fragments disclosed herein may be defined or identified by the conventions of Kabat, Chothia, or Al-Lazikani (Al-Lazikani 1997; Chothia 1985; Chothia 1987; Chothia 1989; Kabat 1987; Kabat 1991). The three CDRs of the heavy or light chain are more conserved than the CDRs themselves and interpose between adjacent stretches known as framework regions (FRs) that form a scaffold for supporting the hypervariable loop. The constant regions of the heavy and light chains do not participate in antigen binding but exhibit various effector functions. Antibodies are assigned to classes based on the amino acid sequence of the constant region of their heavy chain. The five major classes or isotypes of antibodies are IgA, IgD, IgE, IgG, and IgM, characterized by the presence of α, δ, ε, γ, and μ heavy chains, respectively. Some of the major antibody classes are divided into subclasses such as IgG1 (γ1 heavy chain), IgG2 (γ2 heavy chain), IgG3 (γ3 heavy chain), IgG4 (γ4 heavy chain), IgA1 (α1 heavy chain), or IgA2 (α2 heavy chain). In some embodiments, the antibody is a chimeric antibody. In some embodiments, the antibody is a semi-synthetic antibody. In some embodiments, the antibody moiety is a diabody. In some embodiments, the antibody moiety is a humanized antibody. In certain embodiments, the antibody is a multispecific antibody, such as a bispecific antibody. In some embodiments, the antibody moiety is linked to a fusion protein. In some embodiments, the antibody moiety is bound to an immunostimulatory protein such as an interleukin. In some embodiments, the antibody moiety is linked to a protein that facilitates entry across the blood-brain barrier.

[0083] As used herein, the term “antigen-binding fragment” refers to an antibody fragment that includes, for example, a diabody, Fab, Fab', F(ab')2, Fv fragment, disulfide-stabilized Fv fragment (dsFv), (dsFv)2, bispecific dsFv (dsFv-dsFv'), disulfide-stabilized diabody (dsdiabody), single-chain antibody molecule (scFv), scFv dimer (bivalent diabody), multispecific antibody formed from a portion of an antibody containing one or more CDRs, camelized single-domain antibody, nanobody, domain antibody, bivalent domain antibody, or any other antibody fragment that binds to an antigen but does not contain a complete antibody structure. An antigen-binding fragment may bind to the same antigen to which a parent antibody or parent antibody fragment (e.g., parent scFv) binds. In some embodiments, an antigen-binding fragment may include one or more CDRs derived from a particular human antibody grafted onto a framework region derived from one or more different human antibodies.

[0084] The term "chimeric antibody" refers to an antibody in which a portion of the heavy chain and / or light chain is identical or homologous to a corresponding sequence in an antibody originating from a particular species or belonging to a particular antibody class or subclass, while the remainder of the chain(s) is identical or homologous to a corresponding sequence in an antibody originating from another species or belonging to another antibody class or subclass, and includes fragments of such antibodies insofar as they exhibit the desired biological activity (see, for example, U.S. Patent No. 4,816,567 and Morrison et al., Proc. Natl. Acad. Sci. USA, 81:6851-6855 (1984)).

[0085] The term "multispecific antibody," as used herein, refers to a monoclonal antibody that has binding specificity to at least two different sites, i.e., different epitopes on different antigens or different epitopes on the same antigen. In certain embodiments, a multispecific antibody has two binding specificities (a bispecific antibody). In certain embodiments, a multispecific antibody has three or more binding specificities. Multispecific antibodies can be prepared as full-length antibodies or antibody fragments.

[0086] The term "semi-synthetic" with respect to an antibody or antibody moiety means that the antibody or antibody moiety has one or more naturally occurring sequences and one or more unnaturally occurring (i.e., synthetic) sequences.

[0087] "Fv" refers to the smallest antibody fragment containing a complete antigen recognition and binding site. This fragment consists of a dimer in which one heavy chain variable domain and one light chain variable domain are tightly bound noncovalently. The folding of these two domains creates six hypervariable loops (three from the heavy chain and three from the light chain) that provide amino acid residues for antigen binding and give the antibody antigen-binding specificity. However, even a single variable domain (or half of an Fv containing only three antigen-specific CDRs) has the ability to recognize and bind to an antigen, albeit with lower affinity than the entire binding site.

[0088] A "single-stranded Fv," also abbreviated as "sFv" or "scFv," is an antibody fragment containing VH and VL antibody domains linked to a single polypeptide chain. In some embodiments, the scFv polypeptide further includes a polypeptide linker between the VH and VL domains, which allows the scFv to form a structure desirable for antigen binding. For an overview of scFv, see, for example, Pluckthun in The Pharmacology of Monoclonal Antibodies, vol. 113, edited by Rosenburg and Moore, Springer-Verlag, New York, pp. 269–315 (1994).

[0089] The term "diabody" refers to a small antibody fragment prepared by constructing an scFv fragment (see previous paragraph) between the VH and VL domains with a short linker (approximately 5-10 residues) such that interchain pairing, rather than intrachain pairing, is achieved in the V domain, resulting in a bivalent fragment, i.e., a fragment having two antigen-binding sites. A bispecific diabody is a heterodimer of two "cross-reacting" scFv fragments in which the VH and VL domains of two antibodies reside on different polypeptide chains. Diabodies are described in more detail, for example, European Patent No. 404,097, International Publication No. 93 / 11161, and Hollinger et al., Proc. Natl. Acad. Sci. USA, 90:6444-6448 (1993).

[0090] The "humanized" form of a non-human (e.g., rodent) antibody is a chimeric antibody that contains a minimal amount of sequences derived from the non-human antibody. Mostly, a humanized antibody is a human immunoglobulin (recipient antibody) in which residues from the recipient's hypervariable region are replaced by residues from the hypervariable region of a non-human species (donor antibody), such as mouse, rat, rabbit, or non-human primate, possessing the desired antibody specificity, affinity, and capabilities. In some cases, residues in the framework region (FR) of the human immunoglobulin are replaced by corresponding non-human residues. Furthermore, humanized antibodies may contain residues not found in the recipient or donor antibody. These modifications are made to further refine antibody performance. Generally, a humanized antibody contains substantially all of at least one, typically two, variable domains; all, or substantially all, of the hypervariable loops correspond to the hypervariable loops of the non-human immunoglobulin; and all, or substantially all, of the FRs are FRs of the human immunoglobulin sequence. Humanized antibodies also optionally include the constant region (Fc) of immunoglobulins, typically at least a portion of the constant region of human immunoglobulins. For further details, see, for example, Jones et al., Nature, 321:522-525 (1986), Riechmann et al., Nature 332:323-329 (1988), and Presta, Curr. Op. Struct. Biol. 2:593-596 (1992).

[0091] As used herein, the terms “comprising,” “having,” “containing,” and “including,” as well as their grammatical equivalents, are semantically equivalent and open-ended in that the one or more items following any one of these words do not mean an exhaustive list of such one or more items, nor do they mean that the list is limited to only the one or more items. For example, an article “comprising” components A, B, and C may consist of (i.e., contain only) components A, B, and C, or it may also contain one or more other components in addition to components A, B, and C. Accordingly, “comprises” and its similar forms, as well as their grammatical equivalents, are intended and understood to include disclosures of embodiments of “consisting essentially of” or “consisting of.”

[0092] Where a range of values ​​is provided, unless explicitly indicated in the context, each intervening value up to one-tenth of the lower limit between the upper and lower limits of that range, and any other stated values ​​or intervening values ​​within that stated range, are understood to be included in this disclosure, subject to any specifically excluded limitations within the stated range. If the stated range includes one or both limits, the range excluding either or both of those included limits is also included in this disclosure.

[0093] In this specification, any reference to a value or parameter using the term "about" includes (and describes) a variation relating to that value or parameter itself. For example, a statement referring to "about X" includes a statement of "X".

[0094] When used herein and in the appended claims, the singular forms "a," "or," and "the" refer to multiple subjects unless the context otherwise explicitly indicates.

[0095] II. Purification Platform and Process In some embodiments, purification platforms designed for purifying targets from a sample are provided herein, comprising one or more deep filtration steps and / or one or more HIC steps and / or one or more multimodal hydrophobic interaction chromatography / ion exchange (MM-HIC / IEX) chromatography steps. The described purification platforms are useful for obtaining purified compositions with reduced hydrolytic enzyme activity rates compared to the purification of a sample without deep filtration steps and / or HIC steps and / or one or more MM-HIC / IEX chromatography steps. In some embodiments, the purification platform comprises a deep filtration step. In some embodiments, the purification platform comprises an HIC step. In some embodiments, the purification platform comprises a deep filtration step and an HIC step. In some embodiments, the purification platform further comprises one or more additional steps, each selected from an ion exchange (IEX) chromatography step, an MM-HIC / IEX chromatography step, a capture step, a viral filtration step, an ultrafiltration / diafiltration (UFDF) step, and a conditioning step.

[0096] In some embodiments, the purification platform represents a workflow for purifying a target from a sample containing the target to any degree. In some examples of this disclosure, descriptions of the components and features of the purification platform, as well as how to use them, are provided in a modular manner. Those skilled in the art will readily understand that such disclosures do not mean to limit the scope of this application, and that this disclosure encompasses numerous arrangements of the purification platform or its features that are included herein. For example, in some embodiments, it can be readily understood that certain types of chromatographic media are included in the description of the purification platform as encompassing a genus of chromatographic media. Specific features and embodiments of the purification platform included herein, such as methods for carrying out its steps, are described in PCT / US2020 / 031164, which is incorporated herein by reference in its entirety.

[0097] Furthermore, those skilled in the art will recognize that certain chromatographic media described herein may have two or more distinct features that define the interaction between the medium and components such as targets. For example, a multimodal HIC / IEX chromatographic medium may have ligands that have both hydrophobic and electrostatic interaction features. The descriptions of chromatographic media in the following sections are not limited to the types of features that may be present thereon.

[0098] A.Depth filtration process In some embodiments, the purification platform described herein includes a deep filtration step. As described herein, the deep filtration step may be located at one or more positions within the purification platform. In some embodiments, the purification platform described herein includes one or more deep filtration steps, e.g., two, three, four, or five deep filtration steps, located at any stage of the process workflow. In some embodiments where the purification platform includes two or more deep filtration steps, the deep filtration steps are not performed directly and sequentially, i.e., no intervening steps of the purification platform are performed between the deep filtration steps. In some embodiments where the purification platform includes two or more deep filtration steps, the deep filtration steps are the same. In some embodiments where the purification platform includes two or more deep filtration steps, the deep filtration steps are different, e.g., including the use of different depth filters.

[0099] In some embodiments, the deep filtration step is used as load filtration in combination with another aspect of the purification platform. In some embodiments, the use of the term “step” in “deep filtration step” does not exclude the purification platform in which the deep filtration feature of the purification platform is directly combined with another feature, for example, the deep filtration eluate flows directly into a subsequent feature or step of the purification platform.

[0100] Deep filtration processes, including those involving processing via depth filters, are known in the art. See, for example, Yigzaw et al., Biotechnol Prog, 22, 2006, and Liu et al., mAbs, 2, 2010, which are incorporated herein by reference in their entirety. Based on the latest art and the disclosure herein, those skilled in the art will understand the components, conditions, and reagents involved in carrying out deep filtration processes.

[0101] In some embodiments, the deep filtration process includes processing through a depth filter. In some embodiments, the depth filter includes a porous filter medium capable of holding a portion of the sample, such as cellular components and debris, and filtration is carried out, for example, within the depth of the filter material. In some embodiments, the depth filter includes synthetic materials, non-synthetic materials, or a combination thereof. In some embodiments, the depth filter includes a substrate comprising one or more of the following: diatomaceous earth composition, silica composition, cellulose fibers, polymer fibers, polyacrylic fibers, agglomerating resin, synthetic particles, ion-charged resin, and ash composition. In some embodiments, the depth filter includes diatomaceous earth. In some embodiments, the depth filter includes an anion exchange medium. In some embodiments, the depth filter includes a hydrophobic interaction medium. In some embodiments, at least a portion of the substrate of the depth filter includes a surface modification. In some embodiments, the surface modification is one or more of the following: quaternary amine surface modification (quaternary ammonium, Q-functional, etc.), guanidinium surface modification, cationic surface modification, anionic surface modification, and hydrophobic modification. In some embodiments, the surface modification includes a ligand having one or more features designed to facilitate interaction with another component, such as a target, and such features may include, for example, moieties involved in hydrogen bonding, hydrophilic interactions, hydrophobic interactions, and ionic interactions (cations and anions).

[0102] In some embodiments, the deep filtration process is configured to be carried out at a predetermined pH or range, for example, the input material having a predetermined pH or range. In some embodiments, the deep filtration process is configured to be carried out when the input material has a pH of about 4.5 to about 9.5, for example, about 4.5 to about 7, about 5 to about 6, about 5 to about 5.5, about 7 to about 9.5, about 4.5 to about 9, about 5 to about 8.5, or about 7.5 to about 8.5. In some embodiments, the deep filtration step is configured to be performed when the input material has a pH of at least about 4.5, for example, at least about 4.6, 4.7, 4.8, 4.9, 5, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 6, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, 7, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, 8, 8.1, 8.2, 8.3, 8.4, 8.5, 8.6, 8.7, 8.8, 8.9, 9, 9.1, 9.2, 9.3, 9.4, or 9.5. In some embodiments, the deep filtration step is configured to be performed when the input material has a pH lower than, for example, about 9.5, such as about 9.4, 9.3, 9.2, 9.1, 9, 8.9, 8.8, 8.7, 8.6, 8.5, 8.4, 8.3, 8.2, 8.1, 8, 7.9, 7.8, 7.7, 7.6, 7.5, 7.4, 7.3, 7.2, 7.1, 7, 6.9, 6.8, 6.7, 6.6, 6.5, 6.4, 6.3, 6.2, 6.1, 6, 5.9, 5.8, 5.7, 5.6, 5.5, 5.4, 5.3, 5.2, 5.1, 5, 4.9, 4.8, 4.7, 4.6, or 4.5. In some embodiments, the deep filtration step is configured to be performed when the input material has a pH of, for example, approximately 4.5, 4.6, 4.7, 4.8, 4.9, 5, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 6, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, 7, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, 8, 8.1, 8.2, 8.3, 8.4, 8.5, 8.6, 8.7, 8.8, 8.9, 9, 9.1, 9.2, 9.3, 9.4, or 9.5.

[0103] In some embodiments, the depth filter is selected from the group consisting of X0SP depth filter, D0SP depth filter, C0SP depth filter, EMPHAZE® depth filter, PDD1 depth filter, PDE1 depth filter, PDH5 depth filter, ZETA PLUS® 120ZA depth filter, ZETA PLUS® 120ZB depth filter, ZETA PLUS® DELI depth filter, and ZETA PLUS® DELP depth filter.

[0104] In some embodiments, the depth filter includes a silica material, such as a silica filter aid, with or without polyacrylic fibers. In some embodiments, the depth filter includes two or more layers of filter media, the first layer containing a silica material, such as a silica filter aid, and the second layer containing polyacrylic fibers, such as polyacrylic fiber pulp. In some embodiments, the depth filter is a depth filter containing synthetic materials and does not contain diatomaceous earth and / or perlite. In some embodiments, the depth filter is an X0SP depth filter. In some embodiments, the depth filter is a D0SP depth filter. In some embodiments, the depth filter is a C0SP depth filter.

[0105] In some embodiments, the silica filter aid is a precipitated silica filter aid. In some embodiments, the filter aid is a form of filter, such as a layer that helps perform the filtering function. In some embodiments, the silica filter aid is a silica gel filter aid. In some embodiments, the silica filter aid has about 50% silanol ionized at pH 7. In some embodiments, the silica filter aid is a silica gel filter aid, and about 50% of the silanol in the silica filter aid is ionized at pH 7. In some embodiments, the silica filter aid precipitates from silica such as SIPERNAT® (Evonik Industries AG) or silica such as Kieseigel 60 (Merck KGaA). In some embodiments, the polyacrylic fiber is a nonwoven polyacrylic fiber pulp. In some embodiments, the polyacrylic fiber is an electrospun polyacrylic nanofiber. In some embodiments, the degree of fibrillation of the polyacrylic fiber correlates with the Canadian standard filtration capacity (CSF) of about 10 mL to about 800 mL. In some embodiments, the depth filter has a pore size of about 0.05 μm to about 0.2 μm, for example, about 0.1 μm. 2 ~about 1.5m 2 For example, approximately 0.11m 2 , about 0.55m 2 ,0.77m 2 , or approximately 1.1m 2 It has a surface area. In some embodiments, the depth filter does not contain diatomaceous earth and / or perlite. In some embodiments, the depth filter comprises two layers of filter media, the first layer comprising a silica filter aid having about 50% silanol ionized at pH 7, and the second layer comprising polyacrylic fiber pulp having a degree of fibrillation of polyacrylic fibers that correlates with a Canadian standard filtration capacity (CSF) of about 10 mL to about 800 mL, and the depth filter does not contain diatomaceous earth.

[0106] In some embodiments, the depth filter comprises silica, such as a silica filter aid, and polyacrylic fibers, such as an X0SP depth filter, a C0SP depth filter, or a D0SP depth filter, and the deep filtration process is configured to be performed when the input material has a pH of, for example, about 4.5 to about 8, about 5 to about 6, about 5.3 to about 5.7, or about 7.3 to about 7.7. In some embodiments, the depth filter comprises silica, such as a silica filter aid, and polyacrylic fibers, such as an X0SP depth filter, a C0SP depth filter, or a D0SP depth filter, and the deep filtration process is configured to be carried out when the input material has a pH of at least about 4.5, for example, at least about 4.6, 4.7, 4.8, 4.9, 5, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 6, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, 7, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, or 8. In some embodiments, the depth filter comprises silica, such as a silica filter aid, and polyacrylic fibers, such as an X0SP depth filter, a C0SP depth filter, or a D0SP depth filter, and the deep filtration process is configured to be carried out when the input material has a pH less than about 8, for example, less than about 7.9, 7.8, 7.7, 7.6, 7.5, 7.4, 7.3, 7.2, 7.1, 7, 6.9, 6.8, 6.7, 6.6, 6.5, 6.4, 6.3, 6.2, 6.1, 6, 5.9, 5.8, 5.7, 5.6, 5.5, 5.4, 5.3, 5.2, 5.1, 5, 4.9, 4.8, 4.7, 4.6, or 4.5.In some embodiments, the depth filter comprises silica, such as a silica filter aid, and polyacrylic fibers, such as an X0SP depth filter, a C0SP depth filter, or a D0SP depth filter, and the deep filtration process is configured to be carried out when the input material has a pH of, for example, about 4.5, 4.6, 4.7, 4.8, 4.9, 5, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 6, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, 7, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, or 8.

[0107] In some embodiments, the depth filter comprises a hydrogel Q (quaternary amine, also called quaternary ammonium) functionalized nonwoven fabric material and a multizone microporous membrane. In some embodiments, the depth filter comprises four layers comprising the hydrogel Q functionalized nonwoven fabric material and a 9-zone microporous membrane. In some embodiments, the nonwoven fabric material comprises polypropylene. In some embodiments, the depth filter is a depth filter comprising synthetic materials and does not contain diatomaceous earth and / or perlite. In some embodiments, the depth filter is an EMPHAZE® depth filter, e.g., an EMPHAZE® AEX depth filter.

[0108] In some embodiments, the depth filter comprises multiple components or layers. In some embodiments, the depth filter comprises multiple layers, each comprising one or more layers comprising an anion exchange (AEX) functionalized polymer. In some embodiments, the layer comprising the AEX functionalized polymer comprises quaternary ammonium (Q), such as a Q functionalized hydrogel. In some embodiments, the layer comprising the AEX functionalized polymer comprises a quaternary ammonium (Q) functionalized polymer associated with a nonwoven article. In some embodiments, the layer comprising the AEX functionalized polymer comprises a quaternary ammonium (Q) functionalized hydrogel covalently grafted onto a microfiber polypropylene nonwoven scaffold. In some embodiments, the depth filter comprises multiple layers, each comprising a layer comprising a multizone membrane, each comprising a 9-zone membrane having a pore size of about 0.05 μm to about 0.3 μm, for example, about 0.22 μm. In some embodiments, the depth filter does not contain diatomaceous earth.

[0109] In some embodiments, the depth filter comprises a hydrogel Q (quaternary amine, also called quaternary ammonium) functionalized nonwoven material such as EMPHAZE® AEX depth filter, and the deep filtration process is configured to be carried out when the input material has a pH of about 7 to about 9.5, for example, about 7.5 to about 8.5 or about 7.8 to about 8.2. In some embodiments, the depth filter comprises a hydrogel Q (quaternary amine, also called quaternary ammonium) functionalized nonwoven material such as EMPHAZE® Depth, and the deep filtration process is configured such that the input material is carried out at a pH of at least about 7, for example, at least about 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, 8, 8.1, 8.2, 8.3, 8.4, 8.5, 8.6, 8.7, 8.8, 8.9, 9, 9.1, 9.2, 9.3, 9.4, or 9.5. In some embodiments, the depth filter comprises a hydrogel Q (quaternary amine, also called quaternary ammonium) functionalized nonwoven material such as EMPHAZE® AEX depth filter, and the deep filtration process is configured to be carried out when the input material has a pH less than about 9.5, for example, less than any of the following: about 9.4, 9.3, 9.2, 9.1, 9, 8.9, 8.8, 8.7, 8.6, 8.5, 8.4, 8.3, 8.2, 8.1, 8, 7.9, 7.8, 7.7, 7.6, 7.5, 7.4, 7.3, 7.2, 7.1, or 7. In some embodiments, the depth filter comprises a hydrogel Q (quaternary amine, also called quaternary ammonium) functionalized nonwoven material such as EMPHAZE® AEX depth filter, and the deep filtration process is configured to be performed when the input material has a pH of, for example, about 7, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, 8, 8.1, 8.2, 8.3, 8.4, 8.5, 8.6, 8.7, 8.8, 8.9, 9, 9.1, 9.2, 9.3, 9.4, or 9.5.

[0110] In some embodiments, the depth filter comprises a Q (quaternary amine, also called quaternary ammonium) functionalized nonwoven fabric material and a Gu (guanidinium) functionalized film. In some embodiments, the Q functionalized nonwoven fabric material consists of one or more layers, for example, one, two, or three. In some embodiments, the Gu functionalized film consists of one or more layers, for example, one, two, three, or four. In some embodiments, the depth filter comprises three layers of the Q functionalized nonwoven fabric material and four layers of the Gu functionalized film. In some embodiments, the nonwoven fabric material is polypropylene. In some embodiments, the Gu functionalized film is a polyamide film. In some embodiments, the depth filter is a Polisher ST depth filter. In some embodiments, the depth filter comprises a Q-functionalized nonwoven fabric material and a Gu-functionalized membrane such as a Polisher ST depth filter, and the depth filtering process using the depth filter is configured to be carried out when the input material has a pH of, for example, about 4.5, 4.6, 4.7, 4.8, 4.9, 5.0, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, 7.0, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, 8.0, 8.1, 8.2, 8.3, 8.4, 8.5, 8.6, 8.7, 8.8, 8.9, or 9.0.

[0111] In some embodiments, the depth filter comprises a Q (quaternary amine, also known as quaternary ammonium)-functionalized nonwoven fabric material and a Gu (guanidinium)-functionalized membrane such as a Polisher ST depth filter, and the deep filtration process is configured to be carried out when the input material has a pH of about 4.5 to about 9, for example, about 5 to about 8 or about 7 to about 9. In some embodiments, the depth filter comprises a Q (quaternary amine, also known as quaternary ammonium)-functionalized nonwoven fabric material and a Polisher The deep filtration process includes a Gu (guanidinium) functionalized membrane such as an ST depth filter, and is configured to be carried out when the input material has a pH of at least about 4.5, for example, at least about 4.6, 4.7, 4.8, 4.9, 5.0, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, 7.0, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, 8.0, 8.1, 8.2, 8.3, 8.4, 8.5, 8.6, 8.7, 8.8, 8.9, or 9.0. In some embodiments, the depth filter is a Q (quaternary amine, also called quaternary ammonium) functionalized nonwoven fabric material, and Polisher The deep filtration process is configured to be carried out when the input material has a pH less than approximately 9.0, for example, less than any of the following: approximately 8.9, 8.8, 8.7, 8.6, 8.5, 8.4, 8.3, 8.2, 8.1, 8, 7.9, 7.8, 7.7, 7.6, 7.5, 7.4, 7.3, 7.2, 7.1, 7, 6.9, 6.8, 6.7, 6.6, 6.5, 6.4, 6.3, 6.2, 6.1, 6.0, 5.9, 5.8, 5.7, 5.6, 5.5, 5.4, 5.3, 5.2, 5.1, 5.0, 4.9, 4.8, 4.7, 4.6, or 4.5.In some embodiments, the depth filter is a Q (quaternary amine, also called quaternary ammonium) functionalized nonwoven fabric material, and Polisher The deep filtration process includes a Gu (guanidinium) functionalized membrane such as an ST depth filter, and is configured to be carried out when the input material has a pH of approximately 4.5, 4.6, 4.7, 4.8, 4.9, 5.0, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, 7.0, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, 8.0, 8.1, 8.2, 8.3, 8.4, 8.5, 8.6, 8.7, 8.8, 8.9, or 9.0.

[0112] In some embodiments, the depth filter comprises cellulose fibers, diatomaceous earth, and perlite. In some embodiments, the depth filter comprises two layers, each comprising a cellulose filter matrix, the cellulose filter matrix being impregnated with a filter aid comprising one or more diatomaceous earth or perlite. In some embodiments, the depth filter comprises two layers, each comprising a cellulose filter matrix, the cellulose filter matrix being impregnated with a filter aid comprising one or more diatomaceous earth or perlite, and each layer further comprising a resin binder. In some embodiments, the depth filter is a PDD1 depth filter. In some embodiments, the depth filter is a PDE1 depth filter. In some embodiments, the depth filter is a PDH5 depth filter.

[0113] B.HIC process In some embodiments, the purification platform described herein includes HIC steps. As described herein, HIC steps may be located at any one or more positions within the purification platform. In some embodiments, the purification platform described herein includes one or more HIC steps, e.g., two, three, four, or five HIC steps, located at any stage of the process workflow. In some embodiments where the purification platform includes two or more HIC steps, the HIC steps are not performed directly and sequentially, i.e., not without some intervening steps of the purification platform performed between the HIC steps. In some embodiments where the purification platform includes two or more HIC steps, the HIC steps are the same. In some embodiments where the purification platform includes two or more HIC steps, the HIC steps are different, e.g., including the use of different HIC media.

[0114] In some embodiments, the HIC process is used in combination with another aspect of the purification platform. In some embodiments, the use of the term “process” in “HIC process” does not exclude a purification platform in which the HIC feature of the purification platform is directly combined with another feature, for example, in which the eluent flows directly through the HIC feature. In some embodiments, the HIC process includes a chromatography medium containing an HIC feature, which includes a multimodal chromatography medium containing an HIC feature such as MM-HIC / IEX.

[0115] In some embodiments, the HIC process involves processing via an HIC medium, such as an HIC column and / or HIC membrane. HIC processes involving processing via an HIC medium are known in the art. See, for example, Liu et al. mAbs, 2, 2010, which is incorporated herein in its entirety by reference. Based on the latest art and the disclosure herein, those skilled in the art will understand, for example, the components, conditions, and reagents involved in the HIC process.

[0116] The HIC process enables separation based on hydrophobic interactions between the hydrophobic ligand of the HIC medium and components of the sample, such as target or non-target components. For example, in some embodiments, high-salt conditions may be used to reduce the solvation of the target, thereby exposing hydrophobic regions, which are then allowed to interact with the HIC medium. In some embodiments, the HIC medium comprises an inert matrix, such as a substrate including a crosslinked agarose, Sepharose, or resin matrix. In some embodiments, at least a portion of the substrate of the HIC medium includes a surface modification containing a hydrophobic ligand. In some embodiments, the HIC ligand is a ligand containing about 1 to 18 carbon atoms. In some embodiments, the HIC ligand contains one or more carbon atoms, for example, two or more carbon atoms, three or more carbon atoms, four or more carbon atoms, five or more carbon atoms, six or more carbon atoms, seven or more carbon atoms, eight or more carbon atoms, nine or more carbon atoms, ten or more carbon atoms, eleven or more carbon atoms, twelve or more carbon atoms, thirteen or more carbon atoms, fourteen or more carbon atoms, fifteen or more carbon atoms, sixteen or more carbon atoms, seventeen or more carbon atoms, or eighteen or more carbon atoms. In some embodiments, the HIC ligand contains one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, or eighteen carbon atoms. In some embodiments, the hydrophobic ligand is selected from the group consisting of ether groups, methyl groups, ethyl groups, propyl groups, isopropyl groups, butyl groups, t-butyl groups, hexyl groups, octyl groups, phenyl groups, and polypropylene glycol groups. In some embodiments, the HIC medium is a hydrophobic charge-inducing chromatography medium.

[0117] In some embodiments, the HIC process is configured to be carried out at a predetermined pH or range, for example, the input material having a predetermined pH or range. In some embodiments, the HIC process is configured to be carried out when, for example, the input material has a pH of about 4.5 to about 7, for example, about 5 to about 6, about 5 to about 5.5, or about 5.3 to about 5.7. In some embodiments, the HIC process is configured to be carried out when, for example, the input material has a pH of at least about 4.5, for example, at least about 4.6, 4.7, 4.8, 4.9, 5, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 6, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, or 7. In some embodiments, the HIC process is configured to be carried out when the input material has a pH less than about 7, for example, less than any of the following: about 6.9, 6.8, 6.7, 6.6, 6.5, 6.4, 6.3, 6.2, 6.1, 6, 5.9, 5.8, 5.7, 5.6, 5.5, 5.4, 5.3, 5.2, 5.1, 5, 4.9, 4.8, 4.7, 4.6, or 4.5. In some embodiments, the HIC process is configured to be carried out when the input material has a pH less than any of the following: about 4.5, 4.6, 4.7, 4.8, 4.9, 5, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 6, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, or 7.

[0118] In some embodiments, the HIC step includes processing via an HIC medium, and the processing via the HIC medium is carried out in binding-elution mode (i.e., the HIC step is a binding-elution mode HIC step). In some embodiments, the target polypeptide is eluted from the HIC medium using stepwise elution with an aqueous buffer with decreasing salt concentration, increasing surfactant concentration, and / or pH adjustment.

[0119] In some embodiments, the HIC process includes processing through an HIC medium, and the processing through the HIC medium is carried out in flow-through mode (i.e., the HIC process is a flow-through mode HIC process). In some embodiments, the processing through the HIC membrane or HIC column is carried out using low-salt conditions, and salts such as HIC conditioning salts are not added before loading the material into the HIC membrane or HIC column. For example, in some embodiments, the HIC process does not involve conductivity adjustment by adding salts such as HIC conditioning salts. In some embodiments, the HIC conditioning salts include one or more of sodium sulfate, ammonium sulfate, sodium citrate, potassium phosphate, sodium phosphate, or any other salts used to adjust the load of the HIC. In some embodiments, the HIC process is a flow-through mode HIC process carried out using an equilibrium buffer and a washing buffer containing sodium acetate at a pH of about 4.5 to about 6, for example, about 5 or about 6.

[0120] In some embodiments, the HIC medium, such as an HIC membrane or HIC column, is selected from the group consisting of Bakerbond WP HI-Propyl®, Phenyl Sepharose® Fast Flow (phenyl-SFF), Phenyl Sepharose® Fast Flow Hi-sub (phenyl-SFF HS), Toyopearl® Hexyl-650, Poros® Benzyl Ultra, and Sartobind® Phenyl. In some embodiments, Toyopearl® Hexyl-650 is Toyopearl® Hexyl-650M. In some embodiments, Toyopearl® Hexyl-650 is Toyopearl® Hexyl-650C. In some embodiments, Toyopearl® Hexyl-650 is Toyopearl® Hexyl-650S.

[0121] In some embodiments, the HIC medium comprises a propyl group covalently bonded to nitrogen on a polyethyleneimine (PEI) ligand bound to a substrate. In some embodiments, the HIC medium is Bakerbond WP HI-Propyl®. In some embodiments, the substrate is particles, which have an average size of 40 μm (e.g., Bakerbond WP HI-Propyl® C3).

[0122] In some embodiments, the HIC medium comprises crosslinked 6% agarose beads modified with aromatic phenyl groups via uncharged, chemically stable ether bonds. In some embodiments, the agarose beads have an average diameter of 90 μm. In some embodiments, the HIC medium is Phenyl Sepharose® Fast Flow (Phenyl SFF). As described herein, general references to Phenyl SFF include both Sepharose® Fast Flow Low Sub (Phenyl SFF LS) and Sepharose® Fast Flow High Sub (Phenyl SFF HS) unless otherwise specified. In some embodiments, the HIC medium comprises media ranging from approximately 15 μmol phenyl / mL to approximately 30 μmol phenyl / mL, such as approximately 20 μmol phenyl / mL or approximately 25 μmol phenyl / mL. In some embodiments, the HIC medium is Phenyl Sepharose® Fast Flow Low Sub (Phenyl SFF LS). In some embodiments, the HIC medium includes a medium of approximately 35 μmol phenyl / mL to approximately 50 μmol phenyl / mL, such as a medium of approximately 40 μmol phenyl / mL or a medium of approximately 45 μmol phenyl / mL. In some embodiments, the HIC medium is Phenyl Sepharose® Fast Flow High Sub (Phenyl SFF HS).

[0123] In some embodiments, the HIC medium comprises a polymethacrylate-based material with a pore size of 100 nm, bonded to a C6 group (hexyl). In some embodiments, the HIC medium comprises polymethacrylate-based particles having an average size of 100 μm and an average pore size of 100 nm (e.g., Toyopearl® Hexyl-650C). In some embodiments, the HIC medium comprises polymethacrylate-based particles having an average size of 65 μm and an average pore size of 100 nm (e.g., Toyopearl® Hexyl-650M). In some embodiments, the HIC medium comprises polymethacrylate-based particles having an average size of 35 μm and an average pore size of 100 nm (e.g., Toyopearl® Hexyl-650S).

[0124] In some embodiments, the HIC medium comprises crosslinked poly(styrene-divinylbenzene) POROS® beads having an aromatic hydrophobic benzyl ligand. In some embodiments, the HIC medium is Poros® Benzyl Ultra.

[0125] In some embodiments, the HIC medium is a membrane adsorbent containing a hydrophobic ligand. In some embodiments, the HIC medium includes a phenyl moiety conjugated to a stabilized and reinforced cellulose filter. In some embodiments, the HIC medium is Sartobind® phenyl. In some embodiments, the HIC medium includes a phenyl moiety conjugated to a stabilized and reinforced cell filter, e.g., Sartobind® phenyl, and the HIC process is configured to be carried out when the input material has a pH of, for example, about 4.5 to about 7, about 5 to about 6, or about 5.3 to about 5.7. In some embodiments, the HIC medium comprises a stabilizing and strengthening cell filter, for example, a phenyl portion conjugated to Sartobind® phenyl, and the HIC process is configured to be carried out when the input material has a pH of at least about 4.5, for example, at least about 4.6, 4.7, 4.8, 4.9, 5, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 6, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, or 7. In some embodiments, the HIC medium comprises a stabilizing and strengthening cell filter, for example, a phenyl portion conjugated to Sartobind® phenyl, and the HIC process is configured to be carried out when the input material has a pH less than about 7, for example, less than about 6.9, 6.8, 6.7, 6.6, 6.5, 6.4, 6.3, 6.2, 6.1, 6, 5.9, 5.8, 5.7, 5.6, 5.5, 5.4, 5.3, 5.2, 5.1, 5, 4.9, 4.8, 4.7, 4.6, or 4.5. In some embodiments, the HIC medium comprises a stabilizing and strengthening cell filter, for example, a phenyl portion conjugated to Sartobind® phenyl, and the HIC process is configured to be carried out when the input material has a pH of, for example, about 4.5, 4.6, 4.7, 4.8, 4.9, 5, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 6, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, or 7.

[0126] C. Ion exchange chromatography process In some embodiments, the purification platform described herein includes one or more ion exchange (IEX) chromatography steps. As described herein, the IEX chromatography steps may be located at any one or more positions within the purification platform. In some embodiments, the one or more IEX chromatography steps include one or more positions at any stage of the process workflow, such as two, three, four, or five IEX chromatography steps. In some embodiments where the purification platform includes two or more IEX chromatography steps, the IEX chromatography steps are not performed directly and sequentially, i.e., no intervening steps of the purification platform are performed between the IEX chromatography steps. In some embodiments where the purification platform includes two or more IEX chromatography steps, the IEX chromatography steps are the same. In some embodiments where the purification platform includes two or more IEX chromatography steps, the IEX chromatography steps are different, including, for example, the use of different IEX chromatography media.

[0127] In some embodiments, the IEX chromatography process is used in combination with other embodiments of the purification platform. In some embodiments, the use of the term “process” or any term encompassed therein in “IEX chromatography process” does not exclude the case where the IEX chromatography features of the purification platform are directly combined with other features, for example, a purification platform in which the eluate flows directly onto the IEX chromatography features.

[0128] In some embodiments, the IEX chromatography process involves processing via an IEX chromatography medium, such as an IEX column and / or an IEX membrane. IEX chromatography processes, including those involved in the polypeptide IEX chromatography process, are known in the art. See, for example, Liu et al. mAbs, 2, 2010, which is incorporated herein by reference in its entirety. Based on the latest art and the disclosure herein, those skilled in the art will understand, for example, the components, conditions, and reagents involved in the IEX chromatography process.

[0129] In some embodiments, the IEX chromatography step is performed in binding elution mode (i.e., the IEX chromatography step is a binding elution mode IEX chromatography step). In some embodiments, the IEX chromatography step is performed in flow-through mode (i.e., the IEX chromatography step is a flow-through mode IEX chromatography step). In some embodiments, the IEX chromatography step is performed in an overloaded polypeptide purification step (i.e., the IEX chromatography step is an overloaded mode IEX chromatography step).

[0130] The IEX chromatography process enables separation based on electrostatic interactions (anions and cations) between the ligand of the IEX chromatography medium and the components of the sample, such as target or non-target components. In some embodiments, the IEX chromatography medium includes a cation exchange (CEX) medium and / or features. In some embodiments, the IEX chromatography medium includes a strong CEX medium and / or features. In some embodiments, the IEX chromatography medium includes a weak CEX medium and / or features.

[0131] In some embodiments, the IEX chromatography medium includes an anion exchange (AEX) medium and / or features. In some embodiments, the IEX chromatography medium includes a strong AEX medium and / or features. In some embodiments, the IEX chromatography medium includes a weak AEX medium and / or features. In some embodiments, the IEX chromatography medium is a multimodal ion exchange (MMIEX) chromatography medium.

[0132] MMIEX chromatography media include both cation exchange components and / or features, and anion exchange components and / or features. In some embodiments, the MMIEX media is a multimodal anion / cation exchange (MM-AEX / CEX) chromatography media. In some embodiments, the IEX chromatography media is a ceramic hydroxyapatite chromatography media. In some embodiments, the IEX chromatography medium, such as an IEX chromatography column medium or IEX chromatography membrane, is selected from the group consisting of sulfopropyl (SP) Sepharose® Fast Flow (SPSFF), quaternary ammonium (Q) Sepharose® Fast Flow (QSFF), SP Sepharose® XL (SPXL), Streamline® SPXL, ABx® (MM-AEX / CEX medium), Poros® XS, Poros® 50HS, diethylaminoethyl (DEAE), dimethylaminoethyl (DMAE), trimethylaminoethyl (TMAE), quaternary aminoethyl (QAE), mercaptoethylpyridine (MEP)-Hypercel®, HiPrep® QXL, Q Sepharose® XL, and HiPrep® SP XL.

[0133] In some embodiments, the AEX chromatography medium comprises crosslinked 6% agarose beads having quaternary ammonium (Q) strong anion exchange groups. In some embodiments, the AEX chromatography medium is a strong anion exchange medium. In some embodiments, the AEX chromatography medium is Q Sepharose® Fast Flow (QSFF).

[0134] In some embodiments, the CEX chromatography medium comprises crosslinked 6% agarose beads having sulfopropyl (SP) strong cation exchange groups. In some embodiments, the CEX chromatography medium is a strong cation exchange medium. In some embodiments, the CEX chromatography medium is SP Sepharose® Face Flow (SPSFF).

[0135] In some embodiments, the CEX chromatography medium comprises crosslinked 6% agarose beads having dextran chains covalently bonded to an agarose matrix modified with sulfopropyl (SP) strong cation exchange groups. In some embodiments, the CEX chromatography medium is a strong cation exchange medium. In some embodiments, the CEX chromatography medium is SP Sepharose® XL (SPXL). In some embodiments, the CEX chromatography medium is Streamline® SPXL.

[0136] In some embodiments, the CEX chromatography medium comprises rigid polymer resin particles containing crosslinked poly[styrene-divinylbenzene] having a polyhydroxyl surface coating further functionalized with sulfopropyl (SP) strong cation exchange groups. In some embodiments, the average particle size is 50 μm. In some embodiments, the CEX chromatography medium is a strong cation exchange medium. In some embodiments, the CEX chromatography medium is Poros® XS.

[0137] In some embodiments, the CEX chromatography medium comprises rigid polymer resin particles containing crosslinked poly[styrene-divinylbenzene] having a polyhydroxyl surface coating further functionalized with sulfopropyl (SP) strong cation exchange groups. In some embodiments, the average particle size is 50 μm. In some embodiments, the CEX chromatography medium is a strong cation exchange medium. In some embodiments, the CEX chromatography medium is Poros® 50HS.

[0138] In some embodiments, the MM-AEX / CEX chromatography medium comprises silica gel solid-phase particles containing a mixed-mode anion / cation exchanger. In some embodiments, the silica gel solid-phase particles have an average particle size of about 45 μm to about 65 μm. In some embodiments, the MM-AEX / CEX chromatography medium is Bakerbond ABx®.

[0139] D. Multimodal hydrophobic interaction / ion exchange (MM-HIC / IEX) chromatography process In some embodiments, the purification platform described herein includes a multimodal hydrophobic interaction / ion exchange (MM-HIC / IEX) chromatography step.

[0140] As described herein, the MM-HIC / IEX chromatography steps may be placed at any one or more positions within the purification platform. In some embodiments, the purification platform described herein includes one or more MM-HIC / IEX chromatography steps, e.g., two, three, four, or five MM-HIC / IEX chromatography steps, placed at any stage in the process workflow. In some embodiments where the purification platform includes two or more MM-HIC / IEX chromatography steps, the MM-HIC / IEX chromatography steps are not performed in a directly sequential order, i.e., without any intervening steps of the purification platform performed between the MM-HIC / IEX chromatography steps. In some embodiments where the purification platform includes two or more MM-HIC / IEX chromatography steps, the two or more MM-HIC / IEX chromatography steps are the same. In some embodiments where the purification platform includes two or more MM-HIC / IEX chromatography steps, the two or more MM-HIC / IEX chromatography steps are different, e.g., including the use of different MM-HIC / IEX chromatography media.

[0141] In some embodiments, the MM-HIC / IEX chromatography process is used in combination with other aspects of the purification platform. In some embodiments, the use of the term "process" in "MM-HIC / IEX chromatography process" does not exclude purification platforms in which the MM-HIC / IEX chromatography features of the purification platform are directly combined with other features, for example, a purification platform in which a depth filter is used as a load filter in combination with the MM-HIC / IEX chromatography process.

[0142] In some embodiments, the MM-HIC / IEX chromatography medium includes an anion exchange (AEX) material and / or feature (e.g., MM-HIC / AEX chromatography medium). In some embodiments, the AEX material and / or feature is a strong anion exchange material and / or feature. In some embodiments, the AEX material and / or feature is a weak anion exchange material and / or feature.

[0143] In some embodiments, the MM-HIC / IEX chromatography medium includes a cation exchange material and / or feature (e.g., MM-HIC / CEX chromatography medium). In some embodiments, the CEX material and / or feature is a strong anion exchange material and / or feature. In some embodiments, the CEX material and / or feature is a weak anion exchange material and / or feature.

[0144] In some embodiments, the MM-HIC / IEX chromatography step includes processing via an MM-HIC / IEX chromatography column or MM-HIC / IEX chromatography membrane. In some embodiments, the MM-HIC / IEX chromatography column or membrane includes an inert medium containing an MM-HIC / IEX ligand. In some embodiments, the inert medium is a rigid agarose-based matrix, such as agarose particles.

[0145] In some embodiments, the MM-HIC / IEX chromatography step includes processing via Capto® Adhere, Capto® Adhere ImpRes, Capto® MMC, or Capto® MMC ImpRes.

[0146] In some embodiments, the MM-HIC / AEX chromatography medium is a multimodal strong anion exchanger using an N-benzyl-N-methylethanolamine ligand. In some embodiments, the N-benzyl-N-methylethanolamine ligand is capable of protein interactions, including hydrogen bonding, hydrophobic interactions, and electrostatic interactions (with anions). In some embodiments, the MM-HIC / AEX chromatography medium is Capto® Adhere. In some embodiments, the MM-HIC / AEX chromatography medium is Capto® Adhere ImpRes.

[0147] In some embodiments, the MM-HIC / CEX chromatography medium is a multimodal weak cation exchanger using an N-benzoyl-homocysteine ​​ligand. In some embodiments, the N-benzoyl-homocysteine ​​ligand is capable of protein interactions including hydrophobic interactions, hydrogen bonding, thiophilic interactions, and electrostatic interactions (cations). In some embodiments, the MM-HIC / CEX chromatography medium is Capto® MMC. In some embodiments, the MM-HIC / CEX chromatography medium is Capto® MMC ImpRes.

[0148] E. Capture process In some embodiments, the purification platform includes a capture step. In some embodiments, the capture step described herein includes the use of affinity chromatography that utilizes an immobilized ligand to specifically bind to a target or part thereof, such as an antibody.

[0149] For example, capture steps involving processing via affinity chromatography are known in the art. See, for example, Liu et al. mAbs, 2, 2010, incorporated herein by reference. Based on the latest art and the disclosure herein, those skilled in the art will understand the components, conditions, and reagents involved in carrying out the capture steps.

[0150] In some embodiments, affinity chromatography is selected from the group consisting of protein A chromatography, protein G chromatography, protein A / G chromatography, FcXL chromatography, protein XL chromatography, kappa chromatography, and kappa XL chromatography. In some embodiments, affinity chromatography involves the use of an inert matrix on which an affinity ligand, such as protein A or a portion thereof, is immobilized. In some embodiments, the affinity ligand is protein A or a portion thereof. In some embodiments, protein A is recombinant protein A. In some embodiments, protein A is natural protein A. In some embodiments, protein A is a protein A derivative, such as a polypeptide designed based on a protein A sequence and having specific modifications such as amino acid addition, deletion, and / or substitution. In some embodiments, the inert matrix is ​​a silica-based inert matrix, such as a silica-based filter or particles. In some embodiments, the inert matrix is ​​an agarose-based matrix, such as agarose particles. In some embodiments, the inert matrix is ​​an organic polymer-based matrix, such as organic polymer particles.

[0151] In some embodiments, the capture step includes processing via affinity chromatography. In some embodiments, the capture step includes processing via protein A chromatography. In some embodiments, the capture step is carried out in binding elution mode.

[0152] In some embodiments, the protein A chromatography medium is selected from the group consisting of MabSelect®, MabSelect SuRe®, MabSelect SuRe® LX, MabSelect Xtra®, MabSelect® PrismA, ProSep®-vA, ProSep®-vA Ultra, Protein A Sepharose® Fast Flow, Poros® A, and MabCapture®.

[0153] In some embodiments, the protein A chromatography medium comprises a rigid, high-flow agarose matrix and alkali-stabilized protein A-derived ligands, in which alkali-sensitive amino acids are substituted with residues that are more stable in an alkaline environment. In some embodiments, the matrix is ​​spherical particles. In some embodiments, the protein A chromatography medium is MabSelect SuRe®.

[0154] In some embodiments, the protein A chromatography medium comprises a rigid, high-flow agarose matrix and an alkali-stable protein A-derived ligand. In some embodiments, the matrix is ​​spherical particles. In some embodiments, the protein A chromatography medium is MabSelect® PrismA.

[0155] F. Virus filtration process In some embodiments, the purification platform includes a virus filtration step. In some embodiments, the virus filtration step is performed after one or more purification steps.

[0156] Viral filtration processes, including those involved in the processing of the viral filtration process, are known in the art. See, for example, Liu et al. mAbs, 2, 2010, and U.S. Patent Application Publication No. 20140309403, which are incorporated herein by reference. Based on the latest art and the disclosure herein, those skilled in the art will understand the components, conditions, and reagents involved in carrying out the capture process.

[0157] In some embodiments, the virus filtration step includes processing through a virus filter. In some embodiments, the virus filter has a pore size that can hold both enveloped and non-enveloped viruses. In some embodiments, the pore size of the virus filter is based on the size of the target virus.

[0158] G. Ultrafiltration / Diafiltration (UF / DF) Process In some embodiments, the purification platform includes a UF / DF step. In some embodiments, the UF / DF step is performed after other steps of the purification platform, such as an IEX chromatography step, an MM-HIC / IEX chromatography step, an HIC step, or a deep filtration step. In some embodiments, the UF / DF step is performed after a viral filtration step.

[0159] The UF / DF process, including the components involved in the UF / DF process, is known in the art. See, for example, Liu et al. mAbs, 2, 2010, incorporated herein by reference. Based on the latest art and the disclosure herein, those skilled in the art will understand the components, conditions, and reagents involved in carrying out the UF / DF process. In some embodiments, the UF / DF process includes processing via ultrafiltration. In some embodiments, the UF / DF process is carried out in tangential flow filtration (TFF) mode. In some embodiments, the UF / DF process includes processing via tangential flow filtration, such as high-performance tangential flow filtration.

[0160] H. Conditioning Process In some embodiments, the purification platform includes a conditioning step. In some embodiments, the conditioning step includes adjusting the characteristics or properties of the sample or composition obtained from the purification platform before subjecting it to further processing. For example, in some embodiments, the conditioning step includes adjusting the pH. In some embodiments, the conditioning step includes adjusting the temperature. In some embodiments, the conditioning step includes adjusting the buffer or salt concentration.

[0161] In some embodiments, the conditioning step is performed after the capture step. In some embodiments, the conditioning step is performed before the deep filtration step. In some embodiments, the conditioning step is performed before the HIC step. In some embodiments, the conditioning step is performed before the viral filtration step.

[0162] Conditioning processes, including those involved in the treatment for the conditioning process, are known in the art. See, for example, Liu et al. mAbs, 2, 2010, incorporated herein by reference. Based on the latest art and the disclosure herein, those skilled in the art will understand the components, conditions, and reagents involved in carrying out the conditioning process.

[0163] I. Exemplary Purification Platform In some embodiments, a purification platform for purifying a target from a sample is provided herein, comprising one or more deep filtration steps and / or one or more HIC steps and / or one or more MM-HIC / IEX chromatography steps, wherein the purification platform is capable of obtaining a composition with reduced hydrolytic enzyme activity compared to a purification platform that does not include one or more deep filtration steps and / or one or more HIC steps and / or one or more MM-HIC / IEX chromatography steps. In some embodiments, the reduction in hydrolytic enzyme activity is at least about 20%, for example, at least about 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 85%, 90%, or 95%.

[0164] In some embodiments, a purification platform is provided that includes a capture step; one or more ion exchange (IEX) chromatography steps; and a deep filtration step. In some embodiments, the purification platform further includes a viral filtration step and / or a UF / DF step. In some embodiments, the deep filtration step is immediately preceding the viral filtration step or the UF / DF step. In some embodiments, the deep filtration step is sequential with or immediately following the IEX chromatography step. In some embodiments, the deep filtration step includes an X0SP depth filter on an EMPHAZE® depth filter. In some embodiments, the purification platform further includes a HIC step. An exemplary purification platform encompassed within the described purification platform is shown in Figure 1A and described in more detail below.

[0165] In some embodiments, the purification platform includes, in order: (a) a capture step; (b) a CEX chromatography step; (c) an AEX chromatography step; (d) a deep filtration step; (e) a viral filtration step; and (f) a UF / DF step. In some embodiments, the capture step includes processing via a protein A-based affinity medium, e.g., MabSelect SuRe® or MabSelect® PrimaA medium. In some embodiments, the capture step includes a binding elution mode affinity chromatography step. In some embodiments, the CEX chromatography step includes a CEX chromatography medium containing crosslinked 6% agarose beads having sulfopropyl (SP) strong cation exchange groups, e.g., SP Sepharose® Fast Flow (SPSFF) medium. In some embodiments, the AEX chromatography step includes an AEX chromatography medium containing crosslinked 6% agarose beads having quaternary ammonium (Q) strong anion exchange groups, e.g., Q Sepharose® Fast Flow (QSFF) medium. In some embodiments, the deep filtration step includes a depth filter containing silica, such as a silica filter aid, and / or polyacrylic fibers, for example, an X0SP depth filter, a C0SP depth filter, or a D0SP depth filter.

[0166] In some embodiments, the purification platform comprises, in order, a capture step comprising a binding elution affinity chromatography step comprising (a) a protein A-based affinity medium, e.g., MabSelect SuRe® or MabSelect® PrimaA medium; (b) a CEX chromatography step comprising a CEX chromatography medium comprising crosslinked 6% agarose beads having sulfopropyl (SP) strong cation exchange groups, e.g., SP Sepharose® Fast Flow (SPSFF) medium; (c) an AEX chromatography step comprising an AEX chromatography medium comprising crosslinked 6% agarose beads having quaternary ammonium (Q) strong anion exchange groups, e.g., Q Sepharose® Fast Flow (QSFF) medium; and (d) a deep filtration step comprising a depth filter comprising silica such as a silica filter aid and / or polyacrylic fibers such as an X0SP depth filter, C0SP depth filter, or D0SP depth filter; and a UF / DF step. In some embodiments, the purification platform further includes a deep filtration step positioned at any location, the deep filtration step including a depth filter such as a silica filter aid, and / or polyacrylic fibers, e.g., an X0SP depth filter, a C0SP depth filter, or a D0SP depth filter, and the deep filtration step is configured to be carried out when, for example, the input material has a pH of about 5 to about 6.5, e.g., about 5 to about 5.5 or about 5.8 to about 6.2. In some embodiments, the purification platform further includes a deep filtration step positioned at any location, the deep filtration step including a depth filter containing a hydrogel Q (quaternary amine, also called quaternary ammonium) functionalized nonwoven fabric material and a multizone microporous membrane, e.g., an EMPHAZE® AEX depth filter, and the deep filtration step is configured to be carried out when, for example, the input material has a pH of about 7.5 to about 8.5, e.g., about 8.In some embodiments, the purification platform further includes an HIC step positioned at any location, the HIC step including an HIC medium such as an HIC membrane containing a phenyl portion conjugated to a stabilized and strengthened cellulose filter, for example, Sartobind® phenyl medium, and the HIC step is configured to be carried out when the input material has a pH of about 5 to about 6, for example, about 5.5.

[0167] In some embodiments, the purification platform comprises, in order, a capture step comprising a protein A-based affinity medium, e.g., MabSelect SuRe® or MabSelect® PrimaA medium, and configured to be a binding elution affinity chromatography step; a CEX chromatography step comprising a CEX chromatography medium comprising a crosslinked 6% agarose beads having a sulfopropyl (SP) strong cation exchange group, e.g., SP Sepharose® Fast Flow (SPSFF) medium; a CEX chromatography step comprising an AEX chromatography medium comprising a crosslinked 6% agarose beads having a quaternary ammonium (Q) strong anion exchange group, e.g., Q Sepharose® Fast Flow (QSFF) medium; a deep filtration step comprising a depth filter comprising a hydrogel Q (quaternary amine, also called quaternary ammonium) functionalized nonwoven material and a multizone microporous membrane, e.g., EMPHAZE® AEX depth filter; a viral filtration step; and a UF / DF step. In some embodiments, the purification platform further includes a deep filtration step positioned at any location, the deep filtration step including a depth filter comprising silica, such as a silica filter aid, and polyacrylic fibers, such as an X0SP depth filter, a C0SP depth filter, or a D0SP depth filter, and the deep filtration step is configured to be carried out, for example, when the input material has a pH of about 5 to about 6, for example, about 5.5. In some embodiments, the purification platform further includes a deep filtration step positioned at any location, the deep filtration step including a depth filter comprising a hydrogel Q (quaternary amine, also called quaternary ammonium) functionalized nonwoven fabric material and a multizone microporous membrane, for example, an EMPHAZE® AEX depth filter, and the deep filtration step is configured to be carried out, for example, when the input material has a pH of about 7.5 to about 8.5, for example, about 8.In some embodiments, the purification platform further includes an HIC step positioned at any location, the HIC step including an HIC medium such as an HIC membrane containing a phenyl portion conjugated to a stabilized and strengthened cellulose filter, for example, Sartobind® phenyl medium, and the HIC step is configured to be carried out when the input material has a pH of about 5 to about 6, for example, about 5.5.

[0168] In some embodiments, the purification platform comprises, in order, a capture step comprising a protein A-based affinity medium, e.g., MabSelect SuRe® or MabSelect® PrimaA medium, and configured to be a binding elution affinity chromatography step; a CEX chromatography step comprising a CEX chromatography medium comprising a crosslinked 6% agarose beads having a sulfopropyl (SP) strong cation exchange group, e.g., SP Sepharose® Fast Flow (SPSFF) medium; a CEX chromatography step comprising an AEX chromatography medium comprising a crosslinked 6% agarose beads having a quaternary ammonium (Q) strong anion exchange group, e.g., Q Sepharose® Fast Flow (QSFF) medium; a HIC step comprising a stabilized and enhanced cellulose filter, e.g., an HIC medium comprising a phenyl moiety conjugated to Sartobind® phenyl; a virus filtration step; and a UF / DF step. In some embodiments, the purification platform further includes a deep filtration step positioned at any location, the deep filtration step including a depth filter comprising silica, such as a silica filter aid, and polyacrylic fibers, such as an X0SP depth filter, a C0SP depth filter, or a D0SP depth filter, and the deep filtration step is configured to be carried out, for example, when the input material has a pH of about 5 to about 6, for example, about 5.5. In some embodiments, the purification platform further includes a deep filtration step positioned at any location, the deep filtration step including a depth filter comprising a hydrogel Q (quaternary amine, also called quaternary ammonium) functionalized nonwoven fabric material and a multizone microporous membrane, for example, an EMPHAZE® AEX depth filter, and the deep filtration step is configured to be carried out, for example, when the input material has a pH of about 7.5 to about 8.5, for example, about 8.In some embodiments, the purification platform further includes an HIC step positioned at any location, the HIC step including an HIC medium such as an HIC membrane containing a phenyl portion conjugated to a stabilized and strengthened cellulose filter, for example, Sartobind® phenyl medium, and the HIC step is configured to be carried out when the input material has a pH of about 5 to about 6, for example, about 5.5.

[0169] In some embodiments, a purification platform is provided that includes a capture step; a multimodal hydrophobic interaction / ion exchange (MM-HIC / IEX) chromatography step; and a hydrophobic interaction chromatography (HIC) step. In some embodiments, the purification platform further includes a virus filtration step. In some embodiments, the purification platform further includes a UF / DF step. An exemplary purification platform encompassed within the described purification platform is shown in Figure 1B and is described in more detail below.

[0170] In some embodiments, the purification platform comprises, in order, (a) a capture step; (b) an MM-HIC / IEX chromatography step; and (c) an HIC step. In some embodiments, the capture step comprises a protein A-based affinity medium, e.g., MabSelect SuRe® or MabSelect® PrimaA medium. In some embodiments, the capture step comprises a binding-elution mode affinity chromatography step. In some embodiments, the MM-HIC / IEX chromatography step comprises an MM-HIC / AEX chromatography step. In some embodiments, the MM-HIC / AEX chromatography step comprises a medium containing a multimodal strong anion exchanger using an N-benzyl-N-methylethanolamine ligand, e.g., Capto® Adhere medium. In some embodiments, the MM-HIC / IEX chromatography step is an MM-HIC / CEX chromatography step. In some embodiments, the MM-HIC / CEX chromatography step comprises a medium containing a multimodal weak cation exchanger using an N-benzoyl-homocysteine ​​ligand, e.g., Capto® MMC medium. In some embodiments, the HIC step includes a medium containing crosslinked 6% agarose beads modified with aromatic phenyl groups via uncharged, chemically stable ether bonds, such as a Phenyl SFF medium such as Phenyl SFF HS or Phenyl SFF LS. In some embodiments, the HIC step includes a medium containing a polymethacrylate-based material with a pore size of 100 nm bonded to a C6 group (hexyl), such as a Toyopearl® Hexyl-650 medium, such as Toyopearl® Hexyl-650C. In some embodiments, the HIC step includes a medium containing crosslinked poly(styrene-divinylbenzene) POROS® beads having an aromatic hydrophobic benzyl ligand, such as Poros® Benzyl Ultra.

[0171] In some embodiments, a purification platform is provided comprising, in order: (a) a capture step comprising a protein A-based affinity medium, e.g., MabSelect SuRe® or MabSelect® PrimaA medium, and configured to be a binding-elution affinity chromatography step; (b) an MM-HIC / AEX chromatography step comprising a medium comprising a multimodal strong anion exchanger using an N-benzyl-N-methylethanolamine ligand, e.g., Capto® Adhere medium; and (c) an HIC step comprising a medium comprising a Phenyl SFF medium such as Phenyl SFF HS or Phenyl SFF LS, comprising crosslinked 6% agarose beads modified with aromatic phenyl groups via uncharged and chemically stable ether bonds.

[0172] In some embodiments, a purification platform is provided, comprising, in order: (a) a capture step comprising a protein A-based affinity medium, e.g., MabSelect SuRe® or MabSelect® PrimaA medium, and configured to be a binding-elution affinity chromatography step; (b) an MM-HIC / AEX chromatography step comprising a medium comprising a multimodal strong anion exchanger using an N-benzyl-N-methylethanolamine ligand, e.g., Capto® Adhere medium; and (c) an HIC step comprising a medium comprising a polymethacrylate-based material with a pore size of 100 nm bonded to a C6 group (hexyl), e.g., Toyopearl® Hexyl-650 medium.

[0173] In some embodiments, a purification platform is provided, comprising, in order: (a) a capture step comprising a protein A-based affinity medium, e.g., MabSelect SuRe® or MabSelect® PrimaA medium, and configured to be a binding-elution affinity chromatography step; (b) an MM-HIC / AEX chromatography step comprising a medium comprising a multimodal strong anion exchanger using an N-benzyl-N-methylethanolamine ligand, e.g., Capto® Adhere medium; and (c) an HIC step comprising a medium comprising crosslinked poly(styrene-divinylbenzene) POROS®-based beads having an aromatic hydrophobic benzyl ligand, e.g., Poros® Benzyl Ultra medium.

[0174] In some embodiments, a purification platform is provided comprising, in order: (a) a capture step comprising a protein A-based affinity medium, e.g., MabSelect SuRe® or MabSelect® PrimaA medium, and configured to be a binding-elution affinity chromatography step; (b) an MM-HIC / CEX chromatography step comprising a medium comprising a multimodal weak cation exchanger using an N-benzoyl-homocysteine ​​ligand, e.g., Capto® MMC medium; and (c) an HIC step comprising a medium comprising a Phenyl SFF medium such as Phenyl SFF HS or Phenyl SFF LS, comprising crosslinked 6% agarose beads modified with aromatic phenyl groups via uncharged and chemically stable ether bonds.

[0175] In some embodiments, a purification platform is provided, comprising, in order: (a) a capture step comprising a protein A-based affinity medium, e.g., MabSelect SuRe® or MabSelect® PrimaA medium, and configured to be a binding-elution affinity chromatography step; (b) an MM-HIC / CEX chromatography step comprising a medium comprising a multimodal weak cation exchanger using an N-benzoyl-homocysteine ​​ligand, e.g., Capto® MMC medium; and (c) an HIC step comprising a medium comprising a polymethacrylate-based material with a pore size of 100 nm bound to a C6 group (hexyl), e.g., Toyopearl® Hexyl-650 medium.

[0176] In some embodiments, a purification platform is provided, comprising, in order: (a) a capture step comprising a protein A-based affinity medium, e.g., MabSelect SuRe® or MabSelect® PrimaA medium, and configured to be a binding-elution affinity chromatography step; (b) an MM-HIC / CEX chromatography step comprising a medium comprising a multimodal weak cation exchanger using an N-benzoyl-homocysteine ​​ligand, e.g., Capto® MMC medium; and (c) an HIC step comprising a medium comprising crosslinked poly(styrene-divinylbenzene) POROS® system beads having an aromatic hydrophobic benzyl ligand, e.g., Poros® Benzyl Ultra. In some embodiments, the purification platform further comprises a deep filtration step placed at any position.

[0177] In some embodiments, the purification platform comprises, in order, (a) a capture step; (b) an MM-HIC / AEX chromatography step; (c) an HIC step; (d) a viral filtration step; and (e) an UF / DF step. In some embodiments, the capture step comprises processing via a protein A-based affinity medium, e.g., MabSelect SuRe® or MabSelect® PrimaA medium. In some embodiments, the capture step comprises a binding elution mode affinity chromatography step. In some embodiments, the MM-HIC / AEX chromatography step comprises a medium comprising a multimodal strong anion exchanger using an N-benzyl-N-methylethanolamine ligand, e.g., Capto® Adhere medium. In some embodiments, the HIC step comprises a medium comprising crosslinked 6% agarose beads modified with aromatic phenyl groups via uncharged, chemically stable ether bonds, the medium comprising a phenyl / mL medium of about 40-45 μmol, e.g., Phenyl SFF HS medium. In some embodiments, the HIC step includes a medium containing a polymethacrylate-based material with a pore size of 100 nm bonded to a C6 group (hexyl), such as Toyopearl® Hexyl-650 medium. In some embodiments, the HIC step includes a medium containing crosslinked poly(styrene-divinylbenzene) POROS® beads having an aromatic hydrophobic benzyl ligand, such as Poros® Benzyl Ultra.

[0178] In some embodiments, a purification platform is provided comprising, in order: (a) a capture step comprising a protein A-based affinity medium, e.g., MabSelect SuRe® or MabSelect® PrimaA medium, wherein the capture step is configured to be a binding elution affinity chromatography step; (b) an MM-HIC / AEX chromatography step comprising a medium comprising a multimodal strong anion exchanger using an N-benzyl-N-methylethanolamine ligand, e.g., Capto® Adhere medium; (c) an HIC step comprising a medium comprising crosslinked 6% agarose beads modified with aromatic phenyl groups via uncharged and chemically stable ether bonds, and containing about 40-45 μmol of phenyl / mL medium, e.g., Phenyl SFF HS medium; (d) a viral filtration step; and (e) a UF / DF step.

[0179] In some embodiments, a purification platform is provided, comprising, in order: (a) a capture step comprising a protein A-based affinity medium, e.g., MabSelect SuRe® or MabSelect® PrimaA medium, and configured to be a binding-elution affinity chromatography step; (b) an MM-HIC / AEX chromatography step comprising a medium comprising a multimodal strong anion exchanger using an N-benzyl-N-methylethanolamine ligand, e.g., Capto® Adhere medium; (c) an HIC step comprising a medium comprising a polymethacrylate-based material with a pore size of 100 nm bound to a C6 group (hexyl), e.g., Toyopearl® Hexyl-650 medium; (d) a viral filtration step; and (e) a UF / DF step.

[0180] In some embodiments, a purification platform is provided, comprising, in order: (a) a capture step comprising a protein A-based affinity medium, e.g., MabSelect SuRe® or MabSelect® PrimaA medium, and configured to be a binding-elution affinity chromatography step; (b) an MM-HIC / AEX chromatography step comprising a medium comprising a multimodal strong anion exchanger using an N-benzyl-N-methylethanolamine ligand, e.g., Capto® Adhere medium; (c) an HIC step comprising a medium comprising crosslinked poly(styrene-divinylbenzene) POROS® system beads having an aromatic hydrophobic benzyl ligand, e.g., Poros® Benzyl Ultra; (d) a viral filtration step; and (e) a UF / DF step.

[0181] In some embodiments, a purification platform is provided comprising, in order: (a) a capture step; (b) an MM-HIC / AEX chromatography step using a deep filtration step as a load filtration step; and (c) an HIC step. In some embodiments, the capture step includes a binding-elution mode affinity chromatography step. In some embodiments, the capture step includes a protein A-based affinity medium containing a rigid high-flow agarose matrix and an alkali-stabilized protein A-derived ligand (amino acids particularly sensitive to alkali are substituted with residues stable in an alkaline environment), e.g., MabSelect SuRe® medium. In some embodiments, the capture step includes a protein A-based affinity medium containing a rigid high-flow agarose matrix and an alkali-stable protein A-derived ligand, e.g., MabSelect® PrismA medium. In some embodiments, the MM-HIC / AEX chromatography step includes a medium containing a multimodal strong anion exchanger using an N-benzyl-N-methylethanolamine ligand, e.g., Capto® Adhere medium. In some embodiments, the deep filtration step includes a depth filter comprising silica, such as a silica filter aid, and polyacrylic fibers, such as X0SP depth filters, C0SP depth filters, or D0SP depth filters. In some embodiments, the deep filtration step includes a depth filter comprising a hydrogel Q (quaternary amine, also called quaternary ammonium) functionalized nonwoven fabric material and a multizone microporous membrane, such as an EMPHAZE® AEX depth filter. In some embodiments, the HIC step is a flow-through mode HIC step. In some embodiments, the HIC step includes a medium comprising a polymethacrylate material with a pore size of 100 nm bonded to a C6 group (hexyl), such as a Toyopearl® Hexyl-650 medium. In some embodiments, the HIC step includes a medium comprising crosslinked poly(styrene-divinylbenzene) POROS® beads having an aromatic hydrophobic benzyl ligand, such as a Poros® Benzyl Ultra medium.In some embodiments, the HIC step includes a medium containing crosslinked 6% agarose beads modified with aromatic phenyl groups via uncharged, chemically stable ether bonds, the medium containing about 40–45 μmol of phenyl / mL medium, e.g., Phenyl SFF HS medium. In some embodiments, the HIC step includes a pH adjustment step, adjusting the pH of the input material to about 4.5–6. In some embodiments, the HIC step is a low-salt HIC step, such as not adding salts, such as HIC conditioning salts, before packing the material into the HIC membrane or HIC column.

[0182] In some embodiments, a purification platform is provided, comprising: (a) a capture step comprising a protein A-based affinity medium comprising a rigid, high-flow agarose matrix and an alkali-stable protein A-derived ligand, e.g., MabSelect® PrismA medium; (b) an MM-HIC / AEX chromatography step using a deep filtration step as a load filtration step, comprising a medium comprising a multimodal strong anion exchanger using an N-benzyl-N-methylethanolamine ligand, e.g., Capto® Adhere medium, wherein the deep filtration step comprises a depth filter comprising silica such as a silica filter aid and polyacrylic fibers such as an X0SP depth filter, C0SP depth filter, or D0SP depth filter; and (c) an HIC step which is a flow-through mode HIC step comprising a medium comprising a polymethacrylate material with a pore size of 100 nm bonded to a C6 group (hexyl), e.g., Toyopearl® Hexyl-650 medium. In some embodiments, the HIC process includes a pH adjustment process in which the pH of the input material is adjusted to approximately 4.5 to approximately 5.5, for example, approximately 5.0. In some embodiments, the HIC process is a low-salt HIC process, such as not adding salts such as HIC conditioning salts before packing the material into the HIC membrane or HIC column.

[0183] In some embodiments, a purification platform is provided, comprising: (a) a capture step comprising a protein A-based affinity medium comprising a rigid, high-flow agarose matrix and an alkali-stable protein A-derived ligand, e.g., MabSelect® PrismA medium; (b) an MM-HIC / AEX chromatography step using a deep filtration step as a load filtration step, comprising a medium comprising a multimodal strong anion exchanger using an N-benzyl-N-methylethanolamine ligand, e.g., Capto® Adhere medium, wherein the deep filtration step comprises a depth filter comprising silica such as a silica filter aid and polyacrylic fibers such as an X0SP depth filter, C0SP depth filter, or D0SP depth filter; and (c) a flow-through mode HIC step comprising crosslinked poly(styrene-divinylbenzene) POROS® beads, e.g., Poros® Benzyl Ultra, comprising an aromatic hydrophobic benzyl ligand. In some embodiments, the HIC process includes a pH adjustment process in which the pH of the input material is adjusted to approximately 4.5 to approximately 5.5, for example, approximately 5.0. In some embodiments, the HIC process is a low-salt HIC process, such as not adding salts such as HIC conditioning salts before packing the material into the HIC membrane or HIC column.

[0184] In some embodiments, the following are used: (a) a capture step, in order, comprising a protein A-based affinity medium containing a rigid, high-flow agarose matrix and an alkali-stabilized protein A-derived ligand (in which alkali-sensitive amino acids are substituted with residues more stable in an alkaline environment), e.g., MabSelect SuRe® medium; (b) a deep filtration step as a load filtration step, comprising a medium containing a multimodal strong anion exchanger using an N-benzyl-N-methylethanolamine ligand, e.g., Capto®, Adhere medium, wherein the deep filtration step comprises a depth filter containing a hydrogel Q (quaternary amine, also called quaternary ammonium)-functionalized nonwoven material and a multizone microporous membrane, e.g., EMPHAZE® AEX depth filter; (c) a medium containing crosslinked 6% agarose beads modified with aromatic phenyl groups via uncharged, chemically stable ether bonds, with a phenyl / mL concentration of approximately 40-45 μmol, e.g., Phenyl SFF A purification platform is provided which includes an HIC process, in which the HIC process is a flow-through mode HIC process, and which includes an HS medium. In some embodiments, the HIC process includes a pH adjustment process, in which the pH of the input material is adjusted to approximately 5.0 to approximately 6.0, for example, approximately 5.5. In some embodiments, the HIC process is a low-salt HIC process, such as not adding salts such as HIC conditioning salts before packing the material into the HIC membrane or HIC column.

[0185] In some embodiments, a purification platform is provided comprising a capture step; one or more ion exchange (IEX) chromatography steps; and a hydrophobic interaction chromatography (HIC) step. In some embodiments, the IEX chromatography step is a CEX chromatography step. In some embodiments, the purification platform further comprises a viral filtration step. In some embodiments, the purification platform further comprises a UF / DF step. In some embodiments, the purification platform further comprises a deep filtration step. In some embodiments, the purification platform further comprises a HIC step. An exemplary purification platform encompassed within the described purification platform is shown in Figure 1C and is described in more detail below.

[0186] In some embodiments, the purification platform includes, in order: (a) a capture step; (b) a CEX chromatography step; (c) a HIC step; (d) a viral filtration step; and (e) a UF / DF step. In some embodiments, the capture step includes a protein A-based affinity medium, e.g., MabSelect SuRe® or MabSelect® PrimaA medium. In some embodiments, the capture step includes a binding elution mode affinity chromatography step. In some embodiments, the CEX chromatography step includes a CEX chromatography medium, e.g., Poros® XS medium, containing rigid polymer resin particles comprising crosslinked poly[styrene-divinylbenzene] having a polyhydroxyl surface coating further functionalized with sulfopropyl (SP) strong cation exchange groups. In some embodiments, the CEX chromatography step includes a CEX chromatography medium, e.g., Poros® 50HS, containing rigid polymer resin particles comprising crosslinked poly[styrene-divinylbenzene] having a polyhydroxyl surface coating further functionalized with sulfopropyl (SP) strong cation exchange groups. In some embodiments, the HIC step includes crosslinked 6% agarose beads modified with aromatic phenyl groups via uncharged, chemically stable ether bonds, and a medium containing about 40-45 μmol of phenyl / mL, such as Phenyl SFF HS medium. In some embodiments, the HIC step includes a medium containing a polymethacrylate-based material with a pore size of 100 nm bonded to a C6 (hexyl) group, such as Toyopearl® Hexyl-650 medium. In some embodiments, the HIC step includes a medium containing crosslinked poly(styrene-divinylbenzene) POROS® beads having an aromatic hydrophobic benzyl ligand, such as Poros® Benzyl Ultra.

[0187] In some embodiments, the purification platform is provided, comprising, in order: (a) a capture step comprising a protein A-based affinity medium, e.g., MabSelect SuRe® or MabSelect® PrimaA medium, and configured to be a binding elution affinity chromatography step; (b) a CEX chromatography step comprising a CEX chromatography medium, e.g., Poros® XS medium, comprising rigid polymer resin particles containing crosslinked poly[styrene-divinylbenzene] having a polyhydroxyl surface coating further functionalized with sulfopropyl (SP) strong cation exchange groups; (c) a HIC step comprising crosslinked 6% agarose beads modified with aromatic phenyl groups via uncharged chemically stable ether bonds, and a phenyl / mL medium of about 40-45 μmol, e.g., Phenyl SFF HS medium; (d) a viral filtration step; and (e) a UF / DF step.

[0188] In some embodiments, the purification platform is provided, comprising, in order: (a) a capture step comprising a protein A-based affinity medium, e.g., MabSelect SuRe® or MabSelect® PrimaA medium, and configured to be a binding elution affinity chromatography step; (b) a CEX chromatography step comprising a CEX chromatography medium comprising rigid polymer resin particles containing crosslinked poly[styrene-divinylbenzene] having a polyhydroxyl surface coating further functionalized with sulfopropyl (SP) strong cation exchange groups, e.g., Poros® XS medium; (c) an HIC step comprising a medium containing a polymethacrylate-based material with a pore size of 100 nm bonded to a C6 group (hexyl), e.g., Toyopearl® Hexyl-650 medium; (d) a virus filtration step; and (e) a UF / DF step.

[0189] In some embodiments, the purification platform is provided, in order, comprising: (a) a capture step comprising a binding elution mode affinity chromatography step; (b) a CEX chromatography step comprising a CEX chromatography medium comprising rigid polymer resin particles comprising crosslinked poly[styrene-divinylbenzene] having a polyhydroxyl surface coating further functionalized with sulfopropyl (SP) strong cation exchange groups, e.g., Poros® XS medium; (c) a HIC step comprising a medium comprising crosslinked poly(styrene-divinylbenzene) POROS® system beads having an aromatic hydrophobic benzyl ligand, e.g., Poros® Benzyl Ultra medium; (d) a viral filtration step; and (e) a UF / DF step.

[0190] In some embodiments, the purification platform is provided, in order, comprising: (a) a capture step comprising a binding elution mode affinity chromatography step; (b) a CEX chromatography step comprising a CEX chromatography medium, e.g., Poros® 50HS medium, comprising rigid polymer resin particles comprising crosslinked poly[styrene-divinylbenzene] having a polyhydroxyl surface coating further functionalized with sulfopropyl (SP) strong cation exchange groups; (c) a HIC step comprising a crosslinked 6% agarose beads modified with aromatic phenyl groups via uncharged chemically stable ether bonds, and a phenyl / mL medium of about 40-45 μmol, e.g., Phenyl SFF HS medium; (d) a viral filtration step; and (e) a UF / DF step.

[0191] In some embodiments, the purification platform is provided, comprising, in order: (a) a capture step comprising a protein A-based affinity medium, e.g., MabSelect SuRe® or MabSelect® PrimaA medium, and configured to be a binding elution affinity chromatography step; (b) a CEX chromatography step comprising a CEX chromatography medium comprising rigid polymer resin particles containing crosslinked poly[styrene-divinylbenzene] having a polyhydroxyl surface coating further functionalized with sulfopropyl (SP) strong cation exchange groups, e.g., Poros® 50HS medium; (c) an HIC step comprising a medium comprising a polymethacrylate-based material with a pore size of 100 nm bonded to a C6 group (hexyl), e.g., Toyopearl® Hexyl-650 medium; (d) a virus filtration step; and (e) a UF / DF step.

[0192] In some embodiments, the purification platform is provided, comprising, in order: (a) a capture step comprising a protein A-based affinity medium, e.g., MabSelect SuRe® or MabSelect® PrimaA medium, and configured to be a binding elution affinity chromatography step; (b) a CEX chromatography step comprising a CEX chromatography medium comprising rigid polymer resin particles containing crosslinked poly[styrene-divinylbenzene] having a polyhydroxyl surface coating further functionalized with sulfopropyl (SP) strong cation exchange groups, e.g., Poros® 50HS medium; (c) a HIC step comprising a medium comprising crosslinked poly(styrene-divinylbenzene) POROS®-based beads having an aromatic hydrophobic benzyl ligand, e.g., Poros® Benzyl Ultra medium; (d) a viral filtration step; and (e) a UF / DF step. In some embodiments, the purification platform further comprises a deep filtration step placed at any position.

[0193] In some embodiments, a purification platform is provided that includes one or more ion exchange (IEX) chromatography steps; hydrophobic interaction chromatography (HIC) steps; and deep filtration steps. In some embodiments, the purification platform further includes a viral filtration step and / or a UF / DF step. In some embodiments, the deep filtration step and / or HIC step is immediately preceding the viral filtration step of the UF / DF step. In some embodiments, the deep filtration step and / or HIC step is sequential to or immediately following the IEX chromatography step. An exemplary purification platform encompassed within the described purification platform is shown in Figure 1D and described in more detail below.

[0194] In some embodiments, the purification platform includes, in order: (a) a CEX chromatography step; (b) an HIC step; (c) an AEX chromatography step; (d) a deep filtration step; and (f) an UF / DF step. In some embodiments, the CEX chromatography step includes a CEX chromatography medium comprising crosslinked 6% agarose beads having dextran chains covalently bonded to an agarose matrix modified with sulfopropyl (SP) strong cation exchange groups, e.g., SP Sepharose® XL (SPXL) medium or Streamline® SPXL medium. In some embodiments, the HIC step includes an HIC medium comprising a propyl group covalently bonded to nitrogen on a polyethyleneimine (PEI) ligand bound to a substrate, e.g., Bakerbond WP HI-Propyl® medium. In some embodiments, the MMIEX chromatography step includes an MMIEX chromatography medium comprising silica gel solid particles containing a mixed-mode anion / cation exchanger, e.g., Bakerbond ABx® medium. In some embodiments, the AEX chromatography step includes an AEX chromatography medium containing crosslinked 6% agarose beads having quaternary ammonium (Q) strong anion exchange groups, such as Q Sepharose® Fast Flow (QSFF) medium. In some embodiments, the deep filtration step includes a depth filter containing silica, such as a silica filter aid, and polyacrylic fibers, such as an X0SP depth filter, a C0SP depth filter, or a D0SP depth filter.

[0195] In some embodiments, the purification platform comprises, in order: (a) a CEX chromatography step comprising a CEX chromatography medium comprising crosslinked 6% agarose beads having dextran chains covalently bonded to an agarose matrix modified with sulfopropyl (SP) strong cation exchange groups, e.g., SP Sepharose® XL (SPXL) medium or Streamline® SPXL medium; (b) an HIC step comprising an HIC medium comprising a propyl group covalently bonded to nitrogen on a polyethyleneimine (PEI) ligand bound to a substrate, e.g., Bakerbond WP HI-Propyl® medium; (c) an MMIEX chromatography step comprising an MMIEX chromatography medium comprising silica gel solid phase particles comprising a mixed-mode anion / cation exchanger, e.g., Bakerbond ABx® medium; and (d) an AEX chromatography medium comprising crosslinked 6% agarose beads having quaternary ammonium (Q) strong anion exchange groups, e.g., Q Sepharose® Fast The process includes: (a) an AEX chromatography step containing a Flow (QSFF) medium; (b) a deep filtration step containing a depth filter containing silica such as a silica filter aid and polyacrylic fibers such as an X0SP depth filter, a C0SP depth filter, or a D0SP depth filter; and (f) a UF / DF step. In some embodiments, the purification platform further includes a deep filtration step positioned at any location, the deep filtration step including a depth filter containing silica such as a silica filter aid and polyacrylic fibers such as an X0SP depth filter, a C0SP depth filter, or a D0SP depth filter, and the deep filtration step is configured to be carried out when the input material has a pH of about 6 to about 7, for example, about 6.5. In some embodiments, the purification platform further includes a deep filtration step positioned at any location, the deep filtration step including a depth filter containing a hydrogel Q (quaternary amine, also known as quaternary ammonium)-functionalized nonwoven material and a multizone microporous membrane, such as an EMPHAZE® AEX depth filter, the deep filtration step being configured to be carried out when the input material has a pH of, for example, about 8.5 to about 9.5, for example about 9.1.In some embodiments, the purification platform further includes an HIC step positioned at any location, the HIC step including an HIC medium such as an HIC membrane containing a phenyl portion conjugated to a stabilized and strengthened cellulose filter, for example, Sartobind® phenyl medium, and the HIC step is configured to be carried out when the input material has a pH of about 6 to about 7, for example, about 6.5.

[0196] In some embodiments, a purification platform is provided that, in order, includes (a) a capture step; (b) one or more ion exchange (IEX) chromatography steps, such as a CEX chromatography step; (c) a multimodal hydrophobic interaction / ion exchange (MM-HIC / IEX) chromatography step; and (d) one or both of (i) a hydrophobic interaction chromatography (HIC) step and (ii) a deep filtration step. In some embodiments, the purification platform further includes a viral filtration step. In some embodiments, the purification platform further includes a UF / DF step. An exemplary purification platform encompassed within the described purification platform is shown in Figure 1E. In some embodiments, the capture step includes a protein A-based affinity medium, e.g., MabSelect SuRe® or MabSelect® PrimaA medium. In some embodiments, the capture step includes a binding elution mode affinity chromatography step. In some embodiments, the CEX chromatography step includes a CEX chromatography medium, e.g., Poros® XS medium, which includes rigid polymer resin particles containing crosslinked poly[styrene-divinylbenzene] having a polyhydroxyl surface coating further functionalized with sulfopropyl (SP) strong cation exchange groups. In some embodiments, the CEX chromatography step includes a CEX chromatography medium, e.g., Poros® 50HS, comprising rigid polymer resin particles containing crosslinked poly[styrene-divinylbenzene] having a polyhydroxyl surface coating further functionalized with sulfopropyl (SP) strong cation exchange groups. In some embodiments, the MM-HIC / AEX chromatography step includes a medium containing a multimodal strong anion exchanger using an N-benzyl-N-methylethanolamine ligand, e.g., Capto® Adhere medium. In some embodiments, the purification platform further includes a deep filtration step positioned at any location.

[0197] II. How to use a purification platform In some embodiments, this disclosure provides a method for using the purification platform described herein. In some embodiments, the method includes subjecting a sample containing a target to the purification platform described herein.

[0198] In some embodiments, the methods described herein can reduce the hydrolase activity rate of a composition obtained from a purification platform. In some embodiments, the hydrolase activity rate represents the activity rate of one or more hydrolases, e.g., one or more different hydrolases. As discussed in other sections herein, in some embodiments, the hydrolase activity rate is a surrogate measure of the activity of one or more enzymes in the composition. In some embodiments, the hydrolase activity rate is measured via a surrogate substrate. In some embodiments, the hydrolase activity rate is evaluated by measuring the hydrolysis products of one or more hydrolases. In some embodiments, the reduction in hydrolase activity rate is at least about 20%, e.g., at least about 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 85%, 90%, or 95%.

[0199] In some embodiments, a method is provided comprising subjecting a sample to a purification platform for purifying a target from the sample, wherein the purification platform comprises a capture step; one or more ion exchange (IEX) chromatography steps; and a deep filtration step. In some embodiments, the purification platform further comprises a viral filtration step and / or a UF / DF step. In some embodiments, the deep filtration step is immediately preceding the viral filtration step or the UF / DF step. In some embodiments, the deep filtration step is sequential to or immediately following the IEX chromatography step. In some embodiments, the deep filtration step comprises an X0SP depth filter on an EMPHAZE® depth filter. In some embodiments, the purification platform further comprises a HIC step.

[0200] In some embodiments, the method comprises subjecting a sample to a purification platform to purify a target from the sample, the purification platform comprising, in order: (a) a capture step; (b) a CEX chromatography step; (c) an AEX chromatography step; (d) a deep filtration step; (e) a viral filtration step; and (f) a UF / DF step. In some embodiments, the capture step comprises processing via a protein A-based affinity medium, e.g., MabSelect SuRe® or MabSelect® PrimaA medium. In some embodiments, the capture step comprises a binding elution mode affinity chromatography step. In some embodiments, the CEX chromatography step comprises a CEX chromatography medium comprising crosslinked 6% agarose beads having sulfopropyl (SP) strong cation exchange groups, e.g., SP Sepharose® Fast Flow (SPSFF) medium. In some embodiments, the AEX chromatography step comprises an AEX chromatography medium comprising crosslinked 6% agarose beads having quaternary ammonium (Q) strong anion exchange groups, e.g., Q Sepharose® Fast Flow (QSFF) medium. In some embodiments, the deep filtration step includes a depth filter containing silica, such as a silica filter aid, and / or polyacrylic fibers, for example, an X0SP depth filter, a C0SP depth filter, or a D0SP depth filter.

[0201] In some embodiments, the method comprises subjecting a sample to a purification platform for purifying a target from the sample, the purification platform comprising: a capture step comprising a protein A-based affinity medium, e.g., MabSelect SuRe® or MabSelect® PrimaA medium, and configured to be a binding elution affinity chromatography step; (b) a CEX chromatography step comprising a CEX chromatography medium comprising a crosslinked 6% agarose beads having sulfopropyl (SP) strong cation exchange groups, e.g., SP Sepharose® Fast Flow (SPSFF) medium; (c) an AEX chromatography step comprising an AEX chromatography medium comprising a crosslinked 6% agarose beads having quaternary ammonium (Q) strong anion exchange groups, e.g., Q Sepharose® Fast Flow (QSFF) medium; and (d) a deep filtration step comprising a depth filter comprising silica such as a silica filter aid and / or polyacrylic fibers such as an X0SP depth filter, C0SP depth filter, or D0SP depth filter; and a UF / DF step. In some embodiments, the purification platform further includes a deep filtration step positioned at any location, the deep filtration step including a depth filter such as a silica filter aid, and / or polyacrylic fibers, e.g., an X0SP depth filter, a C0SP depth filter, or a D0SP depth filter, and the deep filtration step is configured to be carried out when, for example, the input material has a pH of about 5 to about 6.5, e.g., about 5 to about 5.5 or about 5.8 to about 6.2. In some embodiments, the purification platform further includes a deep filtration step positioned at any location, the deep filtration step including a depth filter containing a hydrogel Q (quaternary amine, also called quaternary ammonium) functionalized nonwoven fabric material and a multizone microporous membrane, e.g., an EMPHAZE® AEX depth filter, and the deep filtration step is configured to be carried out when, for example, the input material has a pH of about 7.5 to about 8.5, e.g., about 8.In some embodiments, the purification platform further includes an HIC step positioned at any location, the HIC step including an HIC medium such as an HIC membrane containing a phenyl portion conjugated to a stabilized and strengthened cellulose filter, for example, Sartobind® phenyl medium, and the HIC step is configured to be carried out when the input material has a pH of about 5 to about 6, for example, about 5.5.

[0202] In some embodiments, the method comprises subjecting a sample to a purification platform to purify a target from the sample, the purification platform comprising: (a) a capture step comprising a protein A-based affinity medium, e.g., MabSelect SuRe® or MabSelect® PrimaA medium, and configured to be a binding elution affinity chromatography step; (b) a CEX chromatography step comprising a CEX chromatography medium comprising crosslinked 6% agarose beads having sulfopropyl (SP) strong cation exchange groups, e.g., SP Sepharose® Face Flow (SPSFF) medium; and (c) an AEX chromatography medium comprising crosslinked 6% agarose beads having quaternary ammonium (Q) strong anion exchange groups, e.g., Q Sepharose® Fast The process includes: an AEX chromatography step including a Flow (QSFF) medium; a deep filtration step including a depth filter containing a hydrogel Q (quaternary amine, also called a quaternary ammonium)-functionalized nonwoven fabric material and a multizone microporous membrane, e.g., EMPHAZE® AEX depth filter; a viral filtration step; and a UF / DF step. In some embodiments, the purification platform further includes a deep filtration step positioned at any location, the deep filtration step including a depth filter containing silica, such as a silica filter aid, and polyacrylic fibers, such as an X0SP depth filter, a C0SP depth filter, or a D0SP depth filter, and the deep filtration step is configured to be carried out, for example, when the input material has a pH of about 5 to about 6, e.g., about 5.5.

[0203] In some embodiments, the purification platform further includes a deep filtration step positioned at any location, the deep filtration step including a depth filter containing a hydrogel Q (quaternary amine, also known as quaternary ammonium)-functionalized nonwoven fabric material and a multizone microporous membrane, e.g., EMPHAZE® AEX depth filter, and the deep filtration step is configured to be carried out, for example, when the input material has a pH of about 7.5 to about 8.5, e.g., about 8. In some embodiments, the purification platform further includes a HIC step positioned at any location, the HIC step including an HIC medium such as an HIC membrane containing a phenyl portion conjugated to a stabilized and strengthened cellulose filter, e.g., Sartobind® phenyl medium, and the HIC step is configured to be carried out, for example, when the input material has a pH of about 5 to about 6, e.g., about 5.5. In some embodiments, the method comprises subjecting a sample to a purification platform to purify a target from the sample, the purification platform comprising: (a) a capture step comprising a protein A-based affinity medium, e.g., MabSelect SuRe® or MabSelect® PrimaA medium, and configured to be a binding elution affinity chromatography step; (b) a CEX chromatography step comprising a CEX chromatography medium comprising a crosslinked 6% agarose beads having a sulfopropyl (SP) strong cation exchange group, e.g., SP Sepharose® Fast Flow (SPSFF) medium; (c) an AEX chromatography step comprising an AEX chromatography medium comprising a crosslinked 6% agarose beads having a quaternary ammonium (Q) strong anion exchange group, e.g., Q Sepharose® Fast Flow (QSFF) medium; (d) an HIC step comprising a stabilized and enhanced cellulose filter, e.g., an HIC medium comprising a phenyl moiety conjugated to Sartobind® phenyl; a viral filtration step; and a UF / DF step.In some embodiments, the purification platform further includes a deep filtration step positioned at any location, the deep filtration step including a depth filter comprising silica, such as a silica filter aid, and polyacrylic fibers, such as an X0SP depth filter, a C0SP depth filter, or a D0SP depth filter, and the deep filtration step is configured to be carried out, for example, when the input material has a pH of about 5 to about 6, for example, about 5.5. In some embodiments, the purification platform further includes a deep filtration step positioned at any location, the deep filtration step including a depth filter comprising a hydrogel Q (quaternary amine, also called quaternary ammonium) functionalized nonwoven fabric material and a multizone microporous membrane, for example, an EMPHAZE® AEX depth filter, and the deep filtration step is configured to be carried out, for example, when the input material has a pH of about 7.5 to about 8.5, for example, about 8. In some embodiments, the purification platform further includes an HIC step positioned at any location, the HIC step including an HIC medium such as an HIC membrane containing a phenyl portion conjugated to a stabilized and strengthened cellulose filter, for example, Sartobind® phenyl medium, and the HIC step is configured to be carried out when the input material has a pH of about 5 to about 6, for example, about 5.5.

[0204] In some embodiments, a method is provided comprising subjecting a sample to a purification platform for purifying a target from the sample, wherein the purification platform comprises a multimodal hydrophobic interaction / ion exchange (MM-HIC / IEX) chromatography step; and a hydrophobic interaction chromatography (HIC) step. In some embodiments, the purification platform further comprises a viral filtration step. In some embodiments, the purification platform further comprises a UF / DF step. An exemplary purification platform encompassed within the described purification platform is shown in Figure 1B and is described in more detail below.

[0205] In some embodiments, the method comprises subjecting a sample to a purification platform to purify a target from the sample, the purification platform comprising, in order: (a) a capture step; (b) an MM-HIC / IEX chromatography step; and (c) an HIC step. In some embodiments, the capture step comprises a protein A-based affinity medium, e.g., MabSelect SuRe® or MabSelect® PrimaA medium. In some embodiments, the capture step comprises a binding-elution mode affinity chromatography step. In some embodiments, the MM-HIC / IEX chromatography step comprises an MM-HIC / AEX chromatography step. In some embodiments, the MM-HIC / AEX chromatography step comprises a medium containing a multimodal strong anion exchanger using an N-benzyl-N-methylethanolamine ligand, e.g., Capto® Adhere medium. In some embodiments, the MM-HIC / IEX chromatography step is an MM-HIC / CEX chromatography step. In some embodiments, the MM-HIC / CEX chromatography step includes a medium containing a multimodal weak cation exchanger using an N-benzoyl-homocysteine ​​ligand, such as Capto® MMC medium. In some embodiments, the HIC step includes a medium containing crosslinked 6% agarose beads modified with aromatic phenyl groups via uncharged, chemically stable ether bonds, such as Phenyl SFF medium such as Phenyl SFF HS or Phenyl SFF LS. In some embodiments, the HIC step includes a medium containing a polymethacrylate-based material with a pore size of 100 nm bonded to a C6 group (hexyl), such as Toyopearl® Hexyl-650 medium, such as Toyopearl® Hexyl-650C. In some embodiments, the HIC step includes a medium containing crosslinked poly(styrene-divinylbenzene) POROS® beads having an aromatic hydrophobic benzyl ligand, such as Poros® Benzyl Ultra.

[0206] In some embodiments, the method comprises subjecting a sample to a purification platform to purify a target from the sample, the purification platform comprising: (a) a capture step comprising a protein A-based affinity medium, e.g., MabSelect SuRe® or MabSelect® PrimaA medium, and configured to be a binding-elution affinity chromatography step; (b) an MM-HIC / AEX chromatography step comprising a medium comprising a multimodal strong anion exchanger using an N-benzyl-N-methylethanolamine ligand, e.g., Capto® Adhere medium; and (c) an HIC step comprising a medium comprising a Phenyl SFF medium such as Phenyl SFF HS or Phenyl SFF LS, comprising crosslinked 6% agarose beads modified with aromatic phenyl groups via uncharged and chemically stable ether bonds.

[0207] In some embodiments, the method comprises subjecting a sample to a purification platform to purify a target from the sample, the purification platform comprising: (a) a capture step configured to be a binding-elution affinity chromatography step comprising a protein A-based affinity medium, e.g., MabSelect SuRe® or MabSelect® PrimaA medium; (b) an MM-HIC / AEX chromatography step comprising a medium comprising a multimodal strong anion exchanger using an N-benzyl-N-methylethanolamine ligand, e.g., Capto® Adhere medium; and (c) an HIC step comprising a medium comprising a polymethacrylate-based material with a pore size of 100 nm bound to a C6 group (hexyl), e.g., Toyopearl® Hexyl-650 medium.

[0208] In some embodiments, the method comprises subjecting a sample to a purification platform to purify a target from the sample, the purification platform comprising: (a) a capture step configured to be a binding-elution affinity chromatography step comprising a protein A-based affinity medium, e.g., MabSelect SuRe® or MabSelect® PrimaA medium; (b) an MM-HIC / AEX chromatography step comprising a medium comprising a multimodal strong anion exchanger using an N-benzyl-N-methylethanolamine ligand, e.g., Capto® Adhere medium; and (c) an HIC step comprising a medium comprising crosslinked poly(styrene-divinylbenzene) POROS®-based beads having an aromatic hydrophobic benzyl ligand, e.g., Poros® Benzyl Ultra medium.

[0209] In some embodiments, the method comprises subjecting a sample to a purification platform for purifying a target from the sample, the purification platform comprising: (a) a capture step comprising a protein A-based affinity medium, e.g., MabSelect SuRe® or MabSelect® PrimaA medium, configured such that the capture step is a binding-elution affinity chromatography step; (b) an MM-HIC / CEX chromatography step comprising a medium comprising a multimodal weak cation exchanger using an N-benzoyl-homocysteine ​​ligand, e.g., Capto® MMC medium; and (c) an HIC step comprising a medium comprising a Phenyl SFF medium such as Phenyl SFF HS or Phenyl SFF LS, comprising crosslinked 6% agarose beads modified with aromatic phenyl groups via uncharged and chemically stable ether bonds.

[0210] In some embodiments, the method comprises subjecting a sample to a purification platform to purify a target from the sample, the purification platform comprising: (a) a capture step configured to be a binding-elution affinity chromatography step comprising a protein A-based affinity medium, e.g., MabSelect SuRe® or MabSelect® PrimaA medium; (b) an MM-HIC / CEX chromatography step comprising a medium comprising a multimodal weak cation exchanger using an N-benzoyl-homocysteine ​​ligand, e.g., Capto® MMC medium; and (c) an HIC step comprising a medium comprising a polymethacrylate-based material with a pore size of 100 nm bound to a C6 group (hexyl), e.g., Toyopearl® Hexyl-650 medium.

[0211] In some embodiments, the method comprises subjecting a sample to a purification platform to purify a target from the sample, the purification platform comprising: (a) a capture step configured to be a binding-elution affinity chromatography step comprising a protein A-based affinity medium, e.g., MabSelect SuRe® or MabSelect® PrimaA medium; (b) an MM-HIC / CEX chromatography step comprising a medium comprising a multimodal weak cation exchanger using an N-benzoyl-homocysteine ​​ligand, e.g., Capto® MMC medium; and (c) an HIC step comprising a medium comprising crosslinked poly(styrene-divinylbenzene) POROS® system beads having an aromatic hydrophobic benzyl ligand, e.g., Poros® Benzyl Ultra. In some embodiments, the purification platform further comprises a deep filtration step placed at any position.

[0212] In some embodiments, the method comprises subjecting a sample to a purification platform to purify a target from the sample, the purification platform comprising, in order: (a) a capture step; (b) an MM-HIC / AEX chromatography step; (c) an HIC step; (d) a viral filtration step; and (e) an UF / DF step. In some embodiments, the capture step comprises processing via a protein A-based affinity medium, e.g., MabSelect SuRe® or MabSelect® PrimaA medium. In some embodiments, the capture step comprises a binding-elution mode affinity chromatography step. In some embodiments, the MM-HIC / AEX chromatography step comprises a medium comprising a multimodal strong anion exchanger using an N-benzyl-N-methylethanolamine ligand, e.g., Capto® Adhere medium. In some embodiments, the HIC step comprises a medium comprising crosslinked 6% agarose beads modified with aromatic phenyl groups via uncharged, chemically stable ether bonds, the medium comprising a phenyl / mL medium of about 40–45 μmol, e.g., Phenyl SFF HS medium. In some embodiments, the HIC step includes a medium containing a polymethacrylate-based material with a pore size of 100 nm bonded to a C6 group (hexyl), such as Toyopearl® Hexyl-650 medium. In some embodiments, the HIC step includes a medium containing crosslinked poly(styrene-divinylbenzene) POROS® beads having an aromatic hydrophobic benzyl ligand, such as Poros® Benzyl Ultra.

[0213] In some embodiments, the method comprises subjecting a sample to a purification platform for purifying a target from the sample, the purification platform comprising: (a) a capture step comprising a protein A-based affinity medium, e.g., MabSelect SuRe® or MabSelect® PrimaA medium, configured such that the capture step is a binding elution affinity chromatography step; (b) an MM-HIC / AEX chromatography step comprising a medium comprising a multimodal strong anion exchanger using an N-benzyl-N-methylethanolamine ligand, e.g., Capto® Adhere medium; (c) an HIC step comprising a medium comprising crosslinked 6% agarose beads modified with aromatic phenyl groups via uncharged and chemically stable ether bonds, and containing about 40-45 μmol of phenyl / mL medium, e.g., Phenyl SFF HS medium; (d) a viral filtration step; and (e) a UF / DF step.

[0214] In some embodiments, the method comprises subjecting a sample to a purification platform to purify a target from the sample, the purification platform comprising, in order: (a) a capture step comprising a protein A-based affinity medium, e.g., MabSelect SuRe® or MabSelect® PrimaA medium, and configured to be a binding-elution affinity chromatography step; (b) an MM-HIC / AEX chromatography step comprising a medium comprising a multimodal strong anion exchanger using an N-benzyl-N-methylethanolamine ligand, e.g., Capto® Adhere medium; (c) an HIC step comprising a medium comprising a 100 nm pore-size polymethacrylate material bound to a C6 group (hexyl), e.g., Toyopearl® Hexyl-650 medium; (d) a viral filtration step; and (e) a UF / DF step.

[0215] In some embodiments, the method comprises subjecting a sample to a purification platform to purify a target from the sample, the purification platform comprising: (a) a capture step configured to be a binding-elution affinity chromatography step comprising a protein A-based affinity medium, e.g., MabSelect SuRe® or MabSelect® PrimaA medium; (b) an MM-HIC / AEX chromatography step comprising a medium comprising a multimodal strong anion exchanger using an N-benzyl-N-methylethanolamine ligand, e.g., Capto® Adhere medium; (c) an HIC step comprising a medium comprising crosslinked poly(styrene-divinylbenzene) POROS® system beads having an aromatic hydrophobic benzyl ligand, e.g., Poros® Benzyl Ultra; (d) a viral filtration step; and (e) a UF / DF step.

[0216] In some embodiments, the method comprises subjecting a sample to a purification platform to purify a target from the sample, the purification platform comprising, in order, (a) a capture step; (b) an MM-HIC / AEX chromatography step using a deep filtration step as a load filtration step; and (c) an HIC step. In some embodiments, the capture step comprises a binding-elution mode affinity chromatography step. In some embodiments, the capture step comprises a protein A-based affinity medium comprising a rigid high-flow agarose matrix and an alkali-stabilized protein A-derived ligand (amino acids particularly sensitive to alkali are substituted with residues stable in an alkaline environment), e.g., MabSelect SuRe® medium. In some embodiments, the capture step comprises a protein A-based affinity medium comprising a rigid high-flow agarose matrix and an alkali-stable protein A-derived ligand, e.g., MabSelect® PrismA medium. In some embodiments, the MM-HIC / AEX chromatography step comprises a medium comprising a multimodal strong anion exchanger using an N-benzyl-N-methylethanolamine ligand, e.g., Capto® Adhere medium. In some embodiments, the deep filtration step includes a depth filter comprising silica, such as a silica filter aid, and polyacrylic fibers, such as X0SP depth filters, C0SP depth filters, or D0SP depth filters. In some embodiments, the deep filtration step includes a depth filter comprising a hydrogel Q (quaternary amine, also called quaternary ammonium) functionalized nonwoven fabric material and a multizone microporous membrane, such as an EMPHAZE® AEX depth filter. In some embodiments, the HIC step is a flow-through mode HIC step. In some embodiments, the HIC step includes a medium comprising a polymethacrylate material with a pore size of 100 nm bonded to a C6 group (hexyl), such as a Toyopearl® Hexyl-650 medium. In some embodiments, the HIC step includes a medium comprising crosslinked poly(styrene-divinylbenzene) POROS® beads having an aromatic hydrophobic benzyl ligand, such as a Poros® Benzyl Ultra medium.In some embodiments, the HIC step includes a medium containing crosslinked 6% agarose beads modified with aromatic phenyl groups via uncharged, chemically stable ether bonds, the medium containing about 40–45 μmol of phenyl / mL medium, e.g., Phenyl SFF HS medium. In some embodiments, the HIC step includes a pH adjustment step, adjusting the pH of the input material to about 4.5–6. In some embodiments, the HIC step is a low-salt HIC step, such as not adding salts, such as HIC conditioning salts, before packing the material into the HIC membrane or HIC column.

[0217] In some embodiments, the method comprises subjecting a sample to a purification platform for purifying a target from the sample, the purification platform comprising: (a) a capture step comprising a rigid, high-flow agarose matrix and a protein A-based affinity medium comprising a protein A-derived ligand having alkali stability, e.g., MabSelect® PrismA medium; (b) an MM-HIC / AEX chromatography step using a deep filtration step as a load filtration step, comprising a medium comprising a multimodal strong anion exchanger using an N-benzyl-N-methylethanolamine ligand, e.g., Capto® Adhere medium, wherein the deep filtration step comprises a depth filter comprising silica such as a silica filter aid and polyacrylic fibers such as an X0SP depth filter, C0SP depth filter, or D0SP depth filter; and (c) an HIC step which is a flow-through mode HIC step comprising a medium comprising a polymethacrylate material with a pore size of 100 nm bonded to a C6 group (hexyl), e.g., Toyopearl® Hexyl-650 medium. In some embodiments, the HIC process includes a pH adjustment process in which the pH of the input material is adjusted to approximately 4.5 to approximately 5.5, for example, approximately 5.0. In some embodiments, the HIC process is a low-salt HIC process, such as not adding salts such as HIC conditioning salts before packing the material into the HIC membrane or HIC column.

[0218] In some embodiments, the method comprises subjecting a sample to a purification platform for purifying a target from the sample, the purification platform comprising: (a) a capture step comprising a rigid, high-flow agarose matrix and a protein A-based affinity medium comprising a protein A-derived ligand having alkali stability, e.g., MabSelect® PrismA medium; (b) an MM-HIC / AEX chromatography step using a deep filtration step as a load filtration step, comprising a medium comprising a multimodal strong anion exchanger using an N-benzyl-N-methylethanolamine ligand, e.g., Capto® Adhere medium, wherein the deep filtration step comprises a depth filter comprising silica such as a silica filter aid and polyacrylic fibers such as an X0SP depth filter, C0SP depth filter, or D0SP depth filter; and (c) a flow-through mode HIC step comprising crosslinked poly(styrene-divinylbenzene) POROS® beads, e.g., Poros® Benzyl Ultra, comprising an aromatic hydrophobic benzyl ligand. In some embodiments, the HIC process includes a pH adjustment process in which the pH of the input material is adjusted to approximately 4.5 to approximately 5.5, for example, approximately 5.0. In some embodiments, the HIC process is a low-salt HIC process, such as not adding salts such as HIC conditioning salts before packing the material into the HIC membrane or HIC column.

[0219] In some embodiments, the method comprises subjecting a sample to a purification platform for purifying a target from the sample, the purification platform comprising: (a) a capture step comprising a rigid, high-flow agarose matrix and a protein A-based affinity medium comprising an alkali-stabilized protein A-derived ligand (in which alkali-sensitive amino acids are substituted with residues more stable in an alkaline environment), e.g., MabSelect SuRe® medium; (b) a deep filtration step as a load filtration step comprising a medium comprising a multimodal strong anion exchanger using an N-benzyl-N-methylethanolamine ligand, e.g., Capto®, Adhere medium, wherein the deep filtration step comprises a depth filter comprising a hydrogel Q (quaternary amine, also called quaternary ammonium)-functionalized nonwoven material and a multizone microporous membrane, e.g., EMPHAZE® AEX depth filter; and (c) a medium comprising crosslinked 6% agarose beads modified with aromatic phenyl groups via uncharged, chemically stable ether bonds, in a phenyl / mL medium of about 40-45 μmol, e.g., Phenyl SFF The HIC process includes an HS medium, and the HIC process is a flow-through mode HIC process. In some embodiments, the HIC process includes a pH adjustment process in which the pH of the input material is adjusted to approximately 5.0 to approximately 6.0, for example, approximately 5.5. In some embodiments, the HIC process is a low-salt HIC process in which no salts, such as HIC conditioning salts, are added before the material is packed into the HIC membrane or HIC column.

[0220] In some embodiments, a method is provided comprising subjecting a sample to a purification platform for purifying a target from the sample, wherein the purification platform comprises one or more ion exchange (IEX) chromatography steps and hydrophobic interaction chromatography (HIC) steps. In some embodiments, the IEX chromatography step is a CEX chromatography step. In some embodiments, the purification platform further comprises a viral filtration step. In some embodiments, the purification platform further comprises a UF / DF step. In some embodiments, the purification platform further comprises a deep filtration step. In some embodiments, the purification platform further comprises an HIC step. An exemplary purification platform encompassed within the described purification platform is shown in Figure 1C and is described in more detail below.

[0221] In some embodiments, the method comprises subjecting a sample to a purification platform for purifying a target from the sample, the purification platform comprising, in order: (a) a capture step; (b) a CEX chromatography step; (c) a HIC step; (d) a viral filtration step; and (e) a UF / DF step. In some embodiments, the capture step comprises a protein A-based affinity medium, e.g., MabSelect SuRe® or MabSelect® PrimaA medium. In some embodiments, the capture step comprises a binding elution mode affinity chromatography step. In some embodiments, the CEX chromatography step comprises a CEX chromatography medium comprising rigid polymer resin particles containing crosslinked poly[styrene-divinylbenzene] having a polyhydroxyl surface coating further functionalized with sulfopropyl (SP) strong cation exchange groups, e.g., Poros® XS medium. In some embodiments, the CEX chromatography step comprises a CEX chromatography medium comprising rigid polymer resin particles containing crosslinked poly[styrene-divinylbenzene] having a polyhydroxyl surface coating further functionalized with sulfopropyl (SP) strong cation exchange groups, e.g., Poros® 50HS. In some embodiments, the HIC step includes crosslinked 6% agarose beads modified with aromatic phenyl groups via uncharged, chemically stable ether bonds, and a medium containing about 40-45 μmol of phenyl / mL, such as Phenyl SFF HS medium. In some embodiments, the HIC step includes a medium containing a polymethacrylate-based material with a pore size of 100 nm bonded to a C6 (hexyl) group, such as Toyopearl® Hexyl-650 medium. In some embodiments, the HIC step includes a medium containing crosslinked poly(styrene-divinylbenzene) POROS® beads having an aromatic hydrophobic benzyl ligand, such as Poros® Benzyl Ultra.

[0222] In some embodiments, the method comprises subjecting a sample to a purification platform for purifying a target from the sample, the purification platform comprising: (a) a capture step comprising a protein A-based affinity medium, e.g., MabSelect SuRe® or MabSelect® PrimaA medium, and configured to be a binding elution affinity chromatography step; (b) a CEX chromatography step comprising a CEX chromatography medium comprising a rigid polymer resin particle containing crosslinked poly[styrene-divinylbenzene] having a polyhydroxyl surface coating further functionalized with sulfopropyl (SP) strong cation exchange groups, e.g., Poros® XS medium; (c) a HIC step comprising crosslinked 6% agarose beads modified with aromatic phenyl groups via uncharged chemically stable ether bonds, and a phenyl / mL medium of about 40-45 μmol, e.g., Phenyl SFF HS medium; (d) a viral filtration step; and (e) a UF / DF step.

[0223] In some embodiments, the method comprises subjecting a sample to a purification platform to purify a target from the sample, the purification platform comprising, in order: (a) a capture step comprising a protein A-based affinity medium, e.g., MabSelect SuRe® or MabSelect® PrimaA medium, and configured to be a binding elution affinity chromatography step; (b) a CEX chromatography step comprising a CEX chromatography medium comprising rigid polymer resin particles containing crosslinked poly[styrene-divinylbenzene] having a polyhydroxyl surface coating further functionalized with sulfopropyl (SP) strong cation exchange groups, e.g., Poros® XS medium; (c) an HIC step comprising a medium comprising a polymethacrylate-based material with a pore size of 100 nm bonded to a C6 group (hexyl), e.g., Toyopearl® Hexyl-650 medium; (d) a viral filtration step; and (e) a UF / DF step.

[0224] In some embodiments, the method comprises subjecting a sample to a purification platform to purify a target from the sample, the purification platform comprising, in order: (a) a capture step comprising a binding elution mode affinity chromatography step; (b) a CEX chromatography step comprising a CEX chromatography medium comprising rigid polymer resin particles comprising crosslinked poly[styrene-divinylbenzene] having a polyhydroxyl surface coating further functionalized with sulfopropyl (SP) strong cation exchange groups, e.g., Poros® XS medium; (c) a HIC step comprising a medium comprising crosslinked poly(styrene-divinylbenzene) POROS® system beads having an aromatic hydrophobic benzyl ligand, e.g., Poros® Benzyl Ultra medium; (d) a viral filtration step; and (e) a UF / DF step.

[0225] In some embodiments, the method comprises subjecting a sample to a purification platform to purify a target from the sample, the purification platform comprising: (a) a capture step comprising a binding elution mode affinity chromatography step; (b) a CEX chromatography step comprising a CEX chromatography medium, e.g., Poros® 50HS medium, comprising rigid polymer resin particles comprising crosslinked poly[styrene-divinylbenzene] having a polyhydroxyl surface coating further functionalized with sulfopropyl (SP) strong cation exchange groups; (c) a HIC step comprising a crosslinked 6% agarose beads modified with aromatic phenyl groups via uncharged chemically stable ether bonds, and a phenyl / mL medium of about 40-45 μmol, e.g., Phenyl SFF HS medium; (d) a viral filtration step; and (e) a UF / DF step.

[0226] In some embodiments, the method comprises subjecting a sample to a purification platform to purify a target from the sample, the purification platform comprising, in order: (a) a capture step comprising a protein A-based affinity medium, e.g., MabSelect SuRe® or MabSelect® PrimaA medium, and configured to be a binding elution affinity chromatography step; (b) a CEX chromatography step comprising a CEX chromatography medium comprising rigid polymer resin particles containing crosslinked poly[styrene-divinylbenzene] having a polyhydroxyl surface coating further functionalized with sulfopropyl (SP) strong cation exchange groups, e.g., Poros® 50HS medium; (c) an HIC step comprising a medium comprising a polymethacrylate-based material with a pore size of 100 nm bonded to a C6 group (hexyl), e.g., Toyopearl® Hexyl-650 medium; (d) a viral filtration step; and (e) a UF / DF step.

[0227] In some embodiments, the method comprises subjecting a sample to a purification platform for purifying a target from the sample, the purification platform comprising, in order: (a) a capture step comprising a protein A-based affinity medium, e.g., MabSelect SuRe® or MabSelect® PrimaA medium, and configured to be a binding elution affinity chromatography step; (b) a CEX chromatography step comprising a CEX chromatography medium comprising rigid polymer resin particles containing crosslinked poly[styrene-divinylbenzene] having a polyhydroxyl surface coating further functionalized with sulfopropyl (SP) strong cation exchange groups, e.g., Poros® 50HS medium; (c) a HIC step comprising a medium comprising crosslinked poly(styrene-divinylbenzene) POROS® system beads having an aromatic hydrophobic benzyl ligand, e.g., Poros® Benzyl Ultra; (d) a viral filtration step; and (e) a UF / DF step. In some embodiments, the purification platform further comprises a deep filtration step positioned at any location.

[0228] In some embodiments, a method is provided comprising subjecting a sample to a purification platform for purifying a target from the sample, wherein the purification platform comprises one or more ion exchange (IEX) chromatography steps; hydrophobic interaction chromatography (HIC) steps; and deep filtration steps. In some embodiments, the purification platform further comprises a viral filtration step and / or a UF / DF step. In some embodiments, the deep filtration step and / or HIC step is immediately preceding the viral filtration step of the UF / DF step. In some embodiments, the deep filtration step and / or HIC step is sequential to or immediately following the IEX chromatography step. An exemplary purification platform encompassed within the described purification platform is shown in Figure 1D and described in more detail below.

[0229] In some embodiments, the method comprises subjecting a sample to a purification platform to purify a target from the sample, the purification platform comprising, in order: (a) a CEX chromatography step; (b) an HIC step; (c) an AEX chromatography step; (d) a deep filtration step; and (f) an UF / DF step. In some embodiments, the CEX chromatography step comprises a CEX chromatography medium comprising crosslinked 6% agarose beads having dextran chains covalently bonded to an agarose matrix modified with sulfopropyl (SP) strong cation exchange groups, e.g., SP Sepharose® XL (SPXL) medium or Streamline® SPXL medium. In some embodiments, the HIC step comprises an HIC medium comprising a propyl group covalently bonded to nitrogen on a polyethyleneimine (PEI) ligand bound to a substrate, e.g., Bakerbond WP HI-Propyl® medium. In some embodiments, the MMIEX chromatography step comprises an MMIEX chromatography medium comprising silica gel solid particles containing a mixed-mode anion / cation exchanger, e.g., Bakerbond ABx® medium. In some embodiments, the AEX chromatography step includes an AEX chromatography medium containing crosslinked 6% agarose beads having quaternary ammonium (Q) strong anion exchange groups, such as Q Sepharose® Fast Flow (QSFF) medium. In some embodiments, the deep filtration step includes a depth filter containing silica, such as a silica filter aid, and polyacrylic fibers, such as an X0SP depth filter, a C0SP depth filter, or a D0SP depth filter.

[0230] In some embodiments, the method comprises subjecting a sample to a purification platform for purifying a target from the sample, the purification platform comprising: (a) a CEX chromatography step comprising a CEX chromatography medium comprising crosslinked 6% agarose beads having dextran chains covalently bonded to an agarose matrix modified with sulfopropyl (SP) strong cation exchange groups, e.g., SP Sepharose® XL (SPXL) medium or Streamline® SPXL medium; (b) an HIC step comprising an HIC medium comprising a propyl group covalently bonded to nitrogen on a polyethyleneimine (PEI) ligand bound to a substrate, e.g., Bakerbond WP HI-Propyl® medium; (c) an MMIEX chromatography step comprising an MMIEX chromatography medium comprising silica gel solid phase particles comprising a mixed-mode anion / cation exchanger, e.g., Bakerbond ABx® medium; and (d) an AEX chromatography medium comprising crosslinked 6% agarose beads having quaternary ammonium (Q) strong anion exchange groups, e.g., Q Sepharose® Fast The process includes: (a) an AEX chromatography step containing a Flow (QSFF) medium; (b) a deep filtration step containing a depth filter containing silica such as a silica filter aid and polyacrylic fibers such as an X0SP depth filter, a C0SP depth filter, or a D0SP depth filter; and (f) a UF / DF step. In some embodiments, the purification platform further includes a deep filtration step positioned at any location, the deep filtration step including a depth filter containing silica such as a silica filter aid and polyacrylic fibers such as an X0SP depth filter, a C0SP depth filter, or a D0SP depth filter, and the deep filtration step is configured to be carried out when the input material has a pH of about 6 to about 7, for example, about 6.5.In some embodiments, the purification platform further includes a deep filtration step positioned at any location, the deep filtration step including a depth filter containing a hydrogel Q (quaternary amine, also known as quaternary ammonium)-functionalized nonwoven fabric material and a multizone microporous membrane, e.g., EMPHAZE® AEX depth filter, and the deep filtration step is configured to be carried out, for example, when the input material has a pH of about 8.5 to about 9.5, e.g., about 9.1. In some embodiments, the purification platform further includes a HIC step positioned at any location, the HIC step including an HIC medium such as an HIC membrane containing a phenyl portion conjugated to a stabilized and strengthened cellulose filter, e.g., Sartobind® phenyl medium, and the HIC step is configured to be carried out, for example, when the input material has a pH of about 6 to about 7, e.g., about 6.5.

[0231] In some embodiments, a method is provided comprising subjecting a sample to a purification platform for purifying a target from the sample, wherein the purification platform comprises (a) a capture step; (b) one or more ion exchange (IEX) chromatography steps, such as a CEX chromatography step; (c) a multimodal hydrophobic interaction / ion exchange (MM-HIC / IEX) chromatography step; and (d)(i) a hydrophobic interaction chromatography (HIC) step; and (ii) a deep filtration step, or both. In some embodiments, the purification platform further comprises a viral filtration step. In some embodiments, a method is provided in which the purification platform further comprises a UF / DF step. An exemplary purification platform encompassed within the described purification platform is shown in Figure 1E. In some embodiments, the capture step comprises a protein A-based affinity medium, e.g., MabSelect SuRe® or MabSelect® PrimaA medium. In some embodiments, the capture step comprises a binding elution mode affinity chromatography step. In some embodiments, the CEX chromatography step includes a CEX chromatography medium, e.g., Poros® XS medium, comprising rigid polymer resin particles containing crosslinked poly[styrene-divinylbenzene] having a polyhydroxyl surface coating further functionalized with sulfopropyl (SP) strong cation exchange groups. In some embodiments, the CEX chromatography step includes a CEX chromatography medium, e.g., Poros® 50HS medium, comprising rigid polymer resin particles containing crosslinked poly[styrene-divinylbenzene] having a polyhydroxyl surface coating further functionalized with sulfopropyl (SP) strong cation exchange groups. In some embodiments, the MM-HIC / AEX chromatography step includes a medium comprising a multimodal strong anion exchanger using an N-benzyl-N-methylethanolamine ligand, e.g., Capto® Adhere medium. In some embodiments, the purification platform further includes a deep filtration step positioned at any location.

[0232] III. Further steps and methods In some embodiments, this disclosure provides additional steps involved in or related to the purification platform described herein. Additional steps involved in or related to the purification platform and methods for performing such steps are known. See, for example, Liu et al. mAbs, 2, 2010, which is incorporated herein in its entirety by reference.

[0233] In some embodiments, the method further includes a cell culture step. In some embodiments, the method further includes a sample processing step, such as a sample preparation step. In some embodiments, the method further includes a clarification step, for example, to clarify HCCF. In some embodiments, the method further includes a host cell and host cell debris removal step, such as removing host cells and host cell debris from the composition obtained from the sample and / or purification platform. In some embodiments, the method further includes a centrifugation step. In some embodiments, the method further includes a sterile filtration step. In some embodiments, the method further includes a tangential flow microfiltration step. In some embodiments, the method further includes an agglutination / precipitation step.

[0234] In some embodiments, the above method further includes a formulation step, such as treating the composition to form a pharmaceutically acceptable composition or a precursor thereof.

[0235] In some embodiments, the method further includes determining the hydrolytic enzyme activity rate of the composition. In some embodiments, the method further includes performing a hydrolytic activity assay on the composition obtained from the purification platform described herein. In some embodiments, the hydrolytic activity assay includes measuring the hydrolytic activity of one or more hydrolytic enzymes by monitoring the conversion of a substrate, such as a non-fluorescent substrate, to a detectable product of the hydrolytic enzyme, such as a fluorescent product. In some embodiments, the substrate includes an ester bond. In some embodiments, the method further includes determining the product of one or more hydrolytic enzymes, for example, as described in International Publication No. 2018035025, which is incorporated herein in its entirety by reference. In some embodiments, the method further includes determining the level of free fatty acids (FFA) in the composition obtained from the purification platform described herein by performing a fatty acid mass spectrometry (FAMS) assay. In some embodiments, to monitor the content of free fatty acids after PS20 degradation in each elution pool, samples were first prepared for PS20 stability testing and subsequently analyzed by mass spectrometry. In some embodiments, the method further includes determining the level of one or more hydrolytic enzymes in the composition.

[0236] In some embodiments, the method further includes determining the shelf life of the composition. In some embodiments, the method further includes determining the level of target aggregates in the composition. In some embodiments, a hydrolysis activity assay (LEAP assay) includes measuring hydrolysis activity by monitoring the conversion of a non-fluorescent substrate to a fluorescent product by cleavage of substrate ester bonds. In some embodiments, the hydrolysis activity at [μMMU / h] is measured against the reaction rate (k) of the sample. raw [RFU / h]) to the reaction rate of the enzyme blank (k self-cleavage [RFU / h]) is subtracted, and the fluorescence signal is converted to μM MU / h by dividing the term by a conversion factor a [RFU / μM]. In some embodiments, the hydrolysis activity is normalized to the protein concentration applied per well. In some embodiments, the hydrolysis activity is reported as a percentage relative to the hydrolysis activity of a reference sample when the reference sample represents 100% hydrolysis activity.

[0237] In some embodiments, the fatty acid mass spectrometry (FAMS) assay involves obtaining extracted ion chromatograms (XICs) for lauric acid, myristic acid, and the masses of isotopically labeled (D 23 )-lauric acid and ( 13 C 14 )-myristic acid. In some embodiments, each peak is integrated and the peak area ratios of lauric acid and D 23 -lauric acid, and of myristic acid and 13 C 14 -myristic acid are determined. In some embodiments, the peak area ratios are used to calculate the concentration of lauric acid and / or myristic acid in the sample. In some embodiments, the amount of FFA (lauric acid (LA) and / or myristic acid (MA)) is reported as a percentage when the amount of the reference sample is set to 100%.

[0238] IV. Samples and Their Components In some embodiments, the purification platforms and methods described herein are useful for purifying a target from a sample containing the target to any degree.

[0239] In some embodiments, the sample is a host cell sample. In some embodiments, the sample is a host cell culture medium (HCCF). In some embodiments, the sample contains a portion of the host cell culture medium. In some embodiments, the sample is derived from the host cell culture medium. In some embodiments, the sample contains host cells. In some embodiments, the sample contains host cell components such as host cell debris. In some embodiments, the host cells are bacterial cells. In some embodiments, the host cells are Escherichia coli (E. coli) cells. In some embodiments, the host cells are insect cells. In some embodiments, the host cells are mammalian cells. In some embodiments, the host cells are Chinese hamster ovary (CHO) cells. In some embodiments, the host cells are human cells.

[0240] In some embodiments, the sample is treated, such as being subjected to a processing step performed before being subjected to the purification platform described herein. In some embodiments, the sample comprises a surfactant. In some embodiments, the sample comprises a polysorbate. In some embodiments, the polysorbate is selected from the group consisting of polysorbate 20, polysorbate 40, polysorbate 60, and polysorbate 80.

[0241] In some embodiments, the sample includes a target. In some embodiments, the target includes a polypeptide. In some embodiments, the target is a polypeptide. In some embodiments, the target is a recombinant polypeptide. In some embodiments, the target is a polypeptide complex. In some embodiments, the target is an antibody moiety. In some embodiments, the antibody moiety is a monoclonal antibody. In some embodiments, the antibody moiety is a humanized antibody. In some embodiments, the antibody moiety is selected from the group consisting of anti-TAU antibody, anti-TGFβ3 antibody, anti-VEGF-A antibody, anti-CD20 antibody, anti-CD40 antibody, anti-HER2 antibody, anti-IL6 antibody, anti-IgE antibody, anti-IL13 antibody, anti-TIGIT antibody, anti-PD-L1 antibody, anti-VEGF-A / ANG2 antibody, anti-CD79b antibody, anti-ST2 antibody, anti-factor D antibody, anti-factor IX antibody, anti-factor X antibody, anti-abeta antibody, anti-CEA antibody, anti-CEA / CD3 antibody, anti-CD20 / CD3 antibody, anti-FcRH5 / CD3 antibody, anti-Her2 / CD3 antibody, anti-FGFR1 / KLB antibody, FAP-4-1BBL fusion protein, FAP-IL2v fusion protein, and TYRP1 TCB antibody. In some embodiments, the antibody portion is selected from the group consisting of ocrelizumab, pertuzumab, ranibizumab, trastuzumab, tocilizumab, falisimab, polatuzumab, gantenerumab, cibisatamab, crenezumab, mosnetuzumab, tilagolmab, bevacizumab, rituximab, atezolizumab, obinutuzumab, lamparizumab, omalizumab, ranibizumab, emicizumab, sericrelumab, pracinezumab, RO6874281, and RO7122290.

[0242] In some embodiments, the sample comprises one or more host cell proteins. In some embodiments, the host cell protein is a hydrolase. In some embodiments, the hydrolase is a lipase, esterase, thioesterase, phospholipase, carboxylesterase, hydrolase, cutinase, or ceramidase. In some embodiments, the hydrolase is a polyenzyme protein. In some embodiments, the polyenzyme protein is a fatty acid synthase. In some embodiments, the fatty acid synthase comprises a thioesterase subunit.

[0243] In some embodiments, the sample has a baseline hydrolase activity rate, such as that measured by a hydrolase activity assay described herein. In some embodiments, the baseline hydrolase activity rate of the sample is at least partially based on the presence of host cell hydrolases. In some embodiments, the hydrolase is a lipase, esterase, thioesterase, phospholipase, carboxylesterase, hydrolase, cutinase, or ceramidase.

[0244] In some embodiments, the sample contains additive components such as surfactants, for example, polysorbates. In some embodiments, the components are added to the sample, for example, HCCF, before purification.

[0245] V. Compositions and pharmaceutical compositions obtained from the purification platform The purification platforms described herein involve numerous steps. In some embodiments, the term “composition” is used herein to describe any input (except the initial sample input to the purification platform), intermediate, or output at any stage of the purification platform. For example, in some embodiments, the use of the term “composition” is not limited to describing the final output of the purification platform. In some embodiments, the composition is processed by a HIC step and / or a deep filtration step and / or an MM-HIC / IEX chromatography step.

[0246] In some embodiments, the composition includes a surfactant. In some embodiments, the composition includes a polysorbate. In some embodiments, the polysorbate is selected from the group consisting of polysorbate 20, polysorbate 40, polysorbate 60, and polysorbate 80.

[0247] In some embodiments, the composition comprises a target. In some embodiments, the target comprises a polypeptide. In some embodiments, the target is a polypeptide. In some embodiments, the target is a polypeptide complex. In some embodiments, the target is an antibody moiety. In some embodiments, the antibody moiety is a monoclonal antibody. In some embodiments, the antibody moiety is a humanized antibody. In some embodiments, the antibody moiety is selected from the group consisting of anti-TAU antibody, anti-TGFβ3 antibody, anti-VEGF-A antibody, anti-CD20 antibody, anti-CD40 antibody, anti-HER2 antibody, anti-IL6 antibody, anti-IgE antibody, anti-IL13 antibody, anti-TIGIT antibody, anti-PD-L1 antibody, anti-VEGF-A / ANG2 antibody, anti-CD79b antibody, anti-ST2 antibody, anti-factor D antibody, anti-factor IX antibody, anti-factor X antibody, anti-abeta antibody, anti-CEA antibody, anti-CEA / CD3 antibody, anti-CD20 / CD3 antibody, anti-FcRH5 / CD3 antibody, anti-Her2 / CD3 antibody, anti-FGFR1 / KLB antibody, FAP-4-1BBL fusion protein, FAP-IL2v fusion protein, and TYRP1 TCB antibody. In some embodiments, the antibody portion is selected from the group consisting of ocrelizumab, pertuzumab, ranibizumab, trastuzumab, tocilizumab, falisimab, polatuzumab, gantenerumab, cibisatamab, crenezumab, mosnetuzumab, tilagolmab, bevacizumab, rituximab, atezolizumab, obinutuzumab, lamparizumab, omalizumab, ranibizumab, emicizumab, sericrelumab, pracinezumab, RO6874281, and RO7122290.

[0248] In some embodiments, the composition comprises one or more host cell proteins. In some embodiments, the host cell protein is a hydrolase. In some embodiments, the hydrolase is a lipase, esterase, thioesterase, phospholipase, carboxylesterase, hydrolase, cutinase, or ceramidase.

[0249] In some embodiments, the composition exhibits a reduced hydrolytic enzyme activity rate, and this reduction is at least about 20%, for example, at least about 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95%, compared to compositions obtained from a purification platform that does not include a HIC step and / or a deep filtration step and / or an MM-HIC / IEX chromatography step, as described in relevant references. In some embodiments, the baseline is from a sample purified using the same purification platform without one or more deep filtration steps and / or one or more HIC steps and / or an MM-HIC / IEX chromatography step.

[0250] In some embodiments, this disclosure provides pharmaceutical compositions obtained from the purification platform described herein. In some embodiments, the pharmaceutical composition is obtained from the method described herein. In some embodiments, the pharmaceutical composition is a purified composition. In some embodiments, the pharmaceutical composition is a sterile pharmaceutical composition.

[0251] In some embodiments, the pharmaceutical composition comprises an antibody moiety. In some embodiments, the pharmaceutical composition comprises an antibody moiety and a polysorbate. In some embodiments, the pharmaceutical composition comprises an antibody moiety, a polysorbate, and host cell impurities such as host cell proteins, e.g., hydrolytic enzymes.

[0252] In some embodiments, the pharmaceutical composition includes polysorbate. In some embodiments, the pharmaceutical composition is selected from the group consisting of polysorbate 20, polysorbate 40, polysorbate 60, and polysorbate 80.

[0253] In some embodiments, the pharmaceutical composition exhibits a reduced hydrolytic enzyme activity rate, and this reduction is at least about 20%, for example, at least about 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or 95%, compared to a pharmaceutical composition obtained from a purification platform that does not include one or more deep filtration steps and / or one or more HIC steps and / or one or more MM-HIC / IEX chromatography steps, as described in relevant references. In some embodiments, the baseline is from a sample purified using the same purification platform that does not include one or more deep filtration steps and / or one or more HIC steps and / or one or more MM-HIC / IEX chromatography steps.

[0254] In some embodiments, the pharmaceutical composition has one or more levels of hydrolytic enzymes reduced compared to a composition obtained from the purification of the same sample using the same purification platform that does not include one or more deep filtration steps and / or one or more HIC steps and / or one or more MM-HIC / IEX chromatography steps.

[0255] In some embodiments, the pharmaceutical compositions exhibit reduced polysorbate degradation compared to compositions obtained from the purification of the same sample using the same purification platform that does not include one or more deep filtration steps and / or one or more HIC steps and / or one or more MM-HIC / IEX chromatography steps.

[0256] In some embodiments, the pharmaceutical compositions have increased shelf life compared to compositions obtained from the purification of the same sample using the same purification platform that does not involve one or more deep filtration steps and / or one or more HIC steps and / or one or more MM-HIC / IEX chromatography steps.

[0257] In some embodiments, the pharmaceutical composition exhibits less polysorbate degradation compared to compositions obtained from the purification of the same sample using the same purification platform that does not include one or more deep filtration steps and / or one or more HIC steps and / or one or more MM-HIC / IEX chromatography steps.

[0258] In some embodiments, the pharmaceutical compositions exhibit reduced target aggregation compared to compositions obtained from the purification of the same sample using the same purification platform that does not include one or more deep filtration steps and / or one or more HIC steps and / or one or more MM-HIC / IEX chromatography steps.

[0259] In some embodiments, this disclosure provides formulated antibody partial compositions obtained from the purification platform described herein. In some embodiments, the formulated antibody partial compositions are obtained from the method described herein.

[0260] In some embodiments, the formulated antibody partial composition comprises an antibody moiety. In some embodiments, the formulated antibody partial composition comprises an antibody moiety and a polysorbate. In some embodiments, the formulated antibody partial composition comprises an antibody moiety, a polysorbate, and host cell impurities such as host cell proteins, e.g., one or more hydrolases.

[0261] In some embodiments, the formulated antibody partial compositions described herein have increased shelf life compared to a standard, for example, a formulated antibody partial composition obtained from the same purification platform that does not include one or more deep filtration steps and / or one or more HIC steps and / or one or more MM-HIC / IEX chromatography steps. In some embodiments, shelf life is assessed (e.g., by measurement) by aggregation of the antibody portion of the formulated antibody partial composition. In some embodiments, shelf life is assessed by measurement or the like by preservation of one or more functionalities of the antibody portion of the formulated antibody partial composition. In some embodiments, shelf life is assessed by measurement or the like by the activity of the antibody portion of the formulated antibody partial composition, for example, by binding activity.

[0262] In some embodiments, formulated antibody partial compositions comprising an antibody moiety and polysorbate exhibit a reduced rate of polysorbate hydrolysis, resulting in a shelf life exceeding approximately 8 months, for example, approximately 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, or 36 months. In some embodiments, the formulated antibody partial composition exhibiting a reduced rate of polysorbate hydrolysis is compared to a baseline, a formulated antibody partial composition obtained from the same purification platform, without, for example, one or more deep filtration steps and / or one or more HIC steps and / or one or more MM-HIC / IEX chromatography steps. In some embodiments, the reduced rate of polysorbate hydrolysis refers to a reduction in the relative rate of polysorbate hydrolysis.

[0263] In some embodiments, the formulated antibody partial composition comprising an antibody moiety and polysorbate exhibits a reduced rate of polysorbate hydrolysis, extending the shelf life of the composition compared to the shelf life indicated in documentation submitted to the health authorities relating to the formulated antibody partial composition, with the shelf life extended by at least about two months, for example, at least about three, four, five, six, seven, eight, nine, ten, eleven, or twelve months, compared to the shelf life indicated in said documentation. In some embodiments, the formulated antibody partial composition with reduced polysorbate hydrolysis is compared to a standard, formulated antibody partial composition obtained from the same purification platform, e.g., without one or more deep filtration steps and / or one or more HIC steps and / or one or more MM-HIC / IEX chromatography steps. In some embodiments, the reduced rate of polysorbate hydrolysis is a reduction in the relative rate of polysorbate hydrolysis.

[0264] In some embodiments, a formulated antibody partial composition comprising an antibody moiety and polysorbate exhibits reduced polysorbate degradation, where the degradation is at least about 5%, for example, at least about 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100%, compared to the degradation indicated in documentation submitted to health authorities for the formulated antibody partial composition. In some embodiments, a formulated antibody partial composition with reduced polysorbate degradation is compared to a baseline, for example, a formulated antibody partial composition obtained from the same purification platform without one or more deep filtration steps and / or one or more HIC steps and / or one or more MM-HIC / IEX chromatography steps. In some embodiments, the reduction in polysorbate degradation is a reduction in the relative degradation of polysorbate.

[0265] In some embodiments, the rate of polysorbate hydrolysis of the formulated antibody partial composition is reduced by at least about 5%, for example, at least about 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% compared to a baseline.

[0266] In some embodiments, the formulated antibody partial composition comprises an antibody partial and a polysorbate, the polysorbate being degraded by approximately 60% or less per year during storage of the liquid composition, for example, approximately 55% or less per year, 50% or less per year, 45% or less per year, 40% or less per year, 35% or less per year, 30% or less per year, 25% or less per year, 20% or less per year, 15% or less per year, 10% or less per year, or 5% or less per year.

[0267] In some embodiments, the formulated antibody partial compositions described herein exhibit reduced aggregate formation for at least about 6 months, for example, at least about 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, or 24 months, compared to a standard, formulated antibody partial composition obtained from the same purification platform that does not include, for example, one or more deep filtration steps and / or one or more HIC steps and / or one or more MM-HIC / IEX chromatography steps. In some embodiments, the formulated antibody partial compositions described herein exhibit reduced aggregate formation for at least about 6 months, for example, at least about 7 months, 8 months, 9 months, 10 months, 11 months, 12 months, 13 months, 14 months, 15 months, 16 months, 17 months, 18 months, 19 months, 20 months, 21 months, 22 months, 23 months, or 24 months, compared to a baseline, by at least about 20%, for example, at least about 25%, 30%, 35%, 40%, 45%, 50%, 55%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100%, respectively, where the baseline is a formulated antibody partial composition obtained from the same purification platform that does not include one or more deep filtration steps and / or one or more HIC steps and / or one or more MM-HIC / IEX chromatography steps. Methods for evaluating aggregate formation, such as measurement, are known in the art and include, for example, visual inspection, dynamic light scattering, static light scattering, and optical density measurement.

[0268] In some embodiments, the formulated antibody partial compositions described herein maintain at least about 50% of the antibody partial activity, for example at least about 55%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%, for at least about 6 months, for example at least about 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, or 24 months, compared to a reference, where the reference is a formulated antibody partial composition obtained from the same purification platform that does not include one or more deep filtration steps and / or one or more HIC steps and / or one or more MM-HIC / IEX chromatography steps.

[0269] In some embodiments, the antibody portion is a monoclonal antibody.

[0270] In some embodiments, the antibody is a human antibody, a humanized antibody, or a chimeric antibody.

[0271] In some embodiments, the antibody moiety is selected from the group consisting of anti-TAU antibody, anti-TGFβ3 antibody, anti-VEGF-A antibody, anti-CD20 antibody, anti-CD40 antibody, anti-HER2 antibody, anti-IL6 antibody, anti-IgE antibody, anti-IL13 antibody, anti-TIGIT antibody, anti-PD-L1 antibody, anti-VEGF-A / ANG2 antibody, anti-CD79b antibody, anti-ST2 antibody, anti-factor D antibody, anti-factor IX antibody, anti-factor X antibody, anti-abeta antibody, anti-CEA antibody, anti-CEA / CD3 antibody, anti-CD20 / CD3 antibody, anti-FcRH5 / CD3 antibody, anti-Her2 / CD3 antibody, anti-FGFR1 / KLB antibody, FAP-4-1BBL fusion protein, FAP-IL2v fusion protein, and TYRP1 TCB antibody.

[0272] In some embodiments, the antibody portion is selected from the group consisting of ocrelizumab, pertuzumab, ranibizumab, trastuzumab, tocilizumab, falisimab, polatuzumab, gantenerumab, cibisatamab, crenezumab, mosnetuzumab, tilagolmab, bevacizumab, rituximab, atezolizumab, obinutuzumab, lamparizumab, omalizumab, ranibizumab, emicizumab, sericrelumab, pracinezumab, RO6874281, and RO7122290.

[0273] In some embodiments, the polysorbate is selected from the group consisting of polysorbate 20, polysorbate 40, polysorbate 60, and polysorbate 80.

[0274] Further embodiments reported herein are formulated antibody compositions exhibiting low polysorbate degradation during storage. One embodiment of the present invention is a formulated antibody composition comprising an antibody / protein and polysorbate, wherein the polysorbate is degraded by about 50% or less per year (e.g., about 45% or less, 40% or less, 35% or less, 30% or less, 25% or less, 20% or less, 15% or less, 10% or less, 9% or less, 8% or less, 7% or less, 6% or less, 5% or less, 4% or less, 3% or less, 2% or less, or 1% or less) during the storage period / shelf life of the formulated antibody composition. In one embodiment, the polysorbate is degraded by 10% or less per year during storage of the liquid composition.

[0275] Another aspect is a formulated antibody composition comprising an antibody and polysorbate, wherein after one year, the polysorbate is present in the composition at a concentration of at least about 50%, such as at least about 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of the initial concentration, where the initial concentration is the concentration at the time of formulation or the start of storage of the antibody in the liquid composition. Those skilled in the art will recognize that several embodiments are possible within the scope and spirit of the present invention. The present disclosure is further illustrated by the following examples, which should not be construed as limiting the scope or spirit of the present disclosure to the specific procedures described therein.

[0276] Exemplary embodiments Embodiment 1. A method for reducing the rate of hydrolytic enzyme activity of a composition obtained from a purification platform, comprising supplying a sample to a purification platform including a capture step; one or more ion exchange (IEX) chromatography steps; and a depth filtration step, thereby reducing the rate of hydrolytic enzyme activity of the composition as compared to the purification of a sample not including the depth filtration step.

[0277] Embodiment 2. The method according to embodiment 1, wherein each of the one or more IEX chromatography steps is selected from the group consisting of an anion exchange (AEX) chromatography step, a cation exchange (CEX) chromatography step, and a multimodal ion exchange (MMIEX) chromatography step.

[0278] Embodiment 3. The method according to embodiment 2, wherein the MMIEX chromatography step comprises a multimodal cation exchange / anion exchange (MM-AEX / CEX) chromatography step.

[0279] Embodiment 4. The method according to any one of embodiments 1 to 3, further comprising a virus filtration step.

[0280] Embodiment 5. The method according to any one of Embodiments 1 to 4, further comprising an ultrafiltration / diafiltration (UF / DF) step.

[0281] Embodiment 6. The method according to Embodiment 5, wherein the purification platform comprises, in order, a capture step; a CEX chromatography step; an AEX chromatography step; a deep filtration step; a viral filtration step; and a UF / DF step.

[0282] Embodiment 7. The method according to any one of Embodiments 1 to 6, wherein the deep filtration step includes processing through a depth filter, the depth filter being an X0SP depth filter, a C0SP depth filter, a D0SP depth filter, a Polisher ST depth filter, or an EMPHAZE® depth filter.

[0283] Embodiment 8. The method according to any one of Embodiments 1 to 6, further comprising an HIC step including treatment via Sartobind® phenyl.

[0284] Embodiment 9. A method for reducing the hydrolytic enzyme activity rate of a composition obtained from a purification platform, comprising subjecting a sample to a purification platform comprising a capture step; a multimodal hydrophobic interaction / ion exchange (MM-HIC / IEX) chromatography step; and a hydrophobic interaction chromatography (HIC) step, thereby reducing the hydrolytic enzyme activity rate of the composition compared to the purification of a sample without the HIC step and / or the MM-HIC / IEX chromatography step.

[0285] Embodiment 10. The method according to Embodiment 9, wherein the MM-HIC / IEX chromatography step includes processing via an MM-HIC / IEX chromatography medium, and the processing is carried out at a pH of about 4.5 to about 9.

[0286] Embodiment 11. The method according to Embodiment 9 or 10, wherein the MM-HIC / IEX chromatography step is a multimodal hydrophobic interaction / anion exchange (MM-HIC / AEX) chromatography step.

[0287] Embodiment 12. The method according to Embodiment 11, wherein the MM-HIC / AEX chromatography step includes processing via Capto® Adhere or Capto® Adhere ImpRes.

[0288] Embodiment 13. The method according to Embodiment 9 or 10, wherein the MM-HIC / IEX chromatography step is a multimodal hydrophobic interaction / cation exchange (MM-HIC / CEX) chromatography step.

[0289] Embodiment 14. The method according to Embodiment 13, wherein the MM-HIC / CEX chromatography step includes Capto® MMC or Capto® MMC ImpRes.

[0290] Embodiment 15. The method according to any one of Embodiments 9 to 14, wherein the purification platform comprises, in order, a capture step; an MM-HIC / IEX chromatography step; and an HIC step.

[0291] Embodiment 16. The method according to any one of Embodiments 9 to 15, further comprising a virus filtration step.

[0292] Embodiment 17. The method according to any one of Embodiments 9 to 16, further comprising an ultrafiltration / diafiltration (UF / DF) step.

[0293] Embodiment 18. The method according to Embodiment 17, wherein the purification platform comprises, in order, a capture step; an MM-HIC / AEX chromatography step; an HIC step; a virus filtration step; and a UF / DF step.

[0294] Embodiment 19. The method according to any one of Embodiments 9 to 18, further comprising a deep filtration step.

[0295] Embodiment 20. The method according to embodiment 19, wherein the purification platform includes, in sequence, a capture step; a depth filtration step; a MM-HIC / AEX chromatography step; and a HIC step.

[0296] Embodiment 21. The method according to embodiment 19 or 20, wherein the depth filtration step includes treatment through a depth filter, and the depth filter is an X0SP depth filter, a C0SP depth filter, a D0SP depth filter, a Polisher ST depth filter, or an EMPHAZE (trademark) depth filter.

[0297] Embodiment 22. The method according to embodiment 19 or 20, wherein the depth filtration step includes treatment through a depth filter, and the depth filter is an EMPHAZE (trademark) depth filter or a Polisher ST depth filter.

[0298] Embodiment 23. The method according to any one of embodiments 19 to 22, wherein the depth filter is used as a load filter together with the MM-HIC / AEX chromatography step.

[0299] Embodiment 24. The method according to embodiment 23, wherein the MM-HIC / AEX chromatography step includes treatment through Capto (trademark) Adhere or Capto (trademark) Adhere ImpRes.

[0300] Embodiment 25. The method according to embodiment 19, wherein the purification platform includes, in sequence, a capture step; a MM-HIC / AEX chromatography step; a depth filtration step; and a HIC step.

[0301] Embodiment 26. The method according to embodiment 25, wherein the depth filtration step includes treatment through a depth filter, and the depth filter is an X0SP depth filter, a C0SP depth filter, or a D0SP depth filter.

[0302] Embodiment 27. The method according to Embodiment 25, wherein the deep filtration step includes processing through a depth filter, the depth filter being an EMPHAZE® depth filter or a Polisher ST depth filter.

[0303] Embodiment 28. The method according to any one of Embodiments 25 to 27, wherein the MM-HIC / AEX chromatography step includes processing via Capto® Adhere or Capto® Adhere ImpRes.

[0304] Embodiment 29. A method for reducing the hydrolytic enzyme activity rate of a composition obtained from a purification platform, comprising subjecting a sample to a purification platform comprising a capture step; one or more ion exchange (IEX) chromatography steps; and a hydrophobic interaction chromatography (HIC) step, thereby reducing the hydrolytic enzyme activity rate of the composition compared to the purification of a sample without the HIC step.

[0305] The method according to Embodiment 29, wherein the IEX chromatography step in Embodiment 30.1 or higher is a cation exchange (CEX) chromatography step.

[0306] Embodiment 31. The method according to Embodiment 29 or 30, further comprising a virus filtration step.

[0307] Embodiment 32. The method according to any one of Embodiments 29 to 31, further comprising an ultrafiltration / diafiltration (UF / DF) step.

[0308] Embodiment 33. The method according to Embodiment 32, further comprising a deep filtration step performed at any stage prior to the UF / DF step.

[0309] Embodiment 34. The method according to Embodiment 33, wherein the purification platform comprises, in order, a capture step; a CEX chromatography step; a HIC step; a virus filtration step; and a UF / DF step.

[0310] Embodiment 35. A method for reducing the hydrolytic enzyme activity rate of a composition obtained from a purification platform, comprising subjecting a sample to a purification platform comprising one or more ion exchange (IEX) chromatography steps; hydrophobic interaction chromatography (HIC) steps; and deep filtration steps, thereby reducing the hydrolytic enzyme activity rate of the composition compared to the purification of a sample without an HIC step or deep filtration step.

[0311] Embodiment 36. The method according to Embodiment 35, wherein the reduction is compared to the purification of the sample without HIC and deep filtration steps.

[0312] The method according to Embodiment 35 or 36, wherein each of the IEX chromatography steps in Embodiment 37.1 or higher is selected from the group consisting of anion exchange (AEX) chromatography steps, cation exchange (CEX) chromatography steps, and multimodal ion exchange (MMIEX) chromatography steps.

[0313] Embodiment 38. The method according to Embodiment 37, wherein the MMIEX chromatography step includes a multimodal cation exchange / anion exchange (MM-AEX / CEX) chromatography step.

[0314] Embodiment 39. The method according to any one of Embodiments 35 to 38, further comprising an ultrafiltration / diafiltration (UF / DF) step.

[0315] Embodiment 40. The method according to Embodiment 39, wherein the purification platform comprises, in order: a CEX chromatography step; a HIC step; an MMIEX chromatography step; an AEX chromatography step; a deep filtration step; and a UF / DF step.

[0316] Embodiment 41. A method for reducing the hydrolytic enzyme activity rate of a composition obtained from a purification platform, comprising subjecting a sample to a purification platform comprising a capture step; one or more ion exchange (IEX) chromatography steps; a multimodal hydrophobic interaction / ion exchange (MM-HIC / IEX) chromatography step; and one or both of a hydrophobic interaction chromatography (HIC) step and a deep filtration step, thereby reducing the hydrolytic enzyme activity rate of the composition compared to the purification of a sample without an HIC step or a deep filtration step.

[0317] Embodiment 42. The method according to Embodiment 41, wherein the reduction is compared to the purification of the sample without HIC and deep filtration steps.

[0318] Embodiment 43. The method according to Embodiment 41 or 42, further comprising a virus filtration step.

[0319] Embodiment 44. The method according to any one of Embodiments 41 to 43, further comprising an ultrafiltration / diafiltration (UF / DF) step.

[0320] Embodiment 45. The method according to any one of Embodiments 41 to 44, wherein the deep filtration step is performed as a load filter for the MM-HIC / IEX chromatography step, as a load filter for the HIC step, or following the HIC step.

[0321] The method according to any one of Embodiments 41 to 45, wherein each of the IEX chromatography steps in Embodiment 46.1 or higher is selected from the group consisting of cation exchange (CEX) chromatography steps, anion exchange (AEX) chromatography steps, and multimodal ion exchange (MMIEX) chromatography steps.

[0322] Embodiment 47. The method according to any one of Embodiments 41 to 46, wherein the MM-HIC / IEX chromatography step is a multimodal hydrophobic interaction / anion exchange (MM-HIC / AEX) chromatography step.

[0323] Embodiment 48. The method according to Embodiment 47, wherein the MM-HIC / AEX chromatography step includes processing via Capto® Adhere or Capto® Adhere ImpRes.

[0324] Embodiment 49. The method according to any one of Embodiments 1 to 34 and 41 to 48, wherein the capture step includes processing via affinity chromatography.

[0325] Embodiment 50. The method according to any one of Embodiments 1-34 and 41-48, wherein the capture step is performed in binding-elution mode.

[0326] Embodiment 51. The method according to Embodiment 49 or 50, wherein the affinity chromatography is selected from the group consisting of protein A chromatography, protein G chromatography, protein A / G chromatography, FcXL chromatography, protein XL chromatography, kappa chromatography, and kappa XL chromatography.

[0327] Embodiment 52. The method according to any one of Embodiments 1-6, 19, 20, and 35-51, wherein the deep filtration step includes processing through a depth filter.

[0328] Embodiment 53. The method according to Embodiment 52, wherein the depth filter is used as a load filter.

[0329] Embodiment 54. The method according to Embodiment 52 or 53, wherein the depth filter comprises a substrate containing one or more of the following: a diatomaceous earth composition, a silica composition, cellulose fibers, polymer fibers, agglomerating resin, and an ash composition.

[0330] Embodiment 55. The method according to Embodiment 54, wherein at least a portion of the substrate of the depth filter includes surface modification.

[0331] Embodiment 56. The method according to Embodiment 55, wherein the surface modification is one or more quaternary amine surface modifications, cation surface modifications, and anions.

[0332] Embodiment 57. The method according to any one of Embodiments 52 to 56, wherein the depth filter is selected from the group consisting of X0SP depth filter, D0SP depth filter, C0SP depth filter, EMPHAZE® depth filter, PDD1 depth filter, PDE1 depth filter, PDH5 depth filter, ZETA PLUS® 120ZA depth filter, ZETA PLUS® 120ZB depth filter, ZETA PLUS® DELI depth filter, ZETA PLUS® DELP depth filter, and Polisher ST depth filter.

[0333] Embodiment 58. The method according to Embodiment 57, wherein the depth filter is the X0SP depth filter, the D0SP depth filter, or the C0SP depth filter, and the treatment through the depth filter is carried out at a pH of about 4.5 to about 8.

[0334] Embodiment 59. The method according to Embodiment 57, wherein the depth filter is the EMPHAZE® depth filter, and the treatment through the depth filter is carried out at a pH of approximately 7 to approximately 9.5.

[0335] Embodiment 60. The method according to Embodiment 57, wherein the depth filter is the Polisher ST depth filter, and the processing through the depth filter is carried out at a pH of approximately 4.5 to approximately 9.

[0336] Embodiment 61. The method according to any one of Embodiments 9 to 60, wherein the HIC step includes processing via an HIC membrane or an HIC column.

[0337] Embodiment 62. The method according to Embodiment 61, wherein the processing via an HIC membrane or HIC column is carried out using a low salt concentration.

[0338] Embodiment 63. The method according to any one of Embodiments 59 to 61, wherein the processing via an HIC membrane or HIC column is carried out in flow-through mode.

[0339] Embodiment 64. The method according to any one of Embodiments 61 to 63, wherein the HIC membrane or HIC column comprises a substrate containing one or more of the following groups: ether group, ethyl group, propyl group, isopropyl group, butyl group, hexyl group, octyl group, and phenyl group.

[0340] Embodiment 65. The method according to any one of Embodiments 61 to 64, wherein the HIC membrane or HIC column is selected from the group consisting of Bakerbond WP HI-Propyl®, Phenyl Sepharose® Fast Flow (phenyl-SFF), Phenyl Sepharose® Fast Flow Hi-sub (phenyl-SFF HS), Toyopearl® Hexyl-650C, Toyopearl® Hexyl-650M, Toyopearl® Hexyl-650S, Poros® Benzyl Ultra, and Sartobind® Phenyl.

[0341] Embodiment 66. The method according to Embodiment 64 or 65, wherein the treatment via the HIC membrane or HIC column is carried out at a pH of about 4.5 to about 7.

[0342] The method according to any one of embodiments 1 to 8 and 29 to 66, wherein each of the IEX chromatography steps in Embodiment 67.1 or higher includes processing via an IEX chromatography membrane or an IEX chromatography column.

[0343] Embodiment 68. The method according to Embodiment 67, wherein the IEX chromatography or IEX chromatography column is selected from the group consisting of SPSFF, QSFF, SPXL, Streamline® SPXL, ABx®, Poros® XS, Poros® 50HS, DEAE, DMAE, TMAE, QAE, and MEP-Hypercel®.

[0344] Embodiment 69. The method according to any one of Embodiments 1 to 68, wherein the purification platform is for purifying the target from the sample, and the sample comprises the target and one or more host cell impurities.

[0345] Embodiment 70. The method according to Embodiment 69, wherein the target comprises a polypeptide.

[0346] Embodiment 71. The method according to any one of Embodiments 1 to 70, wherein the target is an antibody portion.

[0347] Embodiment 72. The method according to Embodiment 71, wherein the antibody portion is a monoclonal antibody.

[0348] Embodiment 73. The method according to Embodiment 71 or 72, wherein the antibody portion is a human antibody, a humanized antibody, or a chimeric antibody.

[0349] Embodiment 74. The method according to any one of Embodiments 71 to 73, wherein the antibody portion is selected from the group consisting of anti-TAU antibody, anti-TGFβ3 antibody, anti-VEGF-A antibody, anti-CD20 antibody, anti-CD40 antibody, anti-HER2 antibody, anti-IL6 antibody, anti-IgE antibody, anti-IL13 antibody, anti-TIGIT antibody, anti-PD-L1 antibody, anti-VEGF-A / ANG2 antibody, anti-CD79b antibody, anti-ST2 antibody, anti-factor D antibody, anti-factor IX antibody, anti-factor X antibody, anti-abeta antibody, anti-CEA antibody, anti-CEA / CD3 antibody, anti-CD20 / CD3 antibody, anti-FcRH5 / CD3 antibody, anti-Her2 / CD3 antibody, anti-FGFR1 / KLB antibody, FAP-4-1BBL fusion protein, FAP-IL2v fusion protein, and TYRP1 TCB antibody.

[0350] Embodiment 75. The method according to any one of Embodiments 71 to 74, wherein the antibody portion is selected from the group consisting of ocrelizumab, pertuzumab, ranibizumab, trastuzumab, tocilizumab, falisimab, polatuzumab, gantenerumab, cibisatamab, crenezumab, mosnetuzumab, tilagolmab, bevacizumab, rituximab, atezolizumab, obinutuzumab, lamparizumab, omalizumab, ranibizumab, emicizumab, sericrelumab, pracinezumab, RO6874281, and RO7122290.

[0351] The method according to any one of Embodiments 69 to 75, wherein the host cell impurities of Embodiment 76.1 or higher include host cell proteins.

[0352] Embodiment 77. The method according to Embodiment 76, wherein the host cell protein is a hydrolase.

[0353] Embodiment 78. The method according to Embodiment 77, wherein the hydrolytic enzyme is lipase, esterase, thioesterase, phospholipase, carboxylesterase, hydrolase, cutinase, or ceramidase.

[0354] Embodiment 79. The method according to any one of Embodiments 1 to 78, wherein the sample comprises a host cell or a component derived therefrom.

[0355] Embodiment 80. The method according to any one of Embodiments 1 to 79, wherein the sample is a cell culture sample or derived from a cell culture sample.

[0356] Embodiment 81. The method according to Embodiment 80, wherein the cell culture sample comprises host cells, and the host cells are Chinese hamster ovary (CHO) cells or Escherichia coli (E. coli) cells.

[0357] Embodiment 82. The method according to any one of Embodiments 1 to 81, further comprising a sample processing step.

[0358] Embodiment 83. The method according to any one of Embodiments 1 to 82, wherein the reduction in the hydrolytic enzyme activity rate is at least about 20%.

[0359] Embodiment 84. The method according to any one of Embodiments 1 to 83, further comprising determining the hydrolytic enzyme activity rate of the composition.

[0360] Embodiment 85. The method according to any one of Embodiments 1 to 84, further comprising determining the level of one or more hydrolytic enzymes in the composition.

[0361] Embodiment 86. The method according to any one of Embodiments 1 to 85, wherein the composition comprises a polysorbate.

[0362] Embodiment 87. The method according to Embodiment 86, wherein the polysorbate is selected from the group consisting of polysorbate 20, polysorbate 40, polysorbate 60, and polysorbate 80.

[0363] Embodiment 88. A pharmaceutical composition obtained by the method described in any one of Embodiments 1 to 87.

[0364] Embodiment 89. A formulated antibody partial composition comprising an antibody moiety and a polysorbate, wherein the rate of polysorbate hydrolysis is reduced and the composition has a shelf life of more than 12 months.

[0365] Embodiment 90. A formulated antibody partial composition comprising an antibody moiety and a polysorbate, wherein the rate of polysorbate hydrolysis activity is reduced, the shelf life of the composition is extended compared to the shelf life indicated in documentation submitted to the health authorities relating to the formulated antibody partial composition, and the shelf life is extended by at least 3 months compared to the shelf life indicated in the documentation.

[0366] Embodiment 91. A formulated antibody partial composition according to Embodiment 89 or 90, wherein the rate of polysorbate hydrolysis is reduced by at least about 20%.

[0367] Embodiment 92. A formulated antibody partial composition comprising an antibody moiety, wherein the degradation of the polysorbate is reduced, and the degradation is at least about 20% lower than the degradation described in the documentation submitted to the health authorities relating to the formulated antibody partial composition.

[0368] Embodiment 93. A formulated antibody partial composition comprising an antibody portion and a polysorbate, wherein the polysorbate is degraded by 50% or less per year during storage of the liquid composition.

[0369] Embodiment 94. A formulated antibody partial composition according to any one of Embodiments 89 to 93, wherein the antibody portion is a monoclonal antibody.

[0370] Embodiment 95. A formulated antibody partial composition according to any one of Embodiments 89 to 94, wherein the antibody portion is a human antibody, a humanized antibody, or a chimeric antibody.

[0371] Embodiment 96. A formulated antibody portion composition according to any one of Embodiments 89 to 95, wherein the antibody portion is selected from the group consisting of anti-TAU antibody, anti-TGFβ3 antibody, anti-VEGF-A antibody, anti-CD20 antibody, anti-CD40 antibody, anti-HER2 antibody, anti-IL6 antibody, anti-IgE antibody, anti-IL13 antibody, anti-TIGIT antibody, anti-PD-L1 antibody, anti-VEGF-A / ANG2 antibody, anti-CD79b antibody, anti-ST2 antibody, anti-factor D antibody, anti-factor IX antibody, anti-factor X antibody, anti-abeta antibody, anti-CEA antibody, anti-CEA / CD3 antibody, anti-CD20 / CD3 antibody, anti-FcRH5 / CD3 antibody, anti-Her2 / CD3 antibody, anti-FGFR1 / KLB antibody, FAP-4-1BBL fusion protein, FAP-IL2v fusion protein, and TYRP1 TCB antibody.

[0372] Embodiment 97. A formulated antibody moiety composition according to any one of Embodiments 89 to 96, wherein the antibody moiety is selected from the group consisting of ocrelizumab, pertuzumab, ranibizumab, trastuzumab, tocilizumab, falisimab, polatuzumab, gantenerumab, cibisatamab, crenezumab, mosnetuzumab, tilagolmab, bevacizumab, rituximab, atezolizumab, obinutuzumab, lamparizumab, omalizumab, ranibizumab, emicizumab, sericrelumab, pracinezumab, RO6874281, and RO7122290.

[0373] Embodiment 98. A formulated antibody partial composition according to any one of Embodiments 89 to 97, wherein the polysorbate is selected from the group consisting of polysorbate 20, polysorbate 40, polysorbate 60, and polysorbate 80. [Examples]

[0374] Example 1 This example demonstrates a comparison between the following purification platforms. The purification platforms include, in order: (1) a capture step, a CEX chromatography step including SP Sepharose® Face Flow (SPSFF), an AEX chromatography step including Q Sepharose® Fast Flow (QSFF), a viral filtration step, and a UF / DF step (control purification platform); (2) a capture step, a CEX chromatography step including SP Sepharose® Face Flow (SPSFF), an AEX chromatography step including Q Sepharose® Fast Flow (QSFF), an HIC step including Sartobind® Phenyl, a viral filtration step, and a UF / DF step; and (3) a capture step, a CEX chromatography step including SP Sepharose® Face Flow (SPSFF), an AEX chromatography step including Q Sepharose® Fast Flow (QSFF), a deep filtration step including X0SP depth filter, a viral filtration step, and a UFF / DF step.

[0375] The hydrolytic activity of the obtained purified compositions was measured using a FAMS assay as described in the Materials and Methods section. As shown in Figure 2, the purification platform (2) having a HIC step containing Sartobind® phenyl and the purification platform (3) having a deep filtration step containing an X0SP depth filter showed reduced hydrolytic activity compared to the control purification platform.

[0376] Example 2 This example demonstrates a comparison of using three different HIC steps with the following purification platform, which includes, in order: (1) a capture step, a Capto® Adhere (MM-HIC / AEX) chromatography step, and a HIC step. The three different HIC media tested were: Phenyl SFF HS, Toyopearl® Hexyl-650C, and Poros® Benzyl Ultra. Each HIC step was performed using a low-salt flow-through mode without adding HIC conditioning salt to the HIC load. The hydrolytic activity of the composition before the HIC step (HIC load) and after the HIC step (HIC pool) was measured. The HIC steps were performed in flow-through and low-salt modes (no HIC conditioning salt was added to the HIC load). The operating conditions for the HIC steps in flow-through and low-salt modes are shown in Table 1 below. [Table 1]

[0377] The hydrolytic activity of HIC loads and HIC pools was measured using a FAMS assay as described in the Materials and Methods section. As shown in Figure 3, the HIC process reduced the hydrolytic activity of the resulting HIC pool compared to the starting material for the HIC loads.

[0378] Example 3 This example demonstrates the effect of including an MM-HIC / AEX chromatography step in a purification platform for purifying two molecules, the purification platform may include, in order, a capture step, a CEX step, e.g., Poros® 50HS, and an MM-HIC / AEX chromatography step including Capto® Adhere. The hydrolytic activity of the purified composition without the MM-HIC / AEX chromatography step, i.e., the purified composition after the Capto® Adhere (Capto® Adhere load) and Capto® Adhere chromatography steps (Capto® Adhere pool), was evaluated. The Capto® Adhere step was performed in flow-through mode, and the tests were conducted at both pH 5.5 and 8. The operating conditions for MM-HIC / AEX in flow-through mode are shown in Table 2 below. [Table 2]

[0379] The hydrolytic activity of Capto® Adhere loads and Capto® Adhere pools was measured using a FAMS assay as described in the Materials and Methods section. As shown in Figure 4, the Capto® Adhere chromatography step reduced the hydrolytic activity of the Capto® Adhere pools obtained from each molecular purification compared to the starting material of the Capto® Adhere loads. This reduction in hydrolytic activity was observed at both pH 5.5 (for molecule A) and pH 8 (for molecule B).

[0380] Example 4 This example demonstrates a comparison between the following purification platforms. The purification platforms include, in order: (1) a CEX chromatography step including SP Sepharose® XL (SPXL), an HIC step including Bakerbond WP HI-Propyl®, a multimodal anion / cation exchange (MM-AEX / CEX) chromatography step including ABx®, an AEX chromatography step including Q Sepharose® Fast Flow (QSFF), and a UF / DF step; (2) a CEX chromatography step including SPXL, an HIC step including Bakerbond WP HI-Propyl®, an MM-AEX / CEX chromatography step including ABx®, an AEX chromatography step including QSFF, a deep filtration step including EMPHAZE® AEX depth filter, and a UF / DF step; (3) a CEX chromatography step including SPXL, Bakerbond WP (4) The process includes an HIC step containing HI-Propyl(trademark), an MM-AEX / CEX chromatography step containing ABx(trademark), an AEX chromatography step containing QSFF, an HIC step containing Sartobind(registered trademark) phenyl, and a UF / DF step; (4) The process includes a CEX chromatography step containing SPXL, an HIC step containing Bakerbond WP HI-Propyl(trademark), an MM-AEX / CEX chromatography step containing ABx(trademark), an AEX chromatography step containing QSFF, a deep filtration step containing X0SP depth filter, and a UF / DF step.

[0381] The hydrolytic activity of the compositions after the purification platform (1) and the deep filtration step (for (2) and (4)), or after the Sartobind® phenyl HIC step, was measured from each platform using a FAMS assay as described in the Materials and Methods section. As shown in Figure 5, purification platform (2), which included a deep filtration step with an EMPHAZE® AEX depth filter, purification platform (3), which included a HIC step with Sartobind® phenyl, and purification platform (4), which included a deep filtration step with an X0SP depth filter, showed reduced hydrolytic activity compared to the control purification platform (1).

[0382] material and method Determination of protein concentration Protein concentrations were determined by UV spectroscopy using either a Cary® 50 UV-Vis spectrophotometer (Varian) or a NanoDrop® OneC (Thermo Scientific). Protein samples were diluted with their respective buffers and measured in double sets. The concentration was determined according to the following formula derived from the Lambert-Beer law: = (280 nm - 320 nm) / · F (protein concentration [mg / ml], absorbance, ε extinction coefficient [ml / (mg·cm)], cell length [cm], and F dilution factor).

[0383] Hydrolysis activity assay (LEAP assay) The hydrolysis activity assay measured hydrolysis activity by monitoring the conversion of a non-fluorescent substrate (4-MU, Chem Impex Int'l Inc.) to a fluorescent product (MU, Sigma-Aldrich) via cleavage of the ester bond of the substrate. The protein pool sample to be analyzed was rebuffered to 150 mM Tris-Cl pH 8.0 using an Amicon Ultra-0.5 ml centrifugal filter unit (10,000 Da cutoff, Merck Millipore). The assay reaction mixture contained 80 μL of reaction buffer (150 mM Tris-Cl pH 8.0, 0.25% (w / v) Triton X-100 and 0.125% (w / v) gum arabic), 10 μL of 4-MU substrate (1 mM in DMSO), and 10 μL of protein pool sample. The protein pool sample concentration was adjusted from 10 to 30 g / L and tested at three different concentrations. Each reaction was set up in three technical iterations on a 96-well half-area polystyrene plate (black transparent flat-bottom with lid, Corning Incorporated), and the increase in fluorescence signal (excited at 355 nm, emitted at 460 nm) was monitored every 10 minutes by incubating the reaction plate at 37°C for 2 hours using an Infinite 200Pro plate reader (Tecan Life Sciences). The MU generation rate was determined from the slope over fluorescence time (0.5 hours to 2 hours), and the raw rate of the reaction (k) was determined. raw [RFU / h]) represents

[0384] The enzyme blank reaction was further set up to measure the non-enzymatic cleavage of the substrate induced by the buffer matrix. A 10 μL protein pool sample was replaced with 10 μL of 150 mM Tris-Cl pH 8.0 in the reaction mixture. The autocleavage rate (k selfThe cleavage rate [RFU / h] was determined from the slope of the fluorescence over time (0.5 hours to 2 hours). A standard triple MU solution was added to each plate to convert the fluorescence signal (RFU) to μM MU. 10 μL of MU (100 μM in DMSO) was supplemented with 10 μL of 150 mM Tris-Cl pH 8.0 and 80 μL of reaction buffer. The conversion coefficient a [RFU / μM] was calculated by averaging the fluorescence signal (0.5 hours-2 hours) and dividing by the final concentration of MU present in the wells.

[0385] The hydrolytic activity of the sample is determined by the reaction rate (k) of the sample. raw [RFU / h]) to the reaction rate of the enzyme blank (k self The fluorescence signal is determined by subtracting cleavage ([RFU / h]) and dividing the term by a conversion factor a [RFU / μM] to convert it to μMMU / h, and is expressed in [μMMU / h]. Activity was normalized to the protein concentration applied per well. To report hydrolytic activity as a percentage, the hydrolytic activity of the reference sample was set to 100%.

[0386] Free fatty acid and mass spectrometry (FAMS) assay To monitor the free fatty acid content after PS20 degradation in each elution pool, samples were first prepared for PS20 stability testing and subsequently analyzed by mass spectrometry. Unless otherwise specified, protein pool samples were adjusted to the same protein concentration (as indicated in the description of each experiment) containing 0.04% (w / v) SR-PS20, 10 mM L-methionine, and 100 mM Tris pH 8. L-methionine was added as an efficient antioxidant to control the oxidative degradation of PS20 during the experimental time course. As a buffer control sample, the applied protein volume was replaced with the same volume of the corresponding elution buffer system.

[0387] All reaction mixtures were incubated in a Thermomixer (Eppendorf) at either 25°C or 40°C. Samples were removed after the specified time points (shown in the respective figures) and stored at -80°C until subsequent analysis.

[0388] A 50 μL sample was transferred to a new Eppendorf cup. 200 μL of FFA solution (500 ng / mL D in acetonitrile) was added. 23 Lauric acid and 500 ng / mL 13 C 14 Myristic acid was added and vortexed briefly. The sample was centrifuged at 14,000 rpm for 5 minutes and transferred to an HPLC vial for MS analysis. Separation of fatty acids from 5 μL of injection sample was performed on a Thermo Scientific® Vanquish® UHPLC system using an ACQUITY UPLC® Peptide BEH C18 column (1.7 μm 2.1 × 150 mm and 300 Å). Eluent A (0.1% aqueous ammonium hydroxide solution) and eluent B (100% acetonitrile) were used with the following gradient at a flow rate of 0.3 mL / min and a column temperature of 60°C. The initial condition was 70% eluent B. The gradient was changed linearly from 0.2 min to 5.5 min, increasing eluent A to 100% and holding up to 6.0 min. Eluent B was set to 70% at 6.1 min and held up to 10.0 min for equilibration. A mass spectrometer (Triple TOF® 6600, AB Sciex) was operated in negative ionization mode with an ion spray voltage of -4500V. The source temperature was set to 450°C, and the TOF mass range was set to 100-1000 m / Z. The decay potential was -120V, and the collision energy was -10V.

[0389] Lauric acid, myristic acid, and isotope-labeled (D 23 )-Lauric acid and ( 13 C 14 XIC was generated with respect to the mass of myristic acid. Each peak was integrated to obtain the values ​​of lauric acid and D. 23 -The peak area ratio between lauric acid and myristic acid and 13 C 14- The ratio between lauric acid and myristic acid was determined. The concentrations of lauric acid and myristic acid in the sample were calculated using the peak area ratio. Measurements were performed in two series. The amount of the reference sample was set to 100% in order to report the amount of FFA (lauric acid (LA) and myristic acid (MA)) as a percentage.

[0390] Example 5 This example demonstrates a comparison between the following purification platforms for purifying molecule D. The purification platforms include, in order: (1) a capture step, a CEX chromatography step including SP Sepharose® Face Flow (SPSFF), an AEX chromatography step including Q Sepharose® Fast Flow (QSFF), a viral filtration step, and a UF / DF step (control purification platform); and (2) a capture step, a CEX chromatography step including SP Sepharose® Face Flow (SPSFF), an AEX chromatography step including Q Sepharose® Fast Flow (QSFF), a deep filtration step including Polisher ST depth filter, a viral filtration step, and a UFF / DF step. For purification platform (2), the deep filtration step was performed at pH 6.

[0391] The hydrolytic activity of the obtained purified composition was measured using a FAMS assay as described in the Materials and Methods section of Example 4. As shown in Figure 6, the purification platform (2) including a deep filtration step with a Polisher ST depth filter provided a composition with reduced hydrolytic activity compared to a control purification platform without the Polisher ST deep filtration step.

[0392] Example 6 This example demonstrates a comparison between the following purification platforms for purifying molecule E. The purification platforms include, in order, (1) an MM-HIC / AEX chromatography step including a capture step, a CEX step, e.g., Poros® 50HS and Capto® Adhere (control purification platform); and (2) a deep filtration step including a Polisher ST depth filter for filtering the load for the MM-HIC / AEX chromatography step including a capture step, a CEX step, e.g., Poros® 50HS and Capto® Adhere. For purification platform (2), the deep filtration step was performed at pH 8.

[0393] The hydrolytic activity of the obtained purified composition was measured using a FAMS assay as described in the Materials and Methods section of Example 4. As shown in Figure 7, the purification platform (2) including a deep filtration step with a Polisher ST depth filter provided a composition with reduced hydrolytic activity compared to a control purification platform without the Polisher ST deep filtration step.

Claims

1. 1. A method for reducing the rate of hydrolytic enzyme activity in a composition obtained from a purification platform, comprising: Capture process; one or more ion exchange (IEX) chromatography steps; and a depth filtration step; This method reduces the rate of hydrolytic enzyme activity of the composition compared to purification of the sample that does not include a depth filtration step.

2. The method of claim 1, wherein each of the one or more IEX chromatography steps is selected from the group consisting of an anion exchange (AEX) chromatography step, a cation exchange (CEX) chromatography step, and a multimodal ion exchange (MMIEX) chromatography step.

3. The method of claim 2, wherein the MMIEX chromatography step includes a multimodal cation exchange / anion exchange (MM-AEX / CEX) chromatography step.

4. The method according to any one of claims 1 to 3, further comprising a virus filtration step.

5. The method according to any one of claims 1 to 4, further comprising an ultrafiltration / diafiltration (UF / DF) step.

6. The purification platform, in turn, Capture process; CEX chromatography step; AEX chromatography step; Depth filtration process; A viral filtration step; and The method of claim 5 , further comprising a UF / DF process.

7. The method of claim 1, wherein the deep filtration step includes treatment through a depth filter, the depth filter being an X0SP depth filter, a C0SP depth filter, a D0SP depth filter, a Polisher ST depth filter, or an EMPHAGE™ depth filter.

8. 7. The method of any one of claims 1 to 6, further comprising a HIC step comprising treatment via Sartobind® phenyl.

9. 1. A method for reducing the rate of hydrolytic enzyme activity in a composition obtained from a purification platform, comprising: one or more ion exchange (IEX) chromatography steps; A hydrophobic interaction chromatography (HIC) step; and a depth filtration step; The method thereby reduces the rate of hydrolytic enzyme activity of the composition compared to purification of the sample that does not include a HIC or depth filtration step.

10. The method of claim 9, wherein the reduction is compared to purification of a sample that does not include a HIC step and a depth filtration step.

11. The method of claim 9 or 10, wherein each of the one or more IEX chromatography steps is selected from the group consisting of an anion exchange (AEX) chromatography step, a cation exchange (CEX) chromatography step, and a multimodal ion exchange (MMIEX) chromatography step.

12. The method of claim 11, wherein the MMIEX chromatography step comprises a multimodal cation exchange / anion exchange (MM-AEX / CEX) chromatography step.

13. The method according to any one of claims 9 to 12, further comprising an ultrafiltration / diafiltration (UF / DF) step.

14. The purification platform, in turn, CEX chromatography step; HIC process; MMIEX chromatography step; AEX chromatography step; A depth filter step; and The method of claim 13, further comprising a UF / DF process.

15. 1. A method for reducing the rate of hydrolytic enzyme activity in a composition obtained from a purification platform, comprising: Capture process; one or more ion exchange (IEX) chromatography steps; A multimodal hydrophobic interaction / ion exchange (MM-HIC / IEX) chromatography step; and one or both of a hydrophobic interaction chromatography (HIC) step and a depth filtration step; and subjecting the resulting mixture to a purification platform comprising: This method reduces the rate of hydrolytic enzyme activity of the composition compared to purification of the sample that does not include a HIC or depth filtration step.

16. The method of claim 15, wherein the reduction is compared to purification of a sample that does not include HIC and the deep filtration step.

17. 17. The method of claim 15 or 16, further comprising a virus filtration step.

18. The method according to any one of claims 15 to 17, further comprising an ultrafiltration / diafiltration (UF / DF) step.

19. The method of claim 15, wherein the depth filtration step is performed as a load filter for a MM-HIC / IEX chromatography step, as a load filter for a HIC step, or subsequent to a HIC step.

20. The method of claim 15, wherein each of the one or more IEX chromatography steps is selected from the group consisting of a cation exchange (CEX) chromatography step, an anion exchange (AEX) chromatography step, and a multimodal ion exchange (MMIEX) chromatography step.

21. The method of claim 15, wherein the MM-HIC / IEX chromatography step is a multimodal hydrophobic interaction / anion exchange (MM-HIC / AEX) chromatography step.

22. The method of claim 21, wherein the MM-HIC / AEX chromatography step includes treatment via Capto™ Adhere or Capto™ Adhere ImpRes.

23. A method according to any one of claims 1 to 8 and 15 to 22, wherein the capture step comprises treatment via affinity chromatography.

24. A method according to any one of claims 1 to 8 and 15 to 22, wherein the capture step is carried out in bind-elute mode.

25. The method of claim 23 or 24, wherein the affinity chromatography is selected from the group consisting of Protein A chromatography, Protein G chromatography, Protein A / G chromatography, FcXL chromatography, Protein XL chromatography, kappa chromatography, and kappa XL chromatography.

26. The method of any one of claims 1 to 6 and 9 to 25, wherein the deep filtration step comprises treatment through a depth filter.

27. The method of claim 26, wherein a depth filter is used as a load filter.

28. The method of claim 26 or 27, wherein the depth filter comprises a substrate comprising one or more of a diatomaceous earth composition, a silica composition, cellulose fibers, polymeric fibers, a flocculating resin, and an ash composition.

29. The method of claim 28, wherein at least a portion of the substrate of the depth filter comprises a surface modification.

30. The method of claim 29, wherein the surface modification is one or more of a quaternary amine surface modification, a cationic surface modification, and an anionic surface modification.

31. The method of any one of claims 26 to 30, wherein the depth filter is selected from the group consisting of an X0SP depth filter, a D0SP depth filter, a C0SP depth filter, an EMPHAZE™ depth filter, a PDD1 depth filter, a PDE1 depth filter, a PDH5 depth filter, a ZETA PLUS™ 120ZA depth filter, a ZETA PLUS™ 120ZB depth filter, a ZETA PLUS™ DELI depth filter, a ZETA PLUS™ DELP depth filter, and a Polisher ST depth filter.

32. The method of claim 31, wherein the depth filter is an X0SP depth filter, a D0SP depth filter, or a C0SP depth filter, and processing through the depth filter is carried out at a pH of about 4.5 to about 8.

33. The method of claim 31, wherein the depth filter is an EMPHAZE™ depth filter and processing through the depth filter is carried out at a pH of about 7 to about 9.

5.

34. The method of claim 31, wherein the depth filter is a Polisher ST depth filter and processing through the depth filter is carried out at a pH of about 4.5 to about 9.

35. A method according to any one of claims 9 to 34, wherein the HIC process comprises treatment via a HIC membrane or a HIC column.

36. The method of claim 35, wherein processing through the HIC membrane or HIC column is carried out using a low salt concentration.

37. A method according to any one of claims 33 to 35, wherein processing via a HIC membrane or HIC column is carried out in flow-through mode.

38. The method of claim 35, wherein the HIC membrane or HIC column comprises a substrate containing one or more of an ether group, an ethyl group, a propyl group, an isopropyl group, a butyl group, a hexyl group, an octyl group, and a phenyl group.

39. The method of any one of claims 35 to 38, wherein the HIC membrane or HIC column is selected from the group consisting of Bakerbond WP HI-Propyl™, Phenyl Sepharose® Fast Flow (phenyl-SFF), Phenyl Sepharose® Fast Flow Hi-sub (phenyl-SFF HS), Toyopearl® Hexyl-650C, Toyopearl® Hexyl-650M, Toyopearl® Hexyl-650S, Poros™ Benzyl Ultra, and Sartobind® Phenyl.

40. The method of claim 38 or 39, wherein the treatment through the HIC membrane or HIC column is carried out at a pH of about 4.5 to about 7.

41. A method according to any one of claims 1 to 40, wherein each of the one or more IEX chromatography steps comprises processing via an IEX chromatography membrane or an IEX chromatography column.

42. The method of claim 41, wherein the IEX chromatography membrane or column is selected from the group consisting of SPSFF, QSFF, SPXL, Streamline™ SPXL, ABx™, Poros™ XS, Poros™ 50HS, DEAE, DMAE, TMAE, QAE, and MEP-Hypercel™.

43. A method according to any one of claims 1 to 42, wherein the purification platform is for purifying a target from a sample, the sample comprising the target and one or more host cell impurities.

44. The method of claim 43, wherein the target comprises a polypeptide.

45. A method according to any one of claims 1 to 44, wherein the target is an antibody moiety.

46. ​​The method of claim 45, wherein the antibody portion is a monoclonal antibody.

47. The method described in claim 45 or 46, wherein the antibody portion is a human antibody, a humanized antibody or a chimeric antibody.

48. The method of any one of claims 45 to 47, wherein the antibody portion is selected from the group consisting of an anti-TAU antibody, an anti-TGFβ3 antibody, an anti-VEGF-A antibody, an anti-CD20 antibody, an anti-CD40 antibody, an anti-HER2 antibody, an anti-IL6 antibody, an anti-IgE antibody, an anti-IL13 antibody, an anti-TIGIT antibody, an anti-PD-L1 antibody, an anti-VEGF-A / ANG2 antibody, an anti-CD79b antibody, an anti-ST2 antibody, an anti-factor D antibody, an anti-factor IX antibody, an anti-factor X antibody, an anti-abeta antibody, an anti-CEA antibody, an anti-CEA / CD3 antibody, an anti-CD20 / CD3 antibody, an anti-FcRH5 / CD3 antibody, an anti-Her2 / CD3 antibody, an anti-FGFR1 / KLB antibody, an FAP-4-1BBL fusion protein, an FAP-IL2v fusion protein, and a TYRP1 TCB antibody.

49. The method of any one of claims 45 to 48, wherein the antibody portion is selected from the group consisting of ocrelizumab, pertuzumab, ranibizumab, trastuzumab, tocilizumab, faricimab, polatuzumab, gantenerumab, civisatamab, crenezumab, mosunetuzumab, tiragolumab, bevacizumab, rituximab, atezolizumab, obinutuzumab, lampalizumab, omalizumab, ranibizumab, emicizumab, seliclerumab, prasinezumab, RO6874281 and RO7122290.

50. The method of any one of claims 43 to 49, wherein the one or more host cell impurities include host cell proteins.

51. The method of claim 50, wherein the host cell protein is a hydrolase.

52. The method of claim 51, wherein the hydrolase is a lipase, esterase, thioesterase, phospholipase, carboxylesterase, hydrolase, cutinase, or ceramidase.

53. A method according to any one of claims 1 to 52, wherein the sample comprises a host cell or a component derived therefrom.

54. A method according to any one of claims 1 to 53, wherein the sample is a cell culture sample or is derived from a cell culture sample.

55. The method of claim 54, wherein the cell culture sample comprises host cells, and the host cells are Chinese hamster ovary (CHO) cells or Escherichia coli (E. coli) cells.

56. 56. The method of any one of claims 1 to 55, further comprising a sample processing step.

57. A method according to any one of claims 1 to 56, wherein the reduction in the rate of hydrolase activity is at least about 20%.

58. The method of any one of claims 1 to 57, further comprising determining a rate of hydrolase activity of the composition.

59. The method of any one of claims 1 to 58, further comprising determining the level of one or more hydrolytic enzymes in the composition.

60. The method of any one of claims 1 to 59, wherein the composition comprises a polysorbate.

61. The method of claim 60, wherein the polysorbate is selected from the group consisting of polysorbate 20, polysorbate 40, polysorbate 60 and polysorbate 80.

62. A pharmaceutical composition obtainable from the method according to any one of claims 1 to 61.

63. A method for producing a pharmaceutical composition, comprising a method described in any one of claims 1 to 61.

64. A formulated antibody portion composition comprising an antibody portion and a polysorbate, wherein the rate of polysorbate hydrolysis is reduced and the composition has a shelf life of greater than 12 months.

65. A formulated antibody portion composition comprising an antibody portion and a polysorbate, wherein the rate of polysorbate hydrolysis activity is reduced and the shelf life of the composition is extended compared to the shelf life set forth in documentation submitted to health authorities relating to the formulated antibody portion composition, wherein the shelf life is extended by at least three months compared to the shelf life set forth in the documentation.

66. The formulated antibody partial composition of claim 64 or 65, wherein the rate of polysorbate hydrolysis is reduced by at least about 20%.

67. A formulated antibody portion composition comprising an antibody portion, the formulated antibody portion composition having reduced degradation of polysorbate, the degradation being reduced by at least about 20% as compared to degradation exhibited in documents submitted to health authorities relating to the formulated antibody portion composition.

68. A formulated antibody portion composition comprising an antibody portion and a polysorbate, wherein the polysorbate degrades by no more than 50% per year during storage of the liquid composition.

69. The formulated antibody portion composition of any one of claims 64 to 68, wherein the antibody portion is a monoclonal antibody.

70. The formulated antibody portion composition of any one of claims 64-69, wherein the antibody portion is a human antibody, a humanized antibody, or a chimeric antibody.

71. The formulated antibody partial composition of any one of claims 64-70, wherein the antibody is selected from the group consisting of an anti-TAU antibody, an anti-TGFβ3 antibody, an anti-VEGF-A antibody, an anti-CD20 antibody, an anti-CD40 antibody, an anti-HER2 antibody, an anti-IL6 antibody, an anti-IgE antibody, an anti-IL13 antibody, an anti-TIGIT antibody, an anti-PD-L1 antibody, an anti-VEGF-A / ANG2 antibody, an anti-CD79b antibody, an anti-ST2 antibody, an anti-Factor D antibody, an anti-Factor IX antibody, an anti-Factor X antibody, an anti-abeta antibody, an anti-CEA antibody, an anti-CEA / CD3 antibody, an anti-CD20 / CD3 antibody, an anti-FcRH5 / CD3 antibody, an anti-Her2 / CD3 antibody, an anti-FGFR1 / KLB antibody, an FAP-4-1BBL fusion protein, an FAP-IL2v fusion protein, and a TYRP1 TCB antibody.

72. The formulated antibody moiety of any one of claims 64 to 71, wherein the antibody moiety is selected from the group consisting of ocrelizumab, pertuzumab, ranibizumab, trastuzumab, tocilizumab, faricimab, polatuzumab, gantenerumab, civisatamab, crenezumab, mosunetuzumab, tiragolumab, bevacizumab, rituximab, atezolizumab, obinutuzumab, lampalizumab, omalizumab, ranibizumab, emicizumab, seliclerumab, prasinezumab, RO6874281, and RO7122290.

73. The formulated antibody partial composition of any one of claims 64 to 72, wherein the polysorbate is selected from the group consisting of polysorbate 20, polysorbate 40, polysorbate 60 and polysorbate 80.